{
  "rss": {
    "version": [
      "2.0"
    ],
    "channel": [
      {
        "title": [
          "ClinicalTrials.gov: Recruiting, Not yet recruiting, Active, not recruiting, Completed, Enrolling by invitation Studies | Interventional Studies | cancer | Last update posted in the last 14 days"
        ],
        "link": [
          "https://clinicaltrials.gov/ct2/results/rss.xml?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14&amp;count=1000"
        ],
        "description": [
          "Studies found on ClinicalTrials.gov by a search of: Recruiting, Not yet recruiting, Active, not recruiting, Completed, Enrolling by invitation Studies | Interventional Studies | cancer | Last update posted in the last 14 days"
        ],
        "language": [
          "en-us"
        ],
        "pubDate": [
          "Wed, 10 Feb 2021 10:17:14 EST"
        ],
        "ttl": [
          "1440"
        ],
        "item": [
          {
            "title": [
              "Individualizing Surveillance Mammography for Older Breast Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03865654?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Other: Communication Tool<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; National Institutes of Health (NIH); National Cancer Institute (NCI)<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT03865654",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 07 Mar 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03739775?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HPV Positive Pelvic Cancer<br/><b>Intervention</b>: Procedure: Blood sampling<br/><b>Sponsor</b>: Institut Curie<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03739775",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 14 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03316586?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Nivolumab; Drug: Cabozantinib<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; Bristol-Myers Squibb; Exelixis<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03316586",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 20 Oct 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04039230?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Talazoparib; Drug: Sacituzumab Govitecan<br/><b>Sponsors</b>: Massachusetts General Hospital; Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04039230",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 31 Jul 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04722718?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Drug: Sintilimab+Apatinib+Albumin paclitaxel+Carboplatin<br/><b>Sponsor</b>: Jiuda Zhao<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04722718",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03495115?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Device: MRI; Device: RSI<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; Radiological Society of North America<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03495115",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 11 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03959891?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Ipatasertib; Drug: Fulvestrant; Drug: Aromatase Inhibitor; Drug: Palbociclib<br/><b>Sponsors</b>: Massachusetts General Hospital; Genentech, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03959891",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 22 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03285412?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Ribociclib; Other: Endocrine therapy<br/><b>Sponsors</b>: Massachusetts General Hospital; Novartis<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03285412",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 18 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Engaging Primary Care in Cancer Survivorship (EPICS) Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04745754?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Colorectal Cancer<br/><b>Intervention</b>: Other: Embedded primary care in cancer survivorship model<br/><b>Sponsors</b>: Kaiser Permanente; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04745754",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04486378?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer Stage II; Colorectal Cancer Stage III<br/><b>Interventions</b>: Drug: RO7198457 intravenous (i.v.); Other: Observational group (no intervention)<br/><b>Sponsor</b>: BioNTech SE<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04486378",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04729114?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Drug: abiraterone decanoate<br/><b>Sponsor</b>: Propella Therapeutics<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04729114",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02297698?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Biological: NeuVax vaccine; Drug: Trastuzumab; Drug: GM-CSF<br/><b>Sponsors</b>: Cancer Insight, LLC; Genentech, Inc.; Sellas Life Sciences Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02297698",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 21 Nov 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib and Tislelizumab in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04734262?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: Sitravatinib; Drug: Tislelizumab<br/><b>Sponsor</b>: Fudan University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04734262",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03798769?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreas Cancer<br/><b>Intervention</b>: Other: Supportive Oncology Care at Home<br/><b>Sponsors</b>: Massachusetts General Hospital; Stand Up To Cancer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03798769",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 10 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Transcutaneous Breast Cancer Diagnosis by Canine Odorology"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04217109?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Diagnostic Test: Odour sampling<br/><b>Sponsor</b>: Institut Curie<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04217109",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 03 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Impact of Family History and Decision Support on High-risk Cancer Screening"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02247336?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Behavioral: MeTree<br/><b>Sponsor</b>: VA Office of Research and Development<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02247336",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 25 Sep 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733963?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Drug: Fruquintinib Plus Capecitabine; Drug: Bevacizumab Plus Capecitabine<br/><b>Sponsor</b>: Second Affiliated Hospital, School of Medicine, Zhejiang University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04733963",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Value Affirmation Intervention in Breast Cancer Patients Taking Aromatase Inhibitors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04651452?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Behavioral: Value Affirmation; Behavioral: Reflective Journaling<br/><b>Sponsors</b>: Carnegie Mellon University; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04651452",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 03 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03686215?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Combination Product: Study Device Arm<br/><b>Sponsors</b>: Lumicell, Inc.; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03686215",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 26 Sep 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "TNT in Rectal Cancer Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04747951?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Combination Product: Concurrent Chemoradiotherapy; Procedure: TME; Drug: consolidation chemotherapy; Drug: adjuvant chemotherapy<br/><b>Sponsor</b>: State Scientific Centre of Coloproctology, Russian Federation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04747951",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01394679?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Interventions</b>: Drug: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose); Drug: 18 F FDG followed by PET/CT imaging<br/><b>Sponsor</b>: Cell>Point LLC<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01394679",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Jul 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03524820?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer of Colon<br/><b>Intervention</b>: Drug: Cetuximab<br/><b>Sponsors</b>: Hadassah Medical Organization; Merck Serono International SA<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03524820",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 15 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04330040?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Breast Cancer<br/><b>Intervention</b>: Drug: Olaparib<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04330040",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 01 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Lifestyle Intervention Among Participants of the French Colorectal Cancer Screening Program"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04257526?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Behavioral: Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.<br/><b>Sponsors</b>: International Agency for Research on Cancer; Centre Leon Berard; Hôpital Edouard Herriot; University of Bordeaux<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04257526",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Feasibility Study of LUM Imaging System for Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04276909?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Intervention</b>: Combination Product: LUM Imaging System<br/><b>Sponsor</b>: Lumicell, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04276909",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 19 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03737370?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Castrate Resistant Prostate Cancer<br/><b>Interventions</b>: Drug: Docetaxel; Radiation: Radium 223<br/><b>Sponsors</b>: Tufts Medical Center; Bayer; Lahey Clinic; Henry Ford Hospital; Ohio State University Comprehensive Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03737370",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 09 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03706365?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Abemaciclib; Drug: Abiraterone Acetate; Drug: Prednisone; Drug: Placebo<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03706365",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04428554?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urothelial Bladder Cancer<br/><b>Intervention</b>: Radiation: Experimental arm<br/><b>Sponsor</b>: Institut Claudius Regaud<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04428554",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01150513?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: EC-T; Drug: TP<br/><b>Sponsor</b>: Chinese Academy of Medical Sciences<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01150513",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Jun 2010 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01436968?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Biological: Aglatimagene besadenovec + valacyclovir; Biological: Placebo + valacyclovir<br/><b>Sponsor</b>: Candel Therapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01436968",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 20 Sep 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04539938?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: tucatinib; Drug: trastuzumab deruxtecan<br/><b>Sponsor</b>: Seagen Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04539938",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "\"Impact of a Nursing Intervention in the Management of Oncological Patients With Lung Cancer Under Treatment With Immunotherapy\""
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04619810?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Intervention</b>: Other: Nurse intervention program<br/><b>Sponsor</b>: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04619810",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736589?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Inetetamab; Drug: Rapamycin; Drug: Pyrotinib; Drug: Chemotherapy<br/><b>Sponsor</b>: Peking Union Medical College<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736589",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00004935?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Herceptin™ (Her); Drug: Herceptin™ (Her) + chemo<br/><b>Sponsor</b>: Swiss Group for Clinical Cancer Research<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00004935",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Jan 2003 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04479436?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Intervention</b>: Drug: U3-1402<br/><b>Sponsor</b>: Daiichi Sankyo, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04479436",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 21 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Nab-Paclitaxel in High Risk Early Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01690702?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Epirubicin; Drug: nab-Paclitaxel; Drug: Cyclophosphamide; Drug: Docetaxel<br/><b>Sponsors</b>: German Breast Group; Celgene; Amgen<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01690702",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Sep 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Radiotherapy for Oligometastatic Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01859221?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Oligometastatic Prostate Cancer<br/><b>Intervention</b>: Radiation: Stereotactic radiation<br/><b>Sponsor</b>: University of Florida<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01859221",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 21 May 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Acupressure for Cancer-Related Fatigue"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03091647?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Behavioral: acupressure intervention; Behavioral: usual care<br/><b>Sponsor</b>: Georgetown University<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03091647",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03964532?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Talazoparib; Drug: Avelumab<br/><b>Sponsors</b>: Georgetown University; Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03964532",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02547987?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Docetaxel; Drug: Carboplatin<br/><b>Sponsor</b>: Mothaffar Rimawi<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02547987",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 14 Sep 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04700332?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Drug: DCFPyL PET/CT<br/><b>Sponsor</b>: Hoag Memorial Hospital Presbyterian<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04700332",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 07 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739761?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Drug: Trastuzumab Deruxtecan<br/><b>Sponsors</b>: AstraZeneca; Daiichi Sankyo, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739761",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Immature Granulocyte Count and Delta Neutrophil Index Factors for Axillary Metastasis of Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04729647?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Breast Cancer Invasive<br/><b>Intervention</b>: Procedure: Mastectomy<br/><b>Sponsor</b>: Kahramanmaras Sutcu Imam University<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04729647",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04380012?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Drug: Pyrotinib; Drug: Pyrotinib in combination with trastuzumab<br/><b>Sponsor</b>: Second Affiliated Hospital, School of Medicine, Zhejiang University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04380012",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04744649?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Cancer; Stomach Neoplasm<br/><b>Interventions</b>: Drug: XELOX or SOX; Drug: S001+XELOX or SOX<br/><b>Sponsors</b>: Nanfang Hospital of Southern Medical University; Shanghai Junshi Bioscience Co., Ltd.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04744649",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03542175?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Rucaparib; Radiation: Radiotherapy<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Clovis Oncology, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03542175",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 31 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03777462?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Interventions</b>: Drug: Neoadjuvant gemcitabine plus nab-paclitaxel; Drug: Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT; Drug: Neoadjuvant S-1 plus nab-paclitaxel with SBRT<br/><b>Sponsor</b>: Changhai Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03777462",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 17 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00002667?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Interventions</b>: Other: cytology specimen collection procedure; Other: immunoenzyme technique; Procedure: study of high risk factors<br/><b>Sponsors</b>: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00002667",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Jul 2004 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Breast Cancer Study of Preoperative Pembrolizumab + Radiation"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03366844?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Pembrolizumab; Radiation: RT Boost<br/><b>Sponsors</b>: Stephen Shiao; United States Department of Defense<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03366844",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03374293?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Interventions</b>: Radiation: Radiation; Drug: Anti-PD-1 Antibody<br/><b>Sponsor</b>: Shixiu Wu<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03374293",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 15 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Adherence to Colon Cancer Screening (ACCS)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02112747?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colon Cancer; Rectal Cancer<br/><b>Intervention</b>: Other: Patient Navigator<br/><b>Sponsor</b>: Ohio State University Comprehensive Cancer Center<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02112747",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 14 Apr 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03103152?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: High dose Aspirin & Vitamin D; Drug: High dose Aspirin, Vitamin D placebo; Drug: Low dose Aspirin , Vitamin D; Drug: Low dose Aspirin, Vitamin D placebo; Drug: Aspirin Placebo, Vitamin D; Drug: Aspirin placebo, Vitamin D placebo<br/><b>Sponsors</b>: Queen Mary University of London; Barts and the London School of Medicine and Dentistry; Cancer Research UK<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03103152",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Apr 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04622319?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer<br/><b>Interventions</b>: Drug: DS-8201a; Drug: T-DM1<br/><b>Sponsors</b>: Daiichi Sankyo, Inc.; AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research Group (SOLTI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04622319",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01186367?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Behavioral: Linear Aerobic Training; Behavioral: Nonlinear Aerobic Training; Behavioral: Progressive Stretching; Other: Cardiopulmonary exercise test (CPET); Other: Blood draws<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Duke University<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01186367",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 23 Aug 2010 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02577341?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small-cell Lung Cancer<br/><b>Interventions</b>: Drug: Nimotuzumab; Drug: docetaxel and cisplatin; Radiation: daily RT to the chest<br/><b>Sponsor</b>: Sun Yat-sen University<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02577341",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Oct 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04740697?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Other: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.<br/><b>Sponsor</b>: Institut Claudius Regaud<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04740697",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Digital Outreach Intervention for Lung Cancer Screening"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04083859?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Interventions</b>: Other: mPATH-Lung; Other: Lung health video<br/><b>Sponsors</b>: Wake Forest University Health Sciences; University of North Carolina, Chapel Hill; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04083859",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04457895?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Behavioral: educational yoga program; Other: no intervention<br/><b>Sponsor</b>: Institut du Cancer de Montpellier - Val d'Aurelle<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04457895",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of FPA144 Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03343301?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastrointestinal Cancer; Gastrointestinal Cancer Metastatic; Gastric Cancer<br/><b>Intervention</b>: Combination Product: FPA144 + mFOLFOX6<br/><b>Sponsor</b>: Five Prime Therapeutics, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03343301",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 17 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04186819?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Drug: rhPSMA-7.3 (18F) Injection<br/><b>Sponsors</b>: Blue Earth Diagnostics; Parexel<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04186819",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01494155?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Interventions</b>: Drug: Capecitabine; Drug: Hydroxychloroquine; Radiation: Proton or Photon Radiation Therapy<br/><b>Sponsor</b>: Massachusetts General Hospital<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01494155",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Dec 2011 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03737643?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Ovarian Cancer<br/><b>Interventions</b>: Drug: Bevacizumab; Drug: Durvalumab; Drug: Olaparib; Drug: Placebo olaparib; Drug: Durvalumab placebo; Drug: Carboplatin+Paclitaxel<br/><b>Sponsors</b>: AstraZeneca; European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation, Inc. (GOG Foundation); Myriad Genetic Laboratories, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03737643",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 09 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Investigating Various Adaptive-Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04667481?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Behavioral: ACTIVATE<br/><b>Sponsors</b>: University of Washington; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04667481",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 14 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03724747?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Castration Resistant Prostate Cancer (mCRPC)<br/><b>Intervention</b>: Drug: BAY 2315497 Injection<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03724747",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Using Connected Health to Increase Lung Cancer Screening"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04612946?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Interventions</b>: Behavioral: Referral to Telemedicine LCS Counseling Visit; Behavioral: Usual Care<br/><b>Sponsors</b>: University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04612946",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 03 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04567459?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Dietary Supplement: Premium Amino Acids<br/><b>Sponsors</b>: Chang Gung Memorial Hospital; Hanben Enterprise<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04567459",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 28 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Changes in Inflammatory Response After Immunonutrition Compared to Standard Nutrition in Colorectal Cancer Tissue"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04732442?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colon Cancer; Nutrition Aspect of Cancer<br/><b>Interventions</b>: Dietary Supplement: Immunonutrition; Dietary Supplement: Standard Oral Nutritional Support<br/><b>Sponsor</b>: Jagiellonian University<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04732442",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03333655?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Intervention</b>: Procedure: Biopsy<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03333655",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04564482?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rectal Cancer Stage; Oesophageal Cancer<br/><b>Interventions</b>: Radiation: CRT; Radiation: SCPRT; Radiation: CROSS Protocol; Diagnostic Test: PD-L1 PET<br/><b>Sponsors</b>: Johannes Laengle, MD, PhD; Christian Doppler Laboratory Applied Metabolomics<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04564482",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03564548?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Breakthrough Cancer Pain<br/><b>Interventions</b>: Drug: PPP001; Drug: Morphine sulfate<br/><b>Sponsors</b>: Tetra Bio-Pharma; Cognitive Research Corporation<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03564548",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03614949?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cervical Cancer; Cervical Cancer Recurrent; Cervical Cancer Metastatic<br/><b>Interventions</b>: Radiation: Stereotactic body radiation therapy (SBRT); Drug: Atezolizumab<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Genentech, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03614949",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 03 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04747717?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Intervention</b>: Procedure: chemotherapy/surgery<br/><b>Sponsor</b>: N.N. Petrov National Medical Research Center of Oncology<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04747717",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01781403?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Intervention</b>: Drug: Temozolomide<br/><b>Sponsor</b>: Asan Medical Center<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01781403",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Feb 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04124601?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Radiation: Chemoradiotherapy; Drug: Ipilimumab; Drug: Nivolumab<br/><b>Sponsors</b>: Johannes Laengle, MD, PhD; Bristol-Myers Squibb<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04124601",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 11 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Detection of ISUP≥2 Prostate Cancers Using Multiparametric MRI: Prospective Multicenter Comparison of the PI-RADS Score and an Artificial Intelligence System"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04732156?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Biological: Blood sample; Other: Follow up questionnaire; Diagnostic Test: Human reading of prostate MR images (PI-RADSv2.1).<br/><b>Sponsor</b>: Hospices Civils de Lyon<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04732156",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Feasibility of Stereotactic Navigation in Laparoscopic Surgery for Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03806244?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Other: Intraoperative acquisition (robotic c-Arm) of images<br/><b>Sponsor</b>: IHU Strasbourg<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03806244",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04625270?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Drug: VS-6766; Drug: VS-6766 and Defactinib<br/><b>Sponsors</b>: Verastem, Inc.; European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04625270",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02999074?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Other: Resistance exercise; Other: Aerobic exercise; Other: Usual care during neoadjuvant chemotherapy/Exercise after surgery<br/><b>Sponsors</b>: German Cancer Research Center; University Hospital Heidelberg<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02999074",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 21 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733820?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Uterine Cervical Neoplasms; Cervical Cancer<br/><b>Intervention</b>: Drug: Adjuvant chemotherapy<br/><b>Sponsors</b>: Huazhong University of Science and Technology; Women's Hospital School Of Medicine Zhejiang University; Qilu Hospital of Shandong University; Obstetrics & Gynecology Hospital of Fudan University; First Affiliated Hospital of Chongqing Medical University; Hunan Cancer Hospital; The Third Xiangya Hospital of Central South University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04733820",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03978624?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bladder Cancer<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: Entinostat<br/><b>Sponsor</b>: UNC Lineberger Comprehensive Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03978624",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 07 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03358563?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Docetaxel; Drug: Degarelix; Drug: Bicalutamide; Radiation: Ferumoxytol-enhanced MRI imaging<br/><b>Sponsors</b>: University of Wisconsin, Madison; United States Department of Defense; National Cancer Institute (NCI); Prostate Cancer Foundation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03358563",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01263951?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Differentiated Thyroid Cancer<br/><b>Interventions</b>: Drug: Everolimus; Drug: Sorafenib<br/><b>Sponsors</b>: Abramson Cancer Center of the University of Pennsylvania; Bayer; Novartis Pharmaceuticals<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01263951",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 21 Dec 2010 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04239014?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Drug: Olaparib; Drug: Ceralasertib; Drug: Placebo to match olaparib<br/><b>Sponsors</b>: AstraZeneca; Parexel<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04239014",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01875367?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Trastuzumab Injectable Solution; Drug: Trastuzumab Injectable Product; Drug: Trastuzumab Injection<br/><b>Sponsor</b>: Spanish Breast Cancer Research Group<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01875367",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 11 Jun 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03888612?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Metastatic<br/><b>Intervention</b>: Drug: ARV-110<br/><b>Sponsor</b>: Arvinas Inc<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03888612",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Mar 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03146637?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Liver Cancer<br/><b>Interventions</b>: Biological: Activated CIK; Biological: CIK<br/><b>Sponsors</b>: Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.; Beijing 302 Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03146637",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 May 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736576?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Device: Wearable device<br/><b>Sponsors</b>: Pfizer; Japan Breast Cancer Research Group (JBCRG)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736576",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02685059?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: MEDI4736 (Anti PD-L1); Drug: Placebo; Drug: nab-Paclitaxel; Drug: Epirubicin; Drug: Cyclophosphamide<br/><b>Sponsors</b>: German Breast Group; AstraZeneca; Celgene<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02685059",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 18 Feb 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "MEtronomic TrEatment Option in Advanced bReast cAncer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02954055?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Paclitaxel; Drug: Cyclophosphamide; Drug: Capecitabine; Drug: Vinorelbine<br/><b>Sponsor</b>: International Breast Cancer Study Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02954055",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 03 Nov 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03915951?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: encorafenib; Drug: binimetinib<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03915951",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Metastatic Solid Cancer Clinical Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739618?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Cancer<br/><b>Interventions</b>: Drug: Keytruda Injectable Product; Drug: Yervoy Injectable Product; Drug: GM-CSF; Procedure: Non-ablative Cryosurgical freezing<br/><b>Sponsor</b>: ImmunSYS, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739618",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04366713?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HER2 Amplified Breast Cancer<br/><b>Interventions</b>: Drug: Neratinib; Drug: Capecitabine; Drug: Loperamide<br/><b>Sponsor</b>: Puma Biotechnology, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04366713",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03415802?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Pancreatic Cancer<br/><b>Intervention</b>: Drug: Nab-paclitaxel and S-1<br/><b>Sponsor</b>: Aiping Zhou<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03415802",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04095234?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer Pain<br/><b>Interventions</b>: Procedure: Acupuncture; Procedure: Massage<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04095234",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 19 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00544765?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: TAC; Drug: NX<br/><b>Sponsors</b>: German Breast Group; Roche Pharma AG; Sanofi; Amgen; University Hospital, Frankfurt<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00544765",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Oct 2007 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00871858?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: anastrozole; Drug: fulvestrant<br/><b>Sponsors</b>: Institut Bergonié; National Cancer Institute, France<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00871858",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 30 Mar 2009 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02272790?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation<br/><b>Interventions</b>: Drug: Adavosertib; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: PLD<br/><b>Sponsor</b>: AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02272790",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Oct 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04690855?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Triple Negative Breast Cancer<br/><b>Interventions</b>: Drug: Talazoparib; Drug: Atezolizumab; Radiation: Radiation<br/><b>Sponsors</b>: Mylin A. Torres, MD; Genentech, Inc.; Pfizer; Emory University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04690855",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 31 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02346526?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Castration-resistant Prostate Cancer; Castration-resistant Prostate Cancer Metastatic to Bone<br/><b>Interventions</b>: Procedure: Blood Tests; Procedure: CT scan and bone scan; Procedure: FACBC PET/MRI in a subset of participants; Drug: Radium-223 dichloride<br/><b>Sponsors</b>: Massachusetts General Hospital; Bayer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02346526",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 27 Jan 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Chemoradiotherapy in Elderly Patients With Oesophagus Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02735057?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Oesophagus Cancer; Elderly Patients<br/><b>Intervention</b>: Drug: Carboplatin<br/><b>Sponsor</b>: Centre Hospitalier Universitaire de Besancon<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02735057",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 12 Apr 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Implementing Pharmacogenetic Testing in Gastrointestinal Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736472?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastrointestinal Cancer<br/><b>Intervention</b>: Device: Pharmacogenetic test<br/><b>Sponsor</b>: University of Pennsylvania<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736472",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01789684?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Other: Active Provider Intervention<br/><b>Sponsors</b>: University of South Florida; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01789684",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 12 Feb 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Impact of Osteopathy on Pain After Breast Cancer Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02621437?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Other: Osteopathy sessions; Other: phone questionnaires<br/><b>Sponsor</b>: Hospices Civils de Lyon<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02621437",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 03 Dec 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04161755?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Biological: RO7198457; Drug: mFOLFIRINOX<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Genentech, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04161755",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 13 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04215146?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer Metastatic<br/><b>Interventions</b>: Drug: Paclitaxel; Biological: Pelareorep; Drug: Avelumab<br/><b>Sponsors</b>: Oncolytics Biotech; PrECOG, LLC.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04215146",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 02 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Immunonutrition and Tolerance to Chemoradiotherapy in Patients With Head-neck Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04611113?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Head and Neck Cancer<br/><b>Interventions</b>: Dietary Supplement: Immunonutrition; Dietary Supplement: Control Nutritional Support<br/><b>Sponsor</b>: IRCCS Policlinico S. Matteo<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04611113",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 02 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02889900?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Recurrent Platinum Resistant Ovarian Cancer<br/><b>Intervention</b>: Drug: cediranib and olaparib<br/><b>Sponsors</b>: AstraZeneca; Myriad Genetic Laboratories, Inc.; Merck Sharp & Dohme Corp.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02889900",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 Sep 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Local Therapy for ER/PR-positive Oligometastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04698252?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Radiation: Radiotherapy; Procedure: Surgery; Other: Radiofrequency ablation<br/><b>Sponsor</b>: Instituto do Cancer do Estado de São Paulo<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04698252",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 06 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "RESISTANCE VERSUS AEROBIC EXERCISES ON Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04656457?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Device: Treadmill; Other: resisted exercises<br/><b>Sponsor</b>: Cairo University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04656457",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04742153?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced or Metastatic Breast Cancer<br/><b>Intervention</b>: Drug: MRG002<br/><b>Sponsor</b>: Shanghai Miracogen Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04742153",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04101851?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer Female; Breast Cancer<br/><b>Intervention</b>: Procedure: omission of SLNB<br/><b>Sponsors</b>: Toralf Reimer, MD PhD; European Breast Cancer Reseach Association of Surgical Trialists; University Medicine Rostock, Rostock, Germany (sponsor); Else Kröner-Fresenius-Stiftung (funding); German Society of Senology (funding)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04101851",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Multi-parametric Breast Ultrasound Imaging as a Potential Biomarker for Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04480437?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Device: mp-BUS data collection<br/><b>Sponsors</b>: Swiss Federal Institute of Technology; Kantonsspital Baden<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04480437",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 21 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03719326?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: TNBC - Triple-Negative Breast Cancer; Ovarian Cancer<br/><b>Interventions</b>: Drug: Etrumadenant; Drug: IPI-549; Drug: Pegylated liposomal doxorubicin (PLD); Drug: nanoparticle albumin-bound paclitaxel (NP)<br/><b>Sponsors</b>: Arcus Biosciences, Inc.; Infinity Pharmaceuticals, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03719326",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 25 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04742361?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Prostate Cancer Recurrent<br/><b>Intervention</b>: Drug: [18F]PSMA-1007<br/><b>Sponsor</b>: ABX advanced biochemical compounds GmbH<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04742361",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 08 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01101438?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: metformin hydrochloride; Other: placebo<br/><b>Sponsors</b>: Canadian Cancer Trials Group; National Cancer Institute (NCI); International Breast Cancer Study Group; ICR-CTSU<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01101438",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 12 Apr 2010 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733417?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Breast Cancer; Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: SHR6390; Drug: famitinib<br/><b>Sponsors</b>: Tianjin Medical University Cancer Institute and Hospital; Jiangsu HengRui Medicine Co., Ltd.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04733417",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02572284?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Radiation: Stereotactic Body Radiation Therapy (SBRT); Procedure: Prostatectomy; Other: Quality of Life Questionnaires<br/><b>Sponsor</b>: H. Lee Moffitt Cancer Center and Research Institute<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02572284",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 08 Oct 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Azacitidine and Pembrolizumab in Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03264404?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreas Cancer<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: Azacitidine<br/><b>Sponsor</b>: Rachael A Safyan, MD<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03264404",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 29 Aug 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03512756?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Interventions</b>: Drug: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus); Drug: Capecitabine, Gemcitabine, and 5-FU<br/><b>Sponsor</b>: Tyme, Inc<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03512756",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "CFI-400945 in Patients With Advanced/Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03624543?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Drug: CFI-400945<br/><b>Sponsors</b>: Canadian Cancer Trials Group; Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03624543",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 10 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00003450?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Peritoneal Cavity Cancer<br/><b>Intervention</b>: Biological: Ad5CMV-p53 gene<br/><b>Sponsors</b>: University of Texas Southwestern Medical Center; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00003450",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Dec 2003 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04166253?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Drug: Vitamin D<br/><b>Sponsor</b>: Damanhour University<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04166253",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 18 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04373031?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Breast Neoplasms<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: IRX 2<br/><b>Sponsors</b>: Providence Health & Services; Merck Sharp & Dohme Corp.; Brooklyn ImmunoTherapeutics, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04373031",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 04 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04538742?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: Trastuzumab deruxtecan; Drug: Durvalumab; Drug: Paclitaxel; Drug: Pertuzumab; Drug: Tucatinib<br/><b>Sponsors</b>: AstraZeneca; Daiichi Sankyo Company, Limited<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04538742",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 04 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Web-Based Communication Education for Breast Cancer Survivorship Care"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03413332?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Other: E-Talkcare; Other: Usual Care<br/><b>Sponsor</b>: Georgetown University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03413332",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 29 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Clinical Trial of Abemaciclib in Combination With Pembrolizumab in Patients With Metastatic or Recurrent Head and Neck Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03938337?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Head and Neck Cancer<br/><b>Interventions</b>: Drug: Cohort 1 Not Previously Treated; Drug: Cohort 2 Treated Previously<br/><b>Sponsor</b>: University of Alabama at Birmingham<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03938337",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 06 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03828799?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Intervention</b>: Combination Product: Folfirinox + regorrafenib<br/><b>Sponsor</b>: Institut du Cancer de Montpellier - Val d'Aurelle<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03828799",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 04 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03225170?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Behavioral: Self Affirmation<br/><b>Sponsor</b>: National Human Genome Research Institute (NHGRI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03225170",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 21 Jul 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03980093?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Behavioral: Education; Behavioral: Values<br/><b>Sponsors</b>: University of Colorado, Boulder; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03980093",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04463771?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Endometrial Cancer<br/><b>Interventions</b>: Drug: retifanlimab; Drug: epacadostat; Drug: pemigatinib<br/><b>Sponsors</b>: Incyte Corporation; GOG Foundation; European Network for Gynaecological Oncological Trial groups(ENGOT)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04463771",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 09 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03555422?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Endometrial Cancer<br/><b>Interventions</b>: Drug: Selinexor; Drug: Matching placebo for selinexor<br/><b>Sponsors</b>: Karyopharm Therapeutics Inc; BGOG - Belgium and Luxembourg Gynaecological Oncology Group; NOGGO - North-Eastern German Society of Gynaecologic Oncology; MITO - Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies; GEICO - Spanish Research Group in Ovarian Cancer; CEEGOG - Central and Eastern European Gynecologic Oncology Group; ISGO - Israel Society of Gynecologic Oncology<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03555422",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 13 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03094884?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Cancer; Esophageal Cancer<br/><b>Interventions</b>: Radiation: Pulsed Low Dose Radiation; Drug: Carboplatin; Drug: Paclitaxel<br/><b>Sponsor</b>: Fox Chase Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03094884",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02655822?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Renal Cell Cancer; Metastatic Castration Resistant Prostate Cancer<br/><b>Interventions</b>: Drug: Ciforadenant; Drug: Ciforadenant + atezolizumab<br/><b>Sponsors</b>: Corvus Pharmaceuticals, Inc.; Genentech, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02655822",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03464942?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Radiation: SABR; Drug: Atezolizumab<br/><b>Sponsors</b>: Peter MacCallum Cancer Centre, Australia; Trans Tasman Radiation Oncology Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03464942",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 14 Mar 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04478266?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Letrozole-matching placebo; Drug: SAR439859-matching placebo; Drug: SAR439859; Drug: Ibrance; Drug: Letrozole; Drug: Goserelin<br/><b>Sponsor</b>: Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04478266",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 20 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03711058?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer; Colon Cancer<br/><b>Interventions</b>: Drug: Copanlisib; Drug: Nivolumab<br/><b>Sponsors</b>: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Bayer; Bristol-Myers Squibb<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03711058",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 18 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01463605?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Esophageal Cancer<br/><b>Intervention</b>: Drug: Nimotuzumab<br/><b>Sponsor</b>: Chinese Academy of Medical Sciences<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01463605",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 02 Nov 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04488159?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colon Cancer Stage III<br/><b>Interventions</b>: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Fluorouracil; Drug: Leucovorin; Device: Immunoscore® assay; Other: Physical exercise<br/><b>Sponsor</b>: Johannes Laengle, MD, PhD<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04488159",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04385433?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: EXPERIMENTAL ARM; Other: CONTROL GROUP; Radiation: Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)<br/><b>Sponsor</b>: Institut du Cancer de Montpellier - Val d'Aurelle<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04385433",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 13 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase 2 Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04191382?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: SAR439859; Drug: letrozole<br/><b>Sponsor</b>: Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04191382",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04634071?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Smoking Cessation; Cancer, Treatment-Related<br/><b>Interventions</b>: Drug: Varenicline; Drug: Bupropion; Drug: Long-acting nicotine replacement therapy; Behavioral: Low-intensity counseling; Behavioral: High-intensity counseling; Other: No nicotine replacement therapy; Drug: Nicotine Replacement Products<br/><b>Sponsor</b>: Joseph Valentino, MD<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04634071",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 18 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "18F-PSMA-1007 PET/CT Imaging in Patients With Biochemically Recurrent or High-risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733768?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Diagnostic Test: 18F-PSMA-1007<br/><b>Sponsor</b>: University of Alberta<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04733768",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02258451?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Interventions</b>: Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Drug: Placebo (saline); Drug: Exemestane; Drug: Everolimus<br/><b>Sponsor</b>: Bayer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02258451",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Oct 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04732598?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Paclitaxel + bevacizumab therapy; Drug: Paclitaxel + bevacizumab + atezolizumab<br/><b>Sponsor</b>: Japanese Foundation for Cancer Research<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04732598",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04189055?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer Colorectal<br/><b>Interventions</b>: Drug: Cetuximab; Drug: Irinotecan<br/><b>Sponsor</b>: GCS IHFB Cognacq-Jay<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04189055",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03980054?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Pyrotinib; Drug: Placebo<br/><b>Sponsor</b>: Jiangsu HengRui Medicine Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03980054",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01957332?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Breast Cancer<br/><b>Intervention</b>: Procedure: Molecular imaging<br/><b>Sponsors</b>: University Medical Center Groningen; VU University Medical Center; University Medical Center Nijmegen<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01957332",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 Oct 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of LY3484356 in Women With Breast Cancer Before Having Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04647487?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Drug: LY3484356<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04647487",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03820830?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer Recurrent<br/><b>Interventions</b>: Drug: Palbociclib 125mg; Drug: Standard endocrine therapy<br/><b>Sponsors</b>: International Breast Cancer Study Group; Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03820830",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 29 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02171325?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small Cell Lung Cancer<br/><b>Intervention</b>: Drug: irinotecan<br/><b>Sponsor</b>: Guangdong Association of Clinical Trials<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02171325",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Jun 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02772731?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Procedure: Partial mastectomy plus additional Shave Margin; Procedure: Partial mastectomy<br/><b>Sponsor</b>: Yale University<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02772731",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 May 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Prophylactic Preoperative Hyperthermic Intraperitoneal Chemotherapy in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04597294?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastric Cancer<br/><b>Interventions</b>: Combination Product: FLOT4 + HIPEC + Surgery; Combination Product: FLOT4 + Surgery<br/><b>Sponsor</b>: Jagiellonian University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04597294",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 22 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739670?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Triple Negative Breast Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Bevacizumab; Drug: Gemcitabine; Drug: Carboplatin<br/><b>Sponsor</b>: Peter MacCallum Cancer Centre, Australia<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739670",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02826512?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Drug: Niraparib<br/><b>Sponsors</b>: The Netherlands Cancer Institute; Tesaro, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02826512",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 11 Jul 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04298983?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Abemaciclib 150 MG by mouth twice daily; Drug: Androgen deprivation therapy (ADT); Radiation: Radiation Therapy<br/><b>Sponsor</b>: University of Alabama at Birmingham<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04298983",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Mar 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04744831?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Colorectal Cancer<br/><b>Interventions</b>: Drug: DS-8201a 5.4 mg/kg Q3W; Drug: DS-8201a 6.4 mg/kg Q3W<br/><b>Sponsors</b>: Daiichi Sankyo, Inc.; AstraZeneca; Syneos Health<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04744831",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04713189?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breakthrough Cancer Pain<br/><b>Interventions</b>: Drug: Inhaled fentanyl aerosol; Drug: Placebo<br/><b>Sponsor</b>: Lee's Pharmaceutical Limited<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04713189",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "CAR T Cell Immunotherapy for Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03323944?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Pancreatic Cancer; Cancer of the Pancreas<br/><b>Intervention</b>: Biological: huCART-meso cells<br/><b>Sponsors</b>: University of Pennsylvania; Stand Up To Cancer; Lustgarten<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03323944",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Oct 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03393845?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: Fulvestrant<br/><b>Sponsors</b>: Nancy Chan, MD; Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03393845",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03488693?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Radiation: Radiation; Other: No Radiation<br/><b>Sponsors</b>: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03488693",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02854618?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Other: additional blood sample<br/><b>Sponsor</b>: Centre Hospitalier Universitaire de Besancon<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02854618",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04264208?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: 68-Ga RM2.; Drug: 68-Ga PSMA11; Device: PET/MRI<br/><b>Sponsor</b>: Andrei Iagaru<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04264208",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 11 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03874325?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Hormone Receptor Positive Tumor<br/><b>Interventions</b>: Drug: Durvalumab; Drug: Anastrozole 1mg; Drug: Letrozole 2.5mg; Drug: Exemestane 25 MG<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03874325",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Mar 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04191499?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: GDC-0077; Drug: Placebo; Drug: Palbociclib; Drug: Fulvestrant<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04191499",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "AASUR in High Risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02772588?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: ARN-509; Drug: Abiraterone; Drug: Leuprolide; Radiation: stereotactic, ultra-fractionated radiotherapy<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Janssen Pharmaceuticals; Weill Medical College of Cornell University; University of Michigan<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02772588",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 May 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Prostate Cancer (PREOP-PSMA )."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04745871?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Diagnostic Test: PSMA PET/CT<br/><b>Sponsor</b>: University Hospital, Brest<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04745871",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04737109?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Castrate Resistant Prostate Cancer<br/><b>Interventions</b>: Drug: Ipatasertib; Drug: Darolutamide; Drug: Androgen Deprivation Therapy<br/><b>Sponsor</b>: David VanderWeele<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04737109",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02933255?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Biological: PROSTVAC-V/F; Drug: Nivolumab<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02933255",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 14 Oct 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02510456?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Device: Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort; Device: Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort<br/><b>Sponsors</b>: Boston Medical Center; American Cancer Society, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02510456",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Jul 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03271047?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: MSS; RAS-mutant Colorectal Cancer<br/><b>Interventions</b>: Drug: binimetinib; Drug: nivolumab; Drug: ipilimumab<br/><b>Sponsors</b>: Pfizer; Bristol-Myers Squibb<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03271047",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02063724?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Biological: HER-2 pulsed Dendritic Cell Vaccine<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Abramson Cancer Center of the University of Pennsylvania<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02063724",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 14 Feb 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733118?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Early Breast Cancer<br/><b>Intervention</b>: Drug: Trastuzumab and Pertuzumab (FDC SC) and T-DM1<br/><b>Sponsors</b>: MedSIR; Hoffmann-La Roche<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04733118",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04729608?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Platinum-resistant Ovarian Cancer<br/><b>Interventions</b>: Drug: AVB-S6-500; Drug: Paclitaxel; Other: Placebo<br/><b>Sponsors</b>: Aravive, Inc.; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04729608",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety Assessment of IRE of Localized Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04192890?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Prostate Adenocarcinoma<br/><b>Intervention</b>: Device: Focal irreversible electroporation of the prostate cancer<br/><b>Sponsor</b>: I.M. Sechenov First Moscow State Medical University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04192890",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03860272?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Cancer<br/><b>Interventions</b>: Drug: AGEN1181; Drug: AGEN2034<br/><b>Sponsor</b>: Agenus Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03860272",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Mar 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04521361?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bone Metastatic Castration-resistant Prostate Cancer<br/><b>Intervention</b>: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04521361",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 20 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Role of TCM on ERAS of Rectal Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04749381?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Combination Product: acupoint with TCM; Combination Product: acupoint with placebo<br/><b>Sponsor</b>: Beijing Cancer Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04749381",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02763566?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Abemaciclib; Drug: Anastrozole; Drug: Letrozole; Drug: Placebo; Drug: Fulvestrant<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02763566",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 May 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03726879?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Placebo; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Trastuzumab; Drug: Pertuzumab; Drug: Trastuzumab Emtansine<br/><b>Sponsors</b>: Hoffmann-La Roche; Chugai Pharmaceutical<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03726879",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 01 Nov 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Sexual and Urological Rehabilitation to Men Operated for Prostate Cancer and Their Partners"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02103088?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Behavioral: Sexual and urological intervention<br/><b>Sponsors</b>: Danish Cancer Society; The Capital Region Research Foundation for Health Research Denmark; Department of Urology Rigshospitalet Copenhagen Denmark; Clinic for Sexology and Center for Psychiatry Copenhagen Denmark; Department of Ergotherapy and Physiotherapy Rigshospitalet Copenhagen Denmark<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02103088",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 03 Apr 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Abemaciclib and Letrozole to Treat Endometrial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04393285?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Endometrial Cancer<br/><b>Interventions</b>: Drug: Abemaciclib; Drug: Letrozole<br/><b>Sponsors</b>: Gynecologic Oncology Group; Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04393285",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Shared Decision-making and Colorectal Cancer Screening"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04748380?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Other: CRC decision aid pamphlet; Other: Home Safety Pamphlet<br/><b>Sponsor</b>: Simmons University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04748380",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03284957?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: SAR439859; Drug: palbociclib; Drug: alpelisib<br/><b>Sponsor</b>: Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03284957",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 15 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03712943?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Metastatic Colorectal Cancer; Colon Cancer<br/><b>Interventions</b>: Drug: Regorafenib; Drug: Nivolumab<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Bristol-Myers Squibb<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03712943",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 19 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04728139?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Diagnostic Test: glypican 3<br/><b>Sponsor</b>: Assiut University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04728139",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Development of a Clinical and Biological Database in Rectum Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04006951?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Neoplasms<br/><b>Intervention</b>: Other: Biological collection<br/><b>Sponsor</b>: Institut du Cancer de Montpellier - Val d'Aurelle<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04006951",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Jul 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04643366?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Drug: Chemotherapy; Radiation: Radiation Therapy<br/><b>Sponsor</b>: Virginia Commonwealth University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04643366",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 25 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03056638?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Degarelix; Radiation: stereotactic body radiosurgery (SBRT)<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Ferring Pharmaceuticals; University of Texas Southwestern Medical Center; University of Michigan<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03056638",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 17 Feb 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Proactive Outreach and Shared Decision Making in Improving Lung Cancer Screening Rates in Primary Care Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03929926?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Interventions</b>: Other: Best Practice; Behavioral: Cancer Educational Materials; Other: Behavioral, Psychological or Informational Intervention; Other: Counseling<br/><b>Sponsor</b>: Thomas Jefferson University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03929926",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 29 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03332797?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: GDC-9545; Drug: Palbociclib; Drug: LHRH Agonist<br/><b>Sponsor</b>: Genentech, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03332797",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 06 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "RNA Precision Oncology in Advanced Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04476537?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Intervention</b>: Other: OncoTreat<br/><b>Sponsor</b>: Columbia University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04476537",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 20 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02139358?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Gemcitabine; Drug: Trastuzumab; Drug: Pertuzumab<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Genentech, Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02139358",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 15 May 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Intraoperative Detection of Residual Cancer in Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03321929?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Combination Product: LUM Imaging System<br/><b>Sponsors</b>: Lumicell, Inc.; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03321929",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Oct 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03725059?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab (K); Drug: Placebo (P); Drug: Paclitaxel (X); Drug: Doxorubicin (A); Drug: Epirubicin (E); Drug: Cyclophosphamide (C); Drug: Endocrine therapy; Radiation: Radiation therapy; Procedure: Surgery<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03725059",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pembrolizumab and GM-CSF in Biliary Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02703714?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Biliary Cancer<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: Sargramostim<br/><b>Sponsors</b>: Robin Kate Kelley; American Society of Clinical Oncology; Merck Sharp & Dohme Corp.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02703714",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 09 Mar 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02603341?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Radiation: Photon; Radiation: Proton<br/><b>Sponsors</b>: Abramson Cancer Center of the University of Pennsylvania; Patient-Centered Outcomes Research Institute<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02603341",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 11 Nov 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03702179?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Invasive Bladder Cancer<br/><b>Interventions</b>: Drug: Durvalumab; Drug: Tremelimumab; Radiation: Radiotherapy<br/><b>Sponsors</b>: Spanish Oncology Genito-Urinary Group; AstraZeneca; MFAR<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03702179",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "OH2 Oncolytic Viral Therapy in Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04637698?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Intervention</b>: Biological: OH2 injection<br/><b>Sponsor</b>: Wuhan Binhui Biotechnology Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04637698",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 20 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04591028?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastric Cancer<br/><b>Intervention</b>: Drug: Indocyanine green<br/><b>Sponsor</b>: Mayo Clinic<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04591028",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Living Well: A Web-Based Program for Ovarian Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04533763?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Behavioral: Technology-based Mindful Living program; Behavioral: Technology-based Healthy Lifestyles program<br/><b>Sponsors</b>: Susan Lutgendorf; University of Washington; University of Miami; University of Iowa<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04533763",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04719273?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Endometrial Cancer<br/><b>Interventions</b>: Drug: Onapristone, Extended-Release Formulation; Drug: Anastrozole 1mg; Other: Quality-of-Life Assessment; Other: Questionnaire Administration<br/><b>Sponsor</b>: Thomas Jefferson University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04719273",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 22 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04511026?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Endometrial Cancer<br/><b>Interventions</b>: Drug: Lymphoseek; Device: Single Photon Emission Computed Tomography (SPECT); Drug: Indocyanine Green (ICG); Device: Neoprobe Gamma Detection System NPB11L(Model1102)<br/><b>Sponsor</b>: Stanford University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04511026",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 12 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04745975?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Cancer<br/><b>Interventions</b>: Drug: Personalized treatment guided by mini-PDX and RNA sequencing; Drug: Nab paclitaxel; Drug: Eribulin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Capecitabine<br/><b>Sponsor</b>: Fudan University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04745975",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03531320?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastrointestinal Cancer; Biliary Tract Cancer<br/><b>Intervention</b>: Drug: D07001-softgel capsules<br/><b>Sponsor</b>: InnoPharmax Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03531320",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 21 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03443661?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Locally Advanced Rectal Cancer<br/><b>Intervention</b>: Drug: FOLFOXIRI<br/><b>Sponsor</b>: Aiping Zhou<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03443661",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 23 Feb 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738630?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bladder Cancer<br/><b>Intervention</b>: Drug: HX008<br/><b>Sponsor</b>: Taizhou Hanzhong biomedical co. LTD<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04738630",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04486352?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Endometrial Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Bevacizumab; Drug: Ipatasertib; Drug: Talazoparib<br/><b>Sponsors</b>: Alliance Foundation Trials, LLC.; Genentech, Inc.; Foundation Medicine; Pfizer<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04486352",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Program for Improved Family Screening for Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03620877?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Behavioral: Personalized intervention<br/><b>Sponsor</b>: Poitiers University Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03620877",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 08 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03555877?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer Metastatic<br/><b>Interventions</b>: Drug: Ribociclib; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Fulvestrant<br/><b>Sponsor</b>: German Breast Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03555877",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04484142?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Intervention</b>: Drug: DS-1062a<br/><b>Sponsors</b>: Daiichi Sankyo, Inc.; AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04484142",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Group Interventions for Breast Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01775085?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer Survivor<br/><b>Interventions</b>: Behavioral: manualized group intervention; Behavioral: standardized, manualized group intervention<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; American Cancer Society, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01775085",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 24 Jan 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04533672?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bladder Cancer<br/><b>Intervention</b>: Diagnostic Test: MRI Sequences<br/><b>Sponsors</b>: University of Zurich; Swiss National Science Foundation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04533672",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 31 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04059484?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer Metastatic<br/><b>Interventions</b>: Drug: Amcenestrant; Drug: Fulvestrant; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Tamoxifen<br/><b>Sponsor</b>: Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04059484",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03781154?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Behavioral: Group Exercise<br/><b>Sponsors</b>: University of Colorado, Denver; National Cancer Institute (NCI); American Cancer Society, Inc.; Colorado State University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03781154",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 19 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04556617?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Castration-resistant Prostate Cancer<br/><b>Interventions</b>: Drug: PLX2853; Drug: Olaparib; Drug: Abiraterone acetate; Drug: Prednisone<br/><b>Sponsor</b>: Plexxikon<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04556617",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 21 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02628041?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Radiation: Permanent Iodine-125 seed implant; Radiation: High-Dose-rate Prostate Brachytherapy<br/><b>Sponsors</b>: CHU de Quebec-Universite Laval; Université de Montréal; Sunnybrook Health Sciences Centre<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02628041",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 11 Dec 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00492999?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Metastatic Cancer<br/><b>Interventions</b>: Drug: dexamethasone; Drug: floxuridine; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00492999",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 27 Jun 2007 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04750382?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple-negative Breast Cancer<br/><b>Intervention</b>: Drug: HX008+Cisplatin+Gemcitabine<br/><b>Sponsor</b>: Taizhou Hanzhong biomedical co. LTD<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04750382",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04633252?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer Of Prostate; Prostate Neoplasms<br/><b>Interventions</b>: Drug: ADT; Drug: Prednisone; Drug: M7824; Drug: Docetaxel; Drug: M9241<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04633252",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 18 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01774071?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: 89Zr- DFO-MSTP2109A; Drug: 89Zr DFO-MSTP2109A<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Genentech, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01774071",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 23 Jan 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03850795?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer Metastatic; Castration-resistant Prostate Cancer<br/><b>Interventions</b>: Drug: HC-1119; Drug: Enzalutamide<br/><b>Sponsor</b>: Hinova Pharmaceuticals USA, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03850795",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 22 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04190056?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Tamoxifen; Drug: Vorinostat<br/><b>Sponsors</b>: University of California, San Francisco; Merck Sharp & Dohme Corp.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04190056",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02981524?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Interventions</b>: Drug: CY; Biological: GVAX; Drug: Pembrolizumab<br/><b>Sponsors</b>: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Merck Sharp & Dohme Corp.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02981524",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 05 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03784755?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Metastatic<br/><b>Interventions</b>: Radiation: Ablative Radiation Therapy; Other: Standard of care<br/><b>Sponsors</b>: Canadian Cancer Trials Group; TerSera Therapeutics LLC; Canadian Cancer Society (CCS)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03784755",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03945721?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Triple Negative Breast Cancer; Residual Disease<br/><b>Interventions</b>: Drug: Niraparib; Radiation: Radiation Therapy<br/><b>Sponsors</b>: Massachusetts General Hospital; Tesaro, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03945721",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 10 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Avelumab With Chemoradiation in Locally Advanced Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03299660?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Drug: Avelumab; Drug: 5 Fluorouracil; Drug: Capecitabine Pill; Radiation: Radiotherapy; Procedure: Surgical Resection<br/><b>Sponsor</b>: Peter MacCallum Cancer Centre, Australia<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03299660",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 03 Oct 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04113122?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Testicular Cancer<br/><b>Interventions</b>: Diagnostic Test: Skin biopsy; Diagnostic Test: Subcutaneous fat biopsy<br/><b>Sponsors</b>: University Medical Center Groningen; Dutch Cancer Society<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04113122",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 02 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02339168?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Enzalutamide; Drug: Metformin Hydrochloride<br/><b>Sponsors</b>: University of California, Davis; National Cancer Institute (NCI); Medivation, Inc.; Astellas Pharma Inc<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02339168",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 15 Jan 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02077335?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Radiation: HDR brachytherapy monotherapy<br/><b>Sponsor</b>: CSSS de Gatineau<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02077335",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Mar 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04734665?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor<br/><b>Intervention</b>: Drug: Niraparib-Bevacizumab<br/><b>Sponsors</b>: Yonsei University; Takeda<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04734665",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03511664?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: 177Lu-PSMA-617; Other: Best supportive/best standard of care<br/><b>Sponsor</b>: Endocyte<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03511664",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 30 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04745988?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastric Cancer<br/><b>Interventions</b>: Drug: Lenvatinib; Drug: Pembrolizumab<br/><b>Sponsor</b>: National Cancer Center Hospital East<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04745988",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "89Zr-atezolizumab PET Scan and Lobular Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04222426?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lobular Metastatic Breast Cancer<br/><b>Intervention</b>: Other: 89Zr-atezolizumab PET scans<br/><b>Sponsor</b>: University Medical Center Groningen<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04222426",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 10 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04722341?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colo-rectal Cancer<br/><b>Interventions</b>: Behavioral: Time-Restricted Eating (TRE); Behavioral: Control<br/><b>Sponsors</b>: Cedars-Sinai Medical Center; National Cancer Institute (NCI); University of Alabama at Birmingham<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04722341",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04486651?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Stomach Cancer<br/><b>Interventions</b>: Drug: Irinotecan Hydrochloride Injection; Drug: HX008; Drug: Placebo<br/><b>Sponsor</b>: Taizhou Hanzhong biomedical co. LTD<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04486651",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04114825?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Recurrent<br/><b>Interventions</b>: Biological: RV001V; Other: Placebo<br/><b>Sponsor</b>: RhoVac APS<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04114825",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 03 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "18F-FLT-PET in Breast Cancer (MK-0000-139)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01015131?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Radiation: 18F-FLT-PET/CT Imaging<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01015131",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 18 Nov 2009 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03364673?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Other: Fitness Tracker; Other: Social Incentive (Way to Health)<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03364673",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 06 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03768570?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bladder Cancer<br/><b>Intervention</b>: Drug: Durvalumab<br/><b>Sponsors</b>: Canadian Cancer Trials Group; AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03768570",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 07 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04322539?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Colorectal Cancer; Metastatic Colon Cancer<br/><b>Interventions</b>: Drug: Fruquintinib; Drug: Placebo<br/><b>Sponsor</b>: Hutchison Medipharma Limited<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04322539",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03638193?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Intervention</b>: Biological: CART-meso cells<br/><b>Sponsors</b>: Shenzhen BinDeBio Ltd.; The First Affiliated Hospital with Nanjing Medical University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03638193",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 20 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Abiraterone Acetate for Castrate Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01961843?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Abiraterone; Drug: Prednisone<br/><b>Sponsor</b>: Massachusetts General Hospital<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01961843",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 11 Oct 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04466891?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HER2-amplified Biliary Tract Cancers<br/><b>Interventions</b>: Drug: ZW25 (Zanidatamab); Diagnostic Test: In situ hybridization (ISH)-based companion diagnostic assay; Diagnostic Test: Immunohistochemistry (IHC)-based companion diagnostic assay<br/><b>Sponsors</b>: Zymeworks Inc.; BeiGene, Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04466891",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 10 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03575819?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Metastatic<br/><b>Intervention</b>: Drug: FOR46<br/><b>Sponsor</b>: Fortis Therapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03575819",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 03 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04584112?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple-Negative Breast Cancer<br/><b>Interventions</b>: Drug: Tiragolumab; Drug: Atezolizumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Granulocyte-macrophage colony-stimulating factor (GM-CSF)<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04584112",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 12 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Short-term Testosterone Replacement in Testicular Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03339635?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Testicular Cancer<br/><b>Interventions</b>: Drug: Androgel (Testosterone gel); Drug: Placebo gel<br/><b>Sponsor</b>: University Medical Center Groningen<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03339635",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 13 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03646162?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Metastatic<br/><b>Interventions</b>: Drug: Veru-944; Drug: Placebo<br/><b>Sponsor</b>: Veru Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03646162",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03262935?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: (vic-)trastuzumab duocarmazine; Drug: Physician's choice<br/><b>Sponsor</b>: Byondis B.V.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03262935",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Aug 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04740918?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: Trastuzumab Emtansine; Drug: Atezolizumab; Other: Placebo<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04740918",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03713021?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Oropharyngeal Cancer<br/><b>Intervention</b>: Device: TraceIT Tissue Marker<br/><b>Sponsor</b>: Washington University School of Medicine<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03713021",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 19 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Trial of Tisotumab Vedotin in Cervical Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03438396?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cervical Cancer<br/><b>Intervention</b>: Drug: tisotumab vedotin<br/><b>Sponsors</b>: Genmab; Seagen Inc.; European Network of Gynaecological Oncological Trial Groups (ENGOT); Belgian Gynaecological Oncology Group; Gynecologic Oncology Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03438396",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Feb 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04162535?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Drug: Lidocaine 1% Injectable Solution; Biological: Blood extraction; Drug: Sevoflurane; Drug: Propofol<br/><b>Sponsors</b>: Iuliu Hatieganu University of Medicine and Pharmacy; Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor; Prof. Dr. I. Chiricuta Institute of Oncology<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04162535",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Atezolizumab Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04148911?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple-Negative Breast Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Nab-Paclitaxel; Drug: Paclitaxel<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04148911",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 04 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Cardiac Safety Study in Patients With HER2 + Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01904903?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HER2 Positive Breast Cancer; Left Ventricular Function Systolic Dysfunction<br/><b>Interventions</b>: Drug: Trastuzumab; Drug: Pertuzumab; Drug: Ado Trastuzumab Emtansine<br/><b>Sponsors</b>: Medstar Health Research Institute; Genentech, Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01904903",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 22 Jul 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Identification of the Optimal Combination Dosing Schedule of Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04730544?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer Metastatic; MSI-H Colorectal Cancer<br/><b>Interventions</b>: Drug: Nivolumab; Drug: Ipilimumab<br/><b>Sponsors</b>: GERCOR - Multidisciplinary Oncology Cooperative Group; Bristol-Myers Squibb<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04730544",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02106507?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: apalutamide; Drug: Everolimus<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Aragon Pharmaceuticals, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02106507",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 Apr 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04524871?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Liver Cancers<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Bevacizumab; Drug: Tiragolumab; Drug: Tocilizumab<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04524871",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01079780?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride<br/><b>Sponsors</b>: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01079780",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Mar 2010 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Adjuvant Low Dose Aspirin in Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02647099?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Drug: Acetylsalicylic acid; Drug: Placebo<br/><b>Sponsors</b>: Anna Martling; Uppsala University Hospital; Skane University Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02647099",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 06 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04630353?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer<br/><b>Interventions</b>: Drug: HB-201 IT; Drug: HB-201 IV<br/><b>Sponsor</b>: Hookipa Biotech GmbH<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04630353",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 16 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02599714?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced and Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: AZD2014; Drug: Palbociclib; Drug: Fulvestrant<br/><b>Sponsor</b>: AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02599714",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Nov 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01717053?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Abiraterone acetate; Drug: Androgen deprivation; Radiation: Radiation Therapy; Drug: Prednisone<br/><b>Sponsors</b>: Duke University; Janssen Pharmaceuticals<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01717053",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Oct 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01901094?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Stage II Breast Cancer; Stage IIIA Breast Cancer<br/><b>Interventions</b>: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy<br/><b>Sponsors</b>: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01901094",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 17 Jul 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03496805?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Recurrent Prostate Cancer<br/><b>Interventions</b>: Drug: MGE; Other: Placebo; Other: ADT<br/><b>Sponsor</b>: Wake Forest University Health Sciences<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03496805",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03148795?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Drug: Talazoparib<br/><b>Sponsors</b>: Pfizer; Medivation, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03148795",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 May 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04300647?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cervical Cancer<br/><b>Interventions</b>: Drug: Tiragolumab; Drug: Atezolizumab<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04300647",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of CFI-400945 Fumarate in Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01954316?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Cancer<br/><b>Intervention</b>: Drug: CFI-400945<br/><b>Sponsors</b>: University Health Network, Toronto; Princess Margaret Cancer Foundation; California Institute for Regenerative Medicine (CIRM)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01954316",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 Oct 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Impact of a Breast cAncer Survivorship Interprofessional Community Care Model"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04660188?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Survivorship; Breast Cancer<br/><b>Intervention</b>: Other: Multidisciplinary collaborative care arm<br/><b>Sponsors</b>: National Cancer Centre, Singapore; National University, Singapore; SingHealth Polyclinics<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04660188",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 09 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04126733?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Drug: Regorafenib (BAY73-4506, Stivarga); Biological: Nivolumab (Opdivo)<br/><b>Sponsors</b>: Bayer; Bristol-Myers Squibb<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04126733",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 15 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03000374?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Drug: Panitumumab; Drug: 5Fluorouracil; Drug: Oxaliplatin; Drug: Leucovorin<br/><b>Sponsors</b>: Grupo Espanol Multidisciplinario del Cancer Digestivo; Pivotal S.L.; Amgen<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03000374",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 22 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02512172?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Drug: Oral CC - 486; Drug: Romidepsin; Drug: MK - 3475<br/><b>Sponsors</b>: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Merck Sharp & Dohme Corp.; Celgene Corporation<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02512172",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 Jul 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Using Behavioral Science to Improve Colorectal Cancer Screening Rates With Mailed FIT Kits"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04746469?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer Screening<br/><b>Intervention</b>: Behavioral: Delayed automated phone call<br/><b>Sponsor</b>: University of California, Los Angeles<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04746469",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736199?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Drug: Darolutamide (Nubeqa, BAY1841788); Drug: Placebo; Other: Androgen deprivation therapy (ADT)<br/><b>Sponsors</b>: Bayer; Orion Corporation, Orion Pharma<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736199",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03649321?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer of Pancreas<br/><b>Interventions</b>: Drug: BGB324; Drug: Nab-paclitaxel; Drug: Gemcitabine; Drug: Cisplatin<br/><b>Sponsors</b>: University of Texas Southwestern Medical Center; Triligent International; Translational Genomics Research Institute; BerGenBio ASA<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03649321",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03908788?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Intervention</b>: Device: Intplex test<br/><b>Sponsor</b>: Institut du Cancer de Montpellier - Val d'Aurelle<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03908788",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02725424?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastric Cancer<br/><b>Interventions</b>: Drug: S-1; Drug: Trastuzumab; Drug: Oxaliplatin; Drug: Docetaxel<br/><b>Sponsor</b>: Chinese Academy of Medical Sciences<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02725424",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Apr 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02210559?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer (Unresectable)<br/><b>Interventions</b>: Drug: FG-3019; Drug: Gemcitabine; Drug: Nab-paclitaxel<br/><b>Sponsor</b>: FibroGen<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02210559",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 06 Aug 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04685135?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: MRTX849; Drug: Docetaxel<br/><b>Sponsor</b>: Mirati Therapeutics Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04685135",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 28 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04550897?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer Metastatic<br/><b>Intervention</b>: Drug: BM7PE<br/><b>Sponsor</b>: Oslo University Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04550897",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03753334?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Dietary Supplement: MAG-EPA; Dietary Supplement: Placebo group<br/><b>Sponsor</b>: CHU de Quebec-Universite Laval<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03753334",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 27 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Electronic Symptom Monitoring Intervention for Hospitalized Patients With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03396510?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Intervention</b>: Other: IMPROVED intervention<br/><b>Sponsors</b>: Massachusetts General Hospital; Alliance for Clinical Trials in Oncology Cancer Control Program (CCP)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03396510",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study)."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03355157?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Breast Cancer<br/><b>Intervention</b>: Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)<br/><b>Sponsors</b>: German Breast Group; Pfizer; AMS Advanced Medical Services GmbH<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03355157",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02067741?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Breast Adenocarcinoma; Breast Cancer<br/><b>Intervention</b>: Drug: CR1447<br/><b>Sponsor</b>: Swiss Group for Clinical Cancer Research<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02067741",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 20 Feb 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase 2 Trial of Maintenance Vigil for High Risk Stage IIIb-IV Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02346747?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Ovarian Neoplasms<br/><b>Interventions</b>: Biological: Vigil; Biological: Placebo<br/><b>Sponsor</b>: Gradalis, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02346747",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 27 Jan 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03154281?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Ovarian Cancer<br/><b>Interventions</b>: Drug: niraparib; Drug: everolimus<br/><b>Sponsor</b>: Avera McKennan Hospital & University Health Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03154281",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 May 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03424005?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Cancer<br/><b>Interventions</b>: Drug: Capecitabine; Drug: Atezolizumab; Drug: Ipatasertib; Drug: SGN-LIV1A; Drug: Bevacizumab; Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin); Drug: Selicrelumab; Drug: Tocilizumab; Drug: Nab-Paclitaxel; Drug: Sacituzumab Govitecan<br/><b>Sponsors</b>: Hoffmann-La Roche; Seagen Inc.; Immunomedics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03424005",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 06 Feb 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04656652?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: DS-1062a; Drug: Docetaxel<br/><b>Sponsors</b>: Daiichi Sankyo, Inc.; AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04656652",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04711252?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: ER-Positive HER2-Negative Breast Cancer<br/><b>Interventions</b>: Drug: AZD9833; Drug: Anastrozole; Drug: Anastrozole placebo; Drug: AZD9833 placebo; Drug: Palbociclib; Drug: Luteinizing hormone-releasing hormone (LHRH) agonist<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04711252",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 15 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03498716?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Paclitaxel; Drug: Dose-dense Doxorubicin or dose-dense Epirubicin; Drug: Cyclophosphamide<br/><b>Sponsors</b>: Hoffmann-La Roche; Breast International Group; Alliance Foundation Trials (AFT); Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU); Frontier Science and Technology Research Foundation Inc (FS)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03498716",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 17 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03785873?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Biliary Tract Cancer<br/><b>Interventions</b>: Drug: Nivolumab; Drug: Nanoliposomal-Irinotecan; Drug: 5-Fluorouracil; Drug: Leucovorin<br/><b>Sponsors</b>: University of Michigan Rogel Cancer Center; Ipsen; Bristol-Myers Squibb<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03785873",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02861573?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Castration-Resistant Prostate Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab 200 mg; Drug: Olaparib 400 mg; Drug: Docetaxel 75 mg/m^2; Drug: Prednisone 5 mg; Drug: Enzalutamide 160 mg; Other: Dexamethasone 8 mg; Drug: Olaparib 300 mg; Drug: Abiraterone acetate 1000 mg; Drug: Lenvatinib; Biological: Vibostolimab (+) Pembrolizumab coformulation; Drug: Carboplatin; Drug: Etoposide<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02861573",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04134897?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rectal Neoplasms Malignant; Rectum Carcinoma; Rectal Cancer<br/><b>Interventions</b>: Drug: Capecitabine; Drug: Oxaliplatin; Radiation: Radiotherapy; Procedure: Rectal cancer surgery<br/><b>Sponsor</b>: Blokhin's Russian Cancer Research Center<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT04134897",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01309230?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Intervention</b>: Biological: Vigil™<br/><b>Sponsor</b>: Gradalis, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01309230",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Mar 2011 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04750122?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HER2-positive Early Breast Cancer<br/><b>Intervention</b>: Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning<br/><b>Sponsor</b>: Peking University People's Hospital<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04750122",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Single Arm, Open, Exploratory Clinical Trial to Evaluate Efficacy and Safety for Combination Treatment of Replication Competent Adenovirus Double Suicide Gene Therapy and Radiation Therapy in Patients With Locally Advanced or Borderline Resectable Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739046?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreas Cancer<br/><b>Intervention</b>: Drug: Theragene arm<br/><b>Sponsors</b>: Seoul National University Bundang Hospital; NewGenPharm Incoporation<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739046",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04735900?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Intervention</b>: Procedure: Liquid biopsy sampling<br/><b>Sponsors</b>: University Hospital, Antwerp; Amgen<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04735900",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01385059?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Stage III Prostate Cancer; Stage IV Prostate Cancer<br/><b>Interventions</b>: Drug: axitinib; Procedure: therapeutic conventional surgery; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis<br/><b>Sponsors</b>: City of Hope Medical Center; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01385059",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Jun 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Combination Therapy for First Line Treatment of Advanced Cervical Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04731038?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Cervical Cancer<br/><b>Intervention</b>: Drug: Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin<br/><b>Sponsor</b>: Ruijin Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04731038",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02536339?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: Pertuzumab; Drug: Trastuzumab<br/><b>Sponsor</b>: Genentech, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02536339",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 31 Aug 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04103697?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rectal Neoplasms Malignant; Rectum Carcinoma; Rectal Cancer<br/><b>Interventions</b>: Drug: Capecitabine; Drug: Oxaliplatin; Radiation: Radiotherapy; Procedure: Rectal cancer surgery<br/><b>Sponsor</b>: Blokhin's Russian Cancer Research Center<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT04103697",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 25 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Appropriate Timing of Surgery After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03287843?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasm, Rectum<br/><b>Interventions</b>: Procedure: Total mesorectal excision before 56 days (4-8 weeks); Procedure: Total mesorectal excision after 56 days (8-12 weeks)<br/><b>Sponsor</b>: Ege University<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03287843",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03125902?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple-Negative Breast Cancer<br/><b>Interventions</b>: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Drug: Atezolizumab Placebo; Drug: Paclitaxel<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03125902",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Apr 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04021238?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Kidney Cancer<br/><b>Interventions</b>: Drug: Perflutren lipid microsphere; Drug: Sulfur hexafluoride lipid microspheres<br/><b>Sponsor</b>: UNC Lineberger Comprehensive Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04021238",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Jul 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01336634?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Interventions</b>: Drug: Dabrafenib; Device: Trametinib<br/><b>Sponsor</b>: Novartis Pharmaceuticals<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01336634",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 18 Apr 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Role of Muscle Cachexia in Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02515513?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreas Cancer<br/><b>Intervention</b>: Procedure: Muscle Tissue Biopsy Sample<br/><b>Sponsors</b>: University of Florida; The V Foundation for Cancer Research; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02515513",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Aug 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02891993?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Interventions</b>: Other: IMPROVED; Other: Usual Care<br/><b>Sponsor</b>: Massachusetts General Hospital<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02891993",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 08 Sep 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03407417?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colo-rectal Cancer<br/><b>Interventions</b>: Other: virtual technology - highly tailored; Other: virtual technology - tailored minimally<br/><b>Sponsors</b>: University of Florida; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03407417",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 23 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02648282?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Cancer<br/><b>Interventions</b>: Drug: Cyclophosphamide; Drug: GVAX; Drug: Pembrolizumab; Radiation: SBRT<br/><b>Sponsors</b>: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Merck Sharp & Dohme Corp.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02648282",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 07 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC)."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04404140?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Castration-Resistant Prostatic Cancer<br/><b>Interventions</b>: Drug: Ipatasertib; Drug: Atezolizumab; Drug: Docetaxel<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04404140",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 27 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03975647?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HER2-positive Breast Cancer<br/><b>Interventions</b>: Drug: tucatinib; Drug: placebo; Drug: T-DM1<br/><b>Sponsor</b>: Seagen Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03975647",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04742075?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Intervention</b>: Drug: Olaparib + durvalumab + UV1<br/><b>Sponsors</b>: Nordic Society of Gynaecological Oncology - Clinical Trials Unit; North Eastern German Society of Gynaecological Oncology; Belgian Gynaecological Oncology Group; Hellenic Cooperative Oncology Group; Arbeitsgemeinschaft Gynaekologische Onkologie Austria; European Network of Gynaecological Oncological Trial Groups (ENGOT)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04742075",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03694522?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastric Cancer<br/><b>Interventions</b>: Drug: bemarituzumab (FPA144); Drug: Placebo; Drug: mFOLFOX6<br/><b>Sponsors</b>: Five Prime Therapeutics, Inc.; Zai Lab (Shanghai) Co., Ltd.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03694522",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03977090?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Interventions</b>: Drug: Geptanolimab Injection; Drug: Fruquintinib<br/><b>Sponsors</b>: Genor Biopharma Co., Ltd.; Hutchison Medipharma Limited<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03977090",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04619004?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor<br/><b>Interventions</b>: Drug: Patritumab Deruxtecan (Fixed dose); Drug: Patritumab Deruxtecan (Up-Titration)<br/><b>Sponsors</b>: Daiichi Sankyo, Inc.; Daiichi Sankyo Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04619004",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02856347?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Medullary Thyroid Cancer<br/><b>Intervention</b>: Other: 18F-DOPA<br/><b>Sponsor</b>: Institut Claudius Regaud<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02856347",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Positron Nuclide Labeled NOTA-FAPI PET Study in Colocrectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04750772?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Tumor, Solid; Positron-Emission Tomography; Colorectal Cancer<br/><b>Interventions</b>: Diagnostic Test: 18F-FDG and 68Ga-NOTA-FAPI04 PET/CT; Diagnostic Test: 18F-FDG and 18F-NOTA-FAPI04 PET/CT<br/><b>Sponsor</b>: Beijing Cancer Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04750772",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC)."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03564938?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Intervention</b>: Drug: Regorafenib (Stivarga, BAY73-4506)<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03564938",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03356223?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Head and Neck Cancer; Advanced Cancer; Metastatic Cancer<br/><b>Intervention</b>: Drug: Abemaciclib<br/><b>Sponsor</b>: Centre Leon Berard<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03356223",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03259035?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Drug: Folfox Protocol; Drug: Capox<br/><b>Sponsor</b>: Canadian Cancer Trials Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03259035",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 23 Aug 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04165317?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-muscle Invasive Bladder Cancer<br/><b>Interventions</b>: Drug: PF-06801591; Drug: Bacillus Calmette-Guerin<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04165317",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 15 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01481545?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Radiation: Radiation therapy; Drug: Oxaliplatin; Drug: Raltitrexed; Drug: levofolinic acid; Drug: 5-fluorouracil; Drug: Bevacizumab<br/><b>Sponsor</b>: National Cancer Institute, Naples<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01481545",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 29 Nov 2011 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04729387?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Drug: Alpelisib; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated liposomal doxorubicin (PLD)<br/><b>Sponsor</b>: Novartis Pharmaceuticals<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04729387",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02340949?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Drug: Aflibercept; Drug: 5-Fluoruracil; Drug: Oxaliplatin; Drug: Leucovorin<br/><b>Sponsors</b>: Grupo Espanol Multidisciplinario del Cancer Digestivo; Pivotal S.L.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02340949",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Jan 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03498521?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer of Unknown Primary Site<br/><b>Interventions</b>: Drug: Alectinib; Drug: Vismodegib; Drug: Ipatasertib; Drug: Olaparib; Drug: Erlotinib; Drug: Bevacizumab; Drug: Vemurafenib; Drug: Cobimetinib; Drug: Trastuzumab Subcutaneous (SC); Drug: Pertuzumab; Drug: Atezolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Cisplatin; Drug: Gemcitabine; Drug: Entrectinib<br/><b>Sponsors</b>: Hoffmann-La Roche; Foundation Medicine, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03498521",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04090528?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Castration-resistant Prostate Cancer; Metastatic Cancer; Prostate Cancer<br/><b>Interventions</b>: Biological: pTVG-HP; Biological: pTVG-AR; Drug: Pembrolizumab; Drug: rhGM-CSF<br/><b>Sponsors</b>: University of Wisconsin, Madison; Merck Sharp & Dohme Corp.; Madison Vaccines, Inc; Prostate Cancer Foundation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04090528",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 16 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02022982?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: KRAS Mutant Non-Small Cell Lung Cancer; Solid Tumors<br/><b>Interventions</b>: Drug: Palbociclib; Drug: PD-0325901<br/><b>Sponsor</b>: Dana-Farber Cancer Institute<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02022982",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 30 Dec 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02425891?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Cancer<br/><b>Interventions</b>: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Drug: Nab-Paclitaxel; Drug: Placebo<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02425891",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Apr 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02966093?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Differentiated Thyroid Cancer (DTC)<br/><b>Interventions</b>: Drug: Lenvatinib; Drug: Placebo<br/><b>Sponsor</b>: Eisai Co., Ltd.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02966093",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Nov 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03223376?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Gastric Cancer<br/><b>Interventions</b>: Combination Product: fruquintinib +paclitaxel; Combination Product: fruquintinib placebo + paclitaxel<br/><b>Sponsors</b>: Hutchison Medipharma Limited; Sun Yat-sen University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03223376",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 21 Jul 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "FS222 First in Human Study in Patients With Advanced Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04740424?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Cancer; Metastatic Cancer<br/><b>Intervention</b>: Drug: FS222<br/><b>Sponsor</b>: F-star Beta Limited<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04740424",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04573231?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer<br/><b>Intervention</b>: Drug: 18F-DCFPyL<br/><b>Sponsor</b>: University of Wisconsin, Madison<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04573231",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 05 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04337580?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Refractory Cancer; Castration Resistant Prostatic Cancer<br/><b>Intervention</b>: Drug: Omeprazole 80 mg twice daily<br/><b>Sponsors</b>: Wake Forest University Health Sciences; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04337580",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "EP0057 in Combination With Olaparib in Advanced Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04669002?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Drug: EP0057; Drug: Olaparib tablets<br/><b>Sponsor</b>: Ellipses Pharma<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04669002",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04490421?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Neoplasm; Small Cell Lung Cancer; PD-1 Inhibitors<br/><b>Intervention</b>: Drug: Camrelizumab combined with Apatinib, Etoposide and Cisplatin<br/><b>Sponsor</b>: Fuzhou General Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04490421",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04511533?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Non Small Cell Lung Cancer<br/><b>Intervention</b>: Drug: Dacomitinib<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04511533",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 13 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04082364?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer<br/><b>Interventions</b>: Combination Product: margetuximab plus INCMGA00012; Combination Product: Margetuximab plus INCMGA00012 plus chemo; Combination Product: Margetuximab plus MGD013 plus chemo; Combination Product: Margetuximab plus chemo; Combination Product: Trastuzumab plus chemo<br/><b>Sponsors</b>: MacroGenics; Zai Lab (Shanghai) Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04082364",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04417465?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors Cancer<br/><b>Interventions</b>: Drug: ABBV-CLS-579; Drug: Programmed Cell Death-1 (PD-1) Inhibitor<br/><b>Sponsors</b>: Calico Life Sciences LLC; AbbVie<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04417465",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04417192?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Drug: Olaparib; Drug: Pembrolizumab<br/><b>Sponsors</b>: National Cancer Center Hospital East; Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04417192",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03837496?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Adherence, Medication<br/><b>Interventions</b>: Other: STRIDE; Other: Medication Monitoring Control<br/><b>Sponsors</b>: Massachusetts General Hospital; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03837496",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 12 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02779751?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non Small Cell Lung Cancer; Breast Cancer<br/><b>Interventions</b>: Drug: Abemaciclib; Drug: Pembrolizumab; Drug: Anastrozole<br/><b>Sponsors</b>: Eli Lilly and Company; Merck Sharp & Dohme Corp.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02779751",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 20 May 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03703297?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Durvalumab; Drug: Tremelimumab; Other: Placebo<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03703297",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04375813?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-muscle Invasive Bladder Cancer<br/><b>Interventions</b>: Drug: eRapa; Drug: Placebos<br/><b>Sponsors</b>: Rapamycin Holdings, Inc. dba Emtora Biosciences; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04375813",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 05 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03402841?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Germline BRCA Mutated Ovarian Cancer<br/><b>Intervention</b>: Drug: Olaparib<br/><b>Sponsors</b>: AstraZeneca; Iqvia Pty Ltd; Myriad Genetics, Inc.; Covance; Theradex; Parexel<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03402841",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 18 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02666378?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Other: Cardiac Magnetic Resonance Imaging (CMR); Other: Echocardiogram (ECHO)<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; American Heart Association<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02666378",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02964078?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Kidney Cancer<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: Interleukin-2<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme Corp.; Prometheus Laboratories<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02964078",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 15 Nov 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04692675?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Diagnostic Test: mpMRI<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04692675",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 05 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01658930?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cervical Cancer<br/><b>Interventions</b>: Procedure: Radical Hysterectomy + pelvic lymph node dissection; Procedure: Simple hysterectomy + pelvic lymph node dissection<br/><b>Sponsors</b>: Canadian Cancer Trials Group; Gynecologic Cancer Intergroup (GCIG); Canadian Institutes of Health Research (CIHR); Korean Gynecologic Oncology Group; Dutch Gynecologic Oncology Group; Cancer Trials Ireland; Arbeitsgemeinschaft Gynaekologische Onkologie Austria; Belgium Gynecologic Oncology Group; Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens; Institute of Cancer Research, United Kingdom; Shanghai Cancer Centre Deptartment of Gynecologic Oncology Fudan University; Hertzen Moscow Scientific Research Institute of Oncology; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany; Institut Claudius Regaud - Institute Universitaire du Cancer de Toulouse - Oncopole<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01658930",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Aug 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Yoga for Psychological Distress in Gynecologic, Gastrointestinal, or Thoracic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03385577?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gynecologic Cancer; Adjustment; Gastrointestinal Cancer; Thoracic Cancer<br/><b>Intervention</b>: Behavioral: Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer<br/><b>Sponsor</b>: University of Florida<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03385577",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739527?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Intervention</b>: Biological: DCP-001<br/><b>Sponsors</b>: University Medical Center Groningen; DCPrime BV<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739527",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03752099?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Castration Resistant Prostate Cancer<br/><b>Intervention</b>: Drug: VERU-111<br/><b>Sponsor</b>: Veru Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03752099",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 23 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04247984?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Interventions</b>: Biological: Bevacizumab; Drug: Capecitabine; Drug: Irinotecan; Drug: 5-FU; Drug: CF<br/><b>Sponsors</b>: Chinese Academy of Medical Sciences; Beijing Hospital; Henan Cancer Hospital; Liaoning Tumor Hospital & Institute; Jiangsu Cancer Institute & Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04247984",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03459846?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Neoplasms<br/><b>Interventions</b>: Drug: Durvalumab; Drug: Olaparib; Drug: Placebo<br/><b>Sponsor</b>: AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03459846",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 09 Mar 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03099174?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Breast Neoplasms<br/><b>Interventions</b>: Drug: Xentuzumab; Drug: Abemaciclib; Drug: Letrozole; Drug: Anastrozole; Drug: Fulvestrant<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03099174",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Apr 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02333370?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer<br/><b>Interventions</b>: Drug: LEE011; Drug: Letrozole; Drug: Tamoxifen; Drug: Fulvestrant; Drug: goserelin<br/><b>Sponsor</b>: Novartis Pharmaceuticals<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02333370",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 Jan 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04410042?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer of the Bone; Limb Salvage<br/><b>Interventions</b>: Drug: Tranexamic Acid; Other: 0.9% sodium chloride<br/><b>Sponsor</b>: St. Jude Children's Research Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04410042",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04581824?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer, Non-Small Cell<br/><b>Interventions</b>: Drug: Dostarlimab; Drug: Pembrolizumab; Drug: Chemotherapy<br/><b>Sponsor</b>: GlaxoSmithKline<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04581824",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 09 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03531827?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Castration Resistant Prostate Cancer; Prostate Neoplasms<br/><b>Interventions</b>: Drug: enzalutamide; Drug: CRLX101<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03531827",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03695380?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: OVARIAN CANCER<br/><b>Interventions</b>: Drug: Cobimetinib; Drug: Niraparib; Drug: Atezolizumab<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03695380",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03398655?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Recurrent Platinum Resistant Ovarian Cancer<br/><b>Interventions</b>: Drug: VB-111 + Paclitaxel; Drug: Placebo + Paclitaxel<br/><b>Sponsors</b>: Vascular Biogenics Ltd. operating as VBL Therapeutics; GOG Foundation, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03398655",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 12 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04734184?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Recurrent<br/><b>Intervention</b>: Diagnostic Test: DCFPyL<br/><b>Sponsor</b>: Curium PET France<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04734184",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04611126?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Ovarian Cancer; Metastatic Fallopian Tube Cancer; Peritoneal Cancer<br/><b>Interventions</b>: Drug: Ipilimumab; Drug: Cyclophosphamid; Drug: Fludarabine Phosphate; Biological: Tumor Infiltrating Lymphocytes infusion; Drug: Nivolumab; Drug: Relatlimab<br/><b>Sponsor</b>: Inge Marie Svane<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04611126",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 02 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04361370?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer<br/><b>Intervention</b>: Drug: Olaparib-Pembrolizumab-Bevacizumab<br/><b>Sponsor</b>: Yonsei University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04361370",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04737187?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Refractory Metastatic Colorectal Cancer<br/><b>Interventions</b>: Drug: Trifluridine/Tipiracil; Drug: Bevacizumab<br/><b>Sponsors</b>: Taiho Oncology, Inc.; Institut de Recherches Internationales Servier<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04737187",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03278717?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Drug: Olaparib; Drug: Cediranib<br/><b>Sponsor</b>: University College, London<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03278717",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 12 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04408924?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Castration-Resistant Prostate Cancer<br/><b>Intervention</b>: Drug: Abemaciclib<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04408924",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04614103?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Non Small Cell Lung Cancer<br/><b>Intervention</b>: Biological: LN-145<br/><b>Sponsor</b>: Iovance Biotherapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04614103",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 03 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02692755?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Hormone Receptor Positive HER-2 Negative Breast Cancer<br/><b>Intervention</b>: Drug: Palbociclib + Letrozole or Fulvestrant<br/><b>Sponsors</b>: Georgetown University; University of Chicago; Thomas Jefferson University<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02692755",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 26 Feb 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04646005?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cervical Cancer<br/><b>Interventions</b>: Drug: Cemiplimab; Biological: ISA101b<br/><b>Sponsors</b>: Regeneron Pharmaceuticals; ISA Pharmaceuticals B.V.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04646005",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03807765?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Breast Cancer; Brain Metastases<br/><b>Interventions</b>: Drug: Nivolumab; Radiation: Stereotactic Radiosurgery<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Bristol-Myers Squibb<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03807765",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02383251?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Interventions</b>: Drug: Pazopanib; Drug: Paclitaxel<br/><b>Sponsors</b>: ARCAGY/ GINECO GROUP; Novartis<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02383251",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Mar 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04135313?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rectal Neoplasms Malignant; Rectum Carcinoma; Rectal Cancer<br/><b>Interventions</b>: Drug: Capecitabine; Drug: Oxaliplatin; Radiation: Radiotherapy; Procedure: Rectal cancer surgery<br/><b>Sponsor</b>: Blokhin's Russian Cancer Research Center<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT04135313",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03913455?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Small Cell Lung Cancer; Extensive-stage Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Guadecitabine; Drug: Carboplatin<br/><b>Sponsors</b>: Shadia Jalal, MD; Astex Pharmaceuticals, Inc.; Indiana University School of Medicine<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03913455",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 12 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Immunotherapy as Second-line in Patient With Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03059667?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Small Cell Lung Cancer; Small Cell Lung Cancer Limited Stage; Small Cell Lung Cancer Extensive Stage<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Topotecan; Drug: Carboplatin; Drug: Etoposide<br/><b>Sponsor</b>: Intergroupe Francophone de Cancerologie Thoracique<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03059667",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Feb 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738292?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Cancer<br/><b>Interventions</b>: Drug: Onapristone; Drug: Fulvestrant<br/><b>Sponsor</b>: University of Wisconsin, Madison<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04738292",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03406715?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Small Cell Lung Cancer; Lung Cancer; Relapsed Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Nivolumab; Drug: Ipilimumab; Biological: Dendritic Cell based p53 Vaccine<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Bristol-Myers Squibb; MultiVir, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03406715",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 23 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04627142?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer (CRC)<br/><b>Interventions</b>: Drug: BI 1701963; Drug: Camptosar®<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04627142",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01627288?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer of the Cervix; Cervical Neoplasms<br/><b>Intervention</b>: Radiation: Boost radiation<br/><b>Sponsor</b>: Duke University<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01627288",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Jun 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03734692?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer Recurrent<br/><b>Interventions</b>: Drug: Rintatolimod; Drug: Pembrolizumab; Drug: Cisplatin<br/><b>Sponsors</b>: Robert Edwards; AIM ImmunoTech Inc.; Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03734692",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 08 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04574583?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Cancer; Solid Tumors<br/><b>Interventions</b>: Drug: SX-682; Drug: M7824; Biological: MVA-BN-CV301; Biological: FPV-CV301<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04574583",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 05 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03924856?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Cancer, Muscle-invasive<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]); Drug: Placebo<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03924856",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 23 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04546009?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer<br/><b>Interventions</b>: Drug: GDC-9545; Drug: GDC-9545-matched Placebo; Drug: Letrozole; Drug: Letrozole-matched Placebo; Drug: Palbociclib; Drug: LHRH Agonist<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04546009",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 11 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02283749?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non Small Cell Lung Cancer With Bone Metastatses<br/><b>Intervention</b>: Biological: Xofigo<br/><b>Sponsors</b>: Angela Taber MD; Rhode Island Hospital; The Miriam Hospital; Bayer<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02283749",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Nov 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03651271?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Metastatic Cancer; Advanced Prostate Cancer<br/><b>Interventions</b>: Biological: Nivolumab Monotherapy; Biological: Nivolumab and Ipilimumab and Combination for Metastatic Cancer; Biological: Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer; Biological: Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer<br/><b>Sponsors</b>: Parker Institute for Cancer Immunotherapy; Bristol-Myers Squibb; Cancer Research Institute, New York City<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03651271",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04316013?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colonic Cancer; Rectal Cancer; Non Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Sevoflurane; Drug: Propofol; Drug: Lidocaine Iv; Other: Placebo<br/><b>Sponsors</b>: Peter MacCallum Cancer Centre, Australia; National Health & Medical Research Council of Australia (NH&MRC); The Australian and New Zealand College of Anaesthetists (ANZCA); Victorian Comprehensive Cancer Centre<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04316013",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 20 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03924895?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Cancer, Muscle-invasive<br/><b>Interventions</b>: Drug: Pembrolizumab; Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]); Drug: Enfortumab Vedotin<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; Seagen Inc.; Astellas Pharma Global Development, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03924895",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 23 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03413995?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Metastatic<br/><b>Intervention</b>: Drug: Rucaparib<br/><b>Sponsors</b>: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Clovis Oncology, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03413995",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 29 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02572843?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: NSCLC Non-small Cell Lung Cancer<br/><b>Intervention</b>: Drug: MEDI4736 (anti-PD-L1)<br/><b>Sponsor</b>: Swiss Group for Clinical Cancer Research<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02572843",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 09 Oct 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04457089?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Recurrent Ovarian Cancer; Platinum-sensitive Ovarian Cancer<br/><b>Intervention</b>: Drug: Simvastatin 40mg<br/><b>Sponsor</b>: Bobbie Jo Rimel, MD<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04457089",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04541537?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Surgery<br/><b>Interventions</b>: Diagnostic Test: Sorbstar®; Diagnostic Test: Dog Detection<br/><b>Sponsor</b>: Institut Curie<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04541537",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 09 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03835949?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumor; Metastatic Cancer<br/><b>Interventions</b>: Drug: TJ004309; Drug: Atezolizumab<br/><b>Sponsor</b>: Tracon Pharmaceuticals Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03835949",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 11 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04740021?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small-cell Lung Cancer<br/><b>Interventions</b>: Drug: LP002; Drug: Carboplatin; Drug: Etoposide<br/><b>Sponsor</b>: Taizhou HoudeAoke Biomedical Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04740021",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01345175?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Cancer<br/><b>Interventions</b>: Drug: Rifaximin; Drug: Placebo<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01345175",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Apr 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03801083?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms<br/><b>Intervention</b>: Biological: Tumor Infiltrating Lymphocytes (TIL)<br/><b>Sponsor</b>: Udai Kammula<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03801083",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 11 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Aerobic Exercise and Cognitive Functioning in Women With Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03277898?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Interventions</b>: Behavioral: Aerobic Exercise; Behavioral: Usual Care (Wait-list Control)<br/><b>Sponsors</b>: University of British Columbia; Canadian Cancer Society (CCS); Avon Foundation; University of Ottawa; British Columbia Cancer Agency<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03277898",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 11 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02340221?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Taselisib; Drug: Placebo; Drug: Fulvestrant<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02340221",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Jan 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04730999?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Etoposide; Drug: Carboplatin; Drug: Bevacizumab; Drug: Atezolizumab<br/><b>Sponsors</b>: Gruppo Oncologico Italiano di Ricerca Clinica; Roche Pharma, Italy; YGHEA, CRO Division of Ecol Studio spa; Dr. Luca Boni U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino - IST NORD CBA<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04730999",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03602859?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Neoplasms; Ovarian Cancer<br/><b>Interventions</b>: Drug: Niraparib; Drug: Dostarlimab (TSR-042); Drug: Placebo; Drug: Standard of care; Drug: Dostarlimab/Placebo; Drug: Niraparib/Placebo<br/><b>Sponsors</b>: Tesaro, Inc.; European Network of Gynaecological Oncological Trial Groups (ENGOT)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03602859",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "68 Ga-PSMA for High Risk Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04614363?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; High Risk<br/><b>Intervention</b>: Drug: 68Ga-PSMA<br/><b>Sponsor</b>: The Methodist Hospital System<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04614363",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 04 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Relugolix in Men With High-Risk Metastatic Castration-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04666129?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Castration-Resistant Prostate Cancer; Metastatic Castration-Sensitive Prostate Cancer<br/><b>Interventions</b>: Drug: Relugolix; Drug: Abiraterone; Drug: Prednisone<br/><b>Sponsor</b>: Myovant Sciences GmbH<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04666129",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 14 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02658734?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer<br/><b>Intervention</b>: Drug: Trastuzumab emtansine<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02658734",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04210037?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: APG-1252; Drug: Paclitaxel<br/><b>Sponsor</b>: Ascentage Pharma Group Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04210037",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03981796?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Interventions</b>: Biological: Dostarlimab; Drug: Placebo; Drug: Carboplatin-paclitaxel<br/><b>Sponsors</b>: Tesaro, Inc.; European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic Oncology Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03981796",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 11 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Clinical Study of PD-L1 Antibody (TQB2450) Plus Chemotherapy (Cisplatin and Etoposide) for Previously Untreated Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04539977?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small-cell Lung Cancer<br/><b>Intervention</b>: Drug: TQB2450<br/><b>Sponsor</b>: Shanghai Pulmonary Hospital, Shanghai, China<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04539977",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736485?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Cancer by AJCC V8 Stage; Resectable Carcinoma<br/><b>Intervention</b>: Drug: perioperative treatment<br/><b>Sponsors</b>: Centre Francois Baclesse; National Cancer Institute, France<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736485",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02973789?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Nonsmall Cell Lung Cancer<br/><b>Interventions</b>: Device: NovoTTF-100L; Drug: Immune checkpoint inhibitors or docetaxel<br/><b>Sponsor</b>: NovoCure Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02973789",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Nov 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Single-arm Phase II Study of NDURE for Patients With HNC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03821064?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer of Head and Neck<br/><b>Intervention</b>: Other: Patient Navigation<br/><b>Sponsor</b>: Medical University of South Carolina<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03821064",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 29 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02989584?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Bladder Cancer; Metastatic Bladder Cancer; Urothelial Carcinoma<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Gemcitabine; Drug: Cisplatin<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Genentech, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02989584",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 12 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04689828?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Radiation: 177Lu-PSMA-617; Radiation: 68Ga-PSMA-11; Drug: ARDT; Other: Best supportive care<br/><b>Sponsor</b>: Novartis Pharmaceuticals<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04689828",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 30 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01623349?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Breast Cancer<br/><b>Interventions</b>: Drug: BKM120 and Olaparib; Drug: BYL719 and Olaparib<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; Novartis; AstraZeneca<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01623349",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Jun 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04172675?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Neoplasms<br/><b>Interventions</b>: Drug: Erdafitinib; Drug: Investigator Choice (Gemcitabine); Drug: Investigator Choice (Mitomycin C)<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04172675",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04713449?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Oral Cancer; Oropharyngeal Cancer; Head and Neck Cancer<br/><b>Interventions</b>: Other: Empowered Survivor Online; Other: Springboard Beyond Cancer; Other: Survey Administration<br/><b>Sponsors</b>: Rutgers, The State University of New Jersey; National Cancer Institute (NCI); The Cancer Registry of Greater California; The New Jersey State Cancer Registry<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04713449",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04336917?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer Surgery; Postoperative Analgesia<br/><b>Intervention</b>: Drug: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic<br/><b>Sponsor</b>: Konya Training and Research Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04336917",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04544189?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Interventions</b>: Drug: Alpelisib; Drug: Fulvestrant; Drug: Placebo<br/><b>Sponsor</b>: Novartis Pharmaceuticals<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04544189",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 10 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03025477?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer, Epithelial<br/><b>Interventions</b>: Drug: CC0 - Carboplatin (IV) - Paclitaxel (IV); Drug: CC0 - Cisplatin (IP) - Epirubicin (IV); Drug: CC>0 - Carboplatin (IV)- Paclitaxel (IV); Drug: CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)<br/><b>Sponsors</b>: Groupe Hospitalier Diaconesses Croix Saint-Simon; GERCOR - Multidisciplinary Oncology Cooperative Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03025477",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 19 Jan 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of TAK-788 in Japanese Adults With Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03807778?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Intervention</b>: Drug: TAK-788<br/><b>Sponsor</b>: Takeda<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03807778",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01372631?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Device: miniature spectral imaging system; Device: Bench-top optical spectrometer; Device: High resolution microendoscope<br/><b>Sponsors</b>: Duke University; National Institutes of Health (NIH); National Institute for Biomedical Imaging and Bioengineering (NIBIB)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01372631",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 14 Jun 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04256421?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Tiragolumab; Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04256421",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03521154?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non Small Cell Lung Cancer (Stage III)<br/><b>Interventions</b>: Drug: Osimertinib 80mg/40mg; Drug: Placebo Osimertinib 80mg/40mg<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03521154",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 11 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Safety and Efficacy Test of Nutri-PEITC Jelly in Head and Neck Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03034603?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Head and Neck Neoplasms; Quality of Life; Nutrition Related Cancer<br/><b>Interventions</b>: Dietary Supplement: Nutri-jelly with PEITC; Dietary Supplement: Nutri-jelly<br/><b>Sponsors</b>: Dental Innovation Foundation Under Royal Patronage; Mahidol University; Srinakharinwirot University; Ministry of Health, Thailand<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03034603",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Jan 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03872206?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Cancers Associated With Mesothelin Expression<br/><b>Intervention</b>: Biological: HPN536<br/><b>Sponsor</b>: Harpoon Therapeutics<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03872206",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 13 Mar 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04728724?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer Stage III<br/><b>Interventions</b>: Drug: Sintilimab; Drug: Chemotherapy<br/><b>Sponsor</b>: Shanghai Pulmonary Hospital, Shanghai, China<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04728724",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Open Label Extension In Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00830180?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Bone Metastases<br/><b>Intervention</b>: Biological: Anti-NGF AB<br/><b>Sponsor</b>: Pfizer<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00830180",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 27 Jan 2009 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04704453?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Head and Neck Cancer<br/><b>Interventions</b>: Drug: Capsaïcin patch (Qutenza®); Drug: Amitriptyline (Laroxyl®)<br/><b>Sponsor</b>: Institut Claudius Regaud<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04704453",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 11 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03711032?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: High-risk Non-muscle Invasive Bladder Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Biological: BCG<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03711032",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 18 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours (Elios-Color-on-Specimen)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04101292?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Other: Characterization of tumor tissue by fluorescence<br/><b>Sponsors</b>: IHU Strasbourg; ARC Foundation for Cancer Research<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04101292",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04624204?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab 200 mg; Biological: Pembrolizumab 400 mg; Drug: Pembrolizumab placebo (saline); Drug: Olaparib 300 mg BID; Drug: Olaparib matching placebo; Drug: Etoposide 100 mg/m^2; Drug: Platinum, investigator's choice; Radiation: Standard Thoracic Radiotherapy; Radiation: Prophylactic Cranial Irradiation (PCI)<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04624204",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04735068?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non-Small Cell Lung Cancer; KRAS Mutation-Related Tumors<br/><b>Interventions</b>: Drug: Binimetinib Pill; Drug: Hydroxychloroquine Pill<br/><b>Sponsors</b>: Abramson Cancer Center of the University of Pennsylvania; Pfizer<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04735068",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pembrolizumab in Elderly Patients With Advanced Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03293680?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non Small Cell Lung Cancer<br/><b>Intervention</b>: Drug: Pembrolizumab<br/><b>Sponsor</b>: Spanish Lung Cancer Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03293680",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 26 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04174352?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: ERα+ Breast Cancer; ESR1 Gene Mutation<br/><b>Interventions</b>: Drug: Tamoxifen; Diagnostic Test: FES PET/CT<br/><b>Sponsor</b>: University of Wisconsin, Madison<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04174352",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 22 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04729205?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Gastro-Intestinal Intraepithelial Neoplasia<br/><b>Intervention</b>: Drug: Promitil<br/><b>Sponsor</b>: Lipomedix Pharmaceuticals Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04729205",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03481114?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Interventions</b>: Combination Product: PET-based, dose-painted, accelerated chemoradiotherapy; Combination Product: Standard chemoradiotherapy<br/><b>Sponsor</b>: Albert Einstein College of Medicine<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03481114",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 29 Mar 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03081689?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Nivolumab 360 mg; Drug: Paclitaxel 200mg/m2; Drug: Carboplatin AUC 6<br/><b>Sponsor</b>: Spanish Lung Cancer Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03081689",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 16 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03785925?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Urinary Bladder Neoplasm; Neoplasm Metastasis<br/><b>Interventions</b>: Biological: Bempegaldesleukin; Biological: Nivolumab<br/><b>Sponsors</b>: Nektar Therapeutics; Bristol-Myers Squibb<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03785925",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01850303?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non Small Cell Lung Cancer (Squamous or Non Squamous)<br/><b>Interventions</b>: Drug: Pemetrexed; Drug: Gemcitabine; Drug: Induction chemotherapy<br/><b>Sponsor</b>: Intergroupe Francophone de Cancerologie Thoracique<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01850303",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 09 May 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02806258?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation; Intermediate and High-risk Luminal and Triple Negative Breast Cancer<br/><b>Interventions</b>: Radiation: Accelerated partial breast irradiation; Drug: Chemotherapy<br/><b>Sponsor</b>: University Hospital, Grenoble<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02806258",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 20 Jun 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04296890?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer<br/><b>Intervention</b>: Drug: Mirvetuximab Soravtansine<br/><b>Sponsors</b>: ImmunoGen, Inc.; IQVIA Biotech<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04296890",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 Mar 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03785249?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease<br/><b>Interventions</b>: Drug: MRTX849; Drug: Pembrolizumab; Drug: Cetuximab; Drug: Afatinib<br/><b>Sponsor</b>: Mirati Therapeutics Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03785249",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04492488?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Tumors; Advanced or Metastatic Gastric Cancer; Advanced or Metastatic Gastroesophageal Junction Cancer<br/><b>Intervention</b>: Drug: MRG002<br/><b>Sponsor</b>: Shanghai Miracogen Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04492488",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04351555?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Osimertinib; Drug: Cisplatin; Drug: Carboplatin; Drug: Placebo; Drug: Pemetrexed<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04351555",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 17 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736173?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non-small-cell Lung Cancer; Lung Cancer<br/><b>Interventions</b>: Drug: Zimberelimab; Drug: AB154; Drug: Carboplatin; Drug: Pemetrexed; Drug: Paclitaxel<br/><b>Sponsor</b>: Arcus Biosciences, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736173",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04743505?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Non Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: APL-101; Drug: Osimertinib<br/><b>Sponsors</b>: Washington University School of Medicine; Apollomics Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04743505",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 08 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03735121?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: rHuPH20<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03735121",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 08 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04676412?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Lenvatinib; Drug: Placebo for lenvatinib<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; Eisai Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04676412",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 21 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03088813?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Irinotecan liposome injection; Drug: Topotecan<br/><b>Sponsor</b>: Ipsen<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03088813",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04508686?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Cervical Cancer<br/><b>Intervention</b>: Drug: Capecitabine, camrelizumab<br/><b>Sponsor</b>: Ruijin Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04508686",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 11 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04209855?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer<br/><b>Interventions</b>: Drug: Mirvetuximab Soravtansine; Drug: Paclitaxel; Drug: Topotecan; Drug: Pegylated liposomal doxorubicin<br/><b>Sponsors</b>: ImmunoGen, Inc.; Gynecologic Oncology Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04209855",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02767804?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: X-396 (ensartinib); Drug: crizotinib<br/><b>Sponsor</b>: Xcovery Holding Company, LLC<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02767804",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 May 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00609791?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: pharmacological study; Other: physiologic testing; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: cognitive assessment; Procedure: psychosocial assessment and care<br/><b>Sponsors</b>: City of Hope Medical Center; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00609791",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 07 Feb 2008 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04294810?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Tiragolumab; Drug: Matching Placebo<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04294810",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 04 Mar 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01511328?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: High-grade Cervical Intraepithelial Neoplasia<br/><b>Intervention</b>: Other: HPV testing<br/><b>Sponsors</b>: Karolinska Institutet; Stockholm County Council, Sweden<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01511328",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 18 Jan 2012 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04641871?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Cancer; Solid Tumor<br/><b>Interventions</b>: Drug: Sym021; Drug: Sym022; Drug: Sym023<br/><b>Sponsor</b>: Symphogen A/S<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04641871",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03924869?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Radiation: Stereotactic Body Radiotherapy (SBRT); Biological: Pembrolizumab; Drug: Placebo<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03924869",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 23 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04191096?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Hormone-Sensitive Prostate Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Enzalutamide; Procedure: Androgen Deprivation Therapy (ADT); Other: Placebo<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04191096",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Intervention For AYAS With Cancer Risk Syndromes"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04323774?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer Risk Syndrome<br/><b>Interventions</b>: Behavioral: AYA-RISE Adolescents and Young Adults Risk Information and Screening Education; Behavioral: Standard clinical visit for genetic counseling<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04323774",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04394624?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer Metastatic<br/><b>Interventions</b>: Drug: SAR408701; Drug: ramucirumab<br/><b>Sponsor</b>: Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04394624",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04211337?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Medullary Thyroid Cancer<br/><b>Interventions</b>: Drug: Selpercatinib; Drug: Cabozantinib; Drug: Vandetanib<br/><b>Sponsors</b>: Eli Lilly and Company; Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04211337",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04513925?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer (NSCLC)<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Tiragolumab; Drug: Durvalumab<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04513925",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 14 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04154956?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer Metastatic<br/><b>Interventions</b>: Drug: SAR408701; Drug: Docetaxel<br/><b>Sponsor</b>: Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04154956",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 07 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04750083?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Nonsquamous Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: HX008; Drug: Pembrolizumab; Drug: pemetrexed; Drug: cisplatin/carboplatin<br/><b>Sponsor</b>: Taizhou Hanzhong biomedical co. LTD<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04750083",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00494234?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Intervention</b>: Drug: KU-0059436 (AZD2281) (PARP inhibitor)<br/><b>Sponsors</b>: AstraZeneca; KuDOS Pharmaceuticals Limited<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00494234",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Jun 2007 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03532880?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Small-cell Lung Cancer; Small Cell Lung Carcinoma<br/><b>Interventions</b>: Drug: Olaparib Pill 50 mg; Drug: Olaparib Pill 100 mg; Drug: Olaparib Pill 150 mg; Drug: Olaparib Pill 200 mg; Drug: Olaparib Pill 250 mg; Drug: Olaparib Pill 300 mg; Radiation: Radiotherapy<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03532880",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04194944?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Selpercatinib; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pembrolizumab<br/><b>Sponsors</b>: Eli Lilly and Company; Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04194944",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 11 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Test Different Doses of BI 836880 Combined With BI 754091 in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03468426?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non-squamous, Non-Small-Cell Lung Cancer; Neoplasms<br/><b>Interventions</b>: Drug: BI 836880; Drug: BI 754091<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03468426",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Mar 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03425643?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Placebo; Drug: Cisplatin; Drug: Gemcitabine; Drug: Pemetrexed<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03425643",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 Feb 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04497844?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Castrate Sensitive Prostate Cancer<br/><b>Interventions</b>: Drug: Niraparib; Drug: Abiraterone acetate (AA); Drug: Prednisone; Drug: Placebo for Niraparib<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04497844",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03516981?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Biological: MK-4280; Drug: Lenvatinib; Drug: Quavonlimab<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03516981",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03720678?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: GastroEsophageal Cancer; Colorectal Cancer<br/><b>Interventions</b>: Drug: etrumadenant; Drug: mFOLFOX<br/><b>Sponsor</b>: Arcus Biosciences, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03720678",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 25 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03742102?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Neoplasms<br/><b>Interventions</b>: Drug: Durvalumab; Drug: Capivasertib; Drug: Oleclumab; Drug: Paclitaxel; Drug: Trastuzumab deruxtecan<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03742102",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 15 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04619797?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer (NSCLC)<br/><b>Interventions</b>: Drug: Tiragolumab; Drug: Atezolizumab; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Tiragolumab Matching Placebo; Drug: Pembrolizumab<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04619797",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02898727?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Intervention</b>: Other: Local Therapy<br/><b>Sponsor</b>: Trans Tasman Radiation Oncology Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02898727",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 13 Sep 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03579472?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8<br/><b>Interventions</b>: Drug: Bintrafusp Alfa; Drug: Eribulin Mesylate<br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03579472",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04024267?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Fatigue; Breast Cancer<br/><b>Interventions</b>: Other: Eurythmy therapy; Other: CoordiFit<br/><b>Sponsors</b>: University of Bern; Breast Cancer Research Foundation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04024267",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 18 Jul 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04302025?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Alectinib; Drug: Entrectinib; Drug: Vemurafenib; Drug: Cobimetinib; Procedure: Resection; Drug: Chemotherapy; Drug: Pralsetinib<br/><b>Sponsors</b>: Genentech, Inc.; Blueprint Medicines Corporation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04302025",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04716933?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Nonsquamous Non-small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Lenvatinib; Drug: Placebo matching lenvatinib<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; Eisai Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04716933",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03191786?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Drug: Vinorelbine; Drug: Gemcitabine<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03191786",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Jun 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pilot Study of a Pharmacy Intervention for Older Adults With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02871115?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Lung Cancer; GI Cancer<br/><b>Interventions</b>: Other: Pharmacy Intervention; Other: Usual Care<br/><b>Sponsor</b>: Massachusetts General Hospital<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02871115",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 18 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04134312?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Metastatic Tumor<br/><b>Intervention</b>: Biological: MVA-BN-Brachyury<br/><b>Sponsor</b>: Bavarian Nordic<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04134312",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04515394?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Neoplasms<br/><b>Interventions</b>: Drug: Tepotinib; Biological: Cetuximab<br/><b>Sponsors</b>: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04515394",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 17 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02384239?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Breast Cancer; Hormone Receptor Positive<br/><b>Intervention</b>: Drug: Palbociclib<br/><b>Sponsor</b>: University of California, San Francisco<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02384239",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Mar 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04129502?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)<br/><b>Interventions</b>: Drug: TAK-788; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin<br/><b>Sponsor</b>: Millennium Pharmaceuticals, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04129502",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02688088?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasm Metastasis<br/><b>Interventions</b>: Drug: Drug Cocktail; Drug: Abemaciclib<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02688088",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 23 Feb 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03657043?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer<br/><b>Intervention</b>: Drug: tisotumab vedotin<br/><b>Sponsors</b>: Seagen Inc.; Genmab<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03657043",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Sep 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02675829?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumor Cancers; Lung Cancer; Bladder Cancer; Urinary Tract Cancers<br/><b>Intervention</b>: Drug: ado-trastuzumab emtansine<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Genentech, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02675829",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02809690?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Neoplasm<br/><b>Interventions</b>: Device: CAT; Drug: 18F-FMAU; Other: Laboratory Biomarker Analysis; Procedure: Multiparametric Magnetic Resonance Imaging; Device: Positron Emission Tomography; Device: Ultrasound<br/><b>Sponsors</b>: University of Southern California; National Cancer Institute (NCI); National Institute for Biomedical Imaging and Bioengineering (NIBIB)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02809690",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 22 Jun 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01817192?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Adjuvant Chemotherapy; Other: Radiographic surveillance; Other: 14-Gene Prognostic Assay<br/><b>Sponsors</b>: Razor Genomics; Encore Clinical<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01817192",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Mar 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02609828?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasm Metastasis; Musculoskeletal Pain<br/><b>Intervention</b>: Drug: Tanezumab<br/><b>Sponsors</b>: Pfizer; Eli Lilly and Company<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02609828",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 20 Nov 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04066491?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer<br/><b>Interventions</b>: Drug: Bintrafusp alfa; Drug: Placebo; Drug: Gemcitabine; Drug: Cisplatin<br/><b>Sponsors</b>: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04066491",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 26 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03829319?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Nonsquamous Non-small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Lenvatinib; Drug: Placebo matching lenvatinib<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; Eisai Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03829319",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 04 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03280563?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Interventions</b>: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody; Drug: Bevacizumab; Drug: Entinostat; Drug: Exemestane; Drug: Fulvestrant; Drug: Ipatasertib; Drug: Tamoxifen; Drug: Abemaciclib<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03280563",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 12 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02854436?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Intervention</b>: Drug: Niraparib<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02854436",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03455829?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Carcinoma, Non-Small-Cell Lung; Lung Cancer; Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: G1T38; Drug: Osimertinib<br/><b>Sponsor</b>: G1 Therapeutics, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03455829",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 Mar 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03585764?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma<br/><b>Interventions</b>: Drug: MOv19-BBz CAR T cells; Device: Alpha Folate Receptor expression test<br/><b>Sponsor</b>: University of Pennsylvania<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03585764",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04552288?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumor; Solid Carcinoma; Solid Tumor, Adult; Hematologic Malignancy<br/><b>Intervention</b>: Drug: Benralizumab<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04552288",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03072160?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Medullary Thyroid Cancer (MTC)<br/><b>Intervention</b>: Drug: Pembrolizumab<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03072160",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Mar 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739696?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Lung Cancer; Colon Cancer; Solid Tumor, Adult<br/><b>Interventions</b>: Behavioral: PEPRR; Behavioral: Pep-Pal<br/><b>Sponsors</b>: University of Colorado, Denver; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739696",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04137536?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Pancreatic Cancer; Advanced Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreatic Neoplasms<br/><b>Intervention</b>: Drug: anti-EGFR-bispecific antibody armed activated T-cells<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; University of Virginia<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04137536",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 24 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "PALbociclib CoLlaborative Adjuvant Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02513394?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Palbociclib; Drug: Standard Adjuvant Endocrine Therapy<br/><b>Sponsors</b>: Alliance Foundation Trials, LLC.; Austrian Breast & Colorectal Cancer Study Group; NSABP Foundation Inc; PrECOG, LLC.; Breast International Group; Pfizer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02513394",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 31 Jul 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02617589?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Brain Cancer<br/><b>Interventions</b>: Drug: Nivolumab; Drug: Temozolomide; Radiation: Radiotherapy<br/><b>Sponsors</b>: Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02617589",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 Dec 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Remote Monitoring of Cancer Patients With Suspected Covid-19"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04397705?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: COVID; Oncology; Haematological Malignancy<br/><b>Intervention</b>: Device: Patient Status Engine<br/><b>Sponsor</b>: The Christie NHS Foundation Trust<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04397705",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Abemaciclib in Indian Women With Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04707196?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Neoplasms; Neoplasm Metastasis<br/><b>Interventions</b>: Drug: Abemaciclib; Drug: Nonsteroidal Aromatase Inhibitor (NSAI); Drug: Fulvestrant<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04707196",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 13 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03767244?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Drug: Apalutamide; Drug: Androgen Deprivation Therapy (ADT); Drug: Placebo<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03767244",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "VisionRT-based Deep Inspiration Breath-hold (DIBH) Respiratory Motion Management Strategy, A Pilot Study for Thoracic and Abdominal Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04686500?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Thoracic Cancer; Abdominal Cancer<br/><b>Intervention</b>: Device: Tidal volume measured by spirometer and DIBH surface from CT image<br/><b>Sponsors</b>: University of Texas Southwestern Medical Center; Vision RT Limited<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04686500",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 28 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase I Dose Escalation Study of ADG126 in Patients With Advanced Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04645069?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced/Metastatic Tumors<br/><b>Intervention</b>: Biological: ADG126<br/><b>Sponsor</b>: Adagene Inc<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04645069",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04557059?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Radiation: Radiotherapy; Drug: LHRHa; Drug: Apalutamide<br/><b>Sponsor</b>: Janssen-Cilag Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04557059",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 21 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04523207?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Drug: Apalutamide; Drug: ADT<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04523207",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 21 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03834493?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Enzalutamide; Drug: Placebo<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03834493",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02810652?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Pancreatic Cancer; Esophageal Cancer; Gastric Cancer<br/><b>Interventions</b>: Other: Usual Care; Other: Perioperative Geriatrics Intervention<br/><b>Sponsors</b>: Massachusetts General Hospital; National Comprehensive Cancer Network<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02810652",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Jun 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Transdisciplinary Intervention Integrating Geriatric And Palliative Care With Oncology Care For Older Adults With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02868112?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Interventions</b>: Other: Usual Oncology Care; Other: Transdisciplinary Intervention<br/><b>Sponsors</b>: Massachusetts General Hospital; National Institute on Aging (NIA)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02868112",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04042116?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Tumor; Gynecologic Cancer<br/><b>Interventions</b>: Drug: Lucitanib; Drug: Nivolumab<br/><b>Sponsors</b>: Clovis Oncology, Inc.; Bristol-Myers Squibb; European Network of Gynaecological Oncological Trial Groups (ENGOT)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04042116",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 01 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04296942?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Triple Negative Breast Cancer; HER2+ Breast Cancer; Hormone Receptor Negative Breast Cancer; Metastatic Breast Cancer<br/><b>Interventions</b>: Biological: Brachyury-TRICOM; Drug: Entinostat; Biological: M7824; Biological: Ado-trastuzumab emtansine<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04296942",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 Mar 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03659136?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Interventions</b>: Drug: Xentuzumab; Drug: Placebo; Drug: Everolimus; Drug: Exemestane<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03659136",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Sep 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04714931?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Sentinel Lymph Node<br/><b>Intervention</b>: Diagnostic Test: Sentinel lymph node detection<br/><b>Sponsor</b>: Acibadem University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04714931",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Sigmoid Colon Organ Motion in Radiotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03259828?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Sigmoid Cancer; Sigmoid Colon Cancer<br/><b>Intervention</b>: Radiation: Adjuvant image-guided radiotherapy<br/><b>Sponsor</b>: National Cheng-Kung University Hospital<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03259828",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 24 Aug 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02591030?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bile Duct Cancer<br/><b>Interventions</b>: Drug: GEMCIS; Drug: mFolfirinox<br/><b>Sponsors</b>: Centre Hospitalier Universitaire de Saint Etienne; Federation Francophone de Cancerologie Digestive<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02591030",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 29 Oct 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03834506?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Docetaxel; Drug: Prednisone; Drug: Placebo; Drug: Dexamethasone<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03834506",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01779050?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Interventions</b>: Drug: Doxorubicin; Biological: Trastuzumab; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Epirubicin; Drug: Docetaxel; Drug: Carboplatin; Drug: Fluorouracil<br/><b>Sponsors</b>: Washington University School of Medicine; Genentech, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01779050",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 29 Jan 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02640586?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Rectal Neoplasms<br/><b>Intervention</b>: Device: three MR examination<br/><b>Sponsor</b>: Sun Ying-Shi<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02640586",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 29 Dec 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04535414?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Cancer; Gastric Neoplasms; Gastric Adenocarcinoma<br/><b>Interventions</b>: Device: Cellvizio (Registered trademark) 100 microscope; Device: Olympus GIF 180 endoscope<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04535414",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 02 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02162719?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Interventions</b>: Drug: Ipatasertib; Drug: Paclitaxel; Drug: Placebo<br/><b>Sponsor</b>: Genentech, Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02162719",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 Jun 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03436745?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Intervention</b>: Drug: Zolpidem<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03436745",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Feb 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pilot Study of a National Screening Programme for Bowel Cancer in Norway"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01538550?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Colorectal Adenomas<br/><b>Interventions</b>: Procedure: Flexible sigmoidoscopy; Procedure: iFOBT<br/><b>Sponsors</b>: Cancer Registry of Norway; University of Oslo<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01538550",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Feb 2012 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03834519?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Olaparib; Drug: Abiraterone acetate; Drug: Prednisone; Drug: Enzalutamide<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03834519",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02200614?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer Non-Metastatic; Castration-Resistant<br/><b>Interventions</b>: Drug: Darolutamide (Nubeqa, BAY1841788); Drug: Placebo<br/><b>Sponsors</b>: Bayer; Orion Corporation, Orion Pharma<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02200614",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Jul 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02650401?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumors; CNS Tumors<br/><b>Intervention</b>: Drug: Entrectinib<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02650401",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04191135?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Neoplasms<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Olaparib; Drug: Carboplatin; Drug: Gemcitabine<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04191135",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03393884?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer<br/><b>Interventions</b>: Biological: GEN-1; Drug: Carboplatin; Drug: Paclitaxel<br/><b>Sponsor</b>: Celsion<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03393884",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03564340?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer<br/><b>Interventions</b>: Drug: REGN4018; Drug: cemiplimab<br/><b>Sponsor</b>: Regeneron Pharmaceuticals<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03564340",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "St. Joe's Invitation Effectiveness Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04658888?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cervical Cancer Screening<br/><b>Intervention</b>: Device: Evalyn Self-Sampling Brush<br/><b>Sponsor</b>: Milton S. Hershey Medical Center<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04658888",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 09 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01061840?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ewings Sarcoma; Non Small Cell Lung Cancer; Liver Cancer<br/><b>Intervention</b>: Biological: Vigil™<br/><b>Sponsor</b>: Gradalis, Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01061840",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2010 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03343054?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Breast Neoplasms<br/><b>Intervention</b>: Drug: talazoparib<br/><b>Sponsor</b>: Pfizer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03343054",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 17 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Physical Activity for Advanced Stage Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02015936?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Interventions</b>: Behavioral: Six Week Physical Activity Intervention; Other: Progress Reporting<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; University of South Florida<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02015936",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 19 Dec 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Virtual Histology of the Bladder Wall for Bladder Cancer Staging"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04369560?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Neoplasms<br/><b>Interventions</b>: Diagnostic Test: Magnetic Resonance Imaging; Drug: Gadobutrol intravesical administration (4mM); Drug: Ferumoxytol intravesical administration (5 mM)<br/><b>Sponsors</b>: Jodi Maranchie; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04369560",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04634877?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Endometrial Neoplasms<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo for pembrolizumab; Drug: Docetaxel; Drug: Cisplatin; Radiation: External Beam Radiotherapy (EBRT); Drug: Cisplatin (as radiosensitizer); Radiation: Brachytherapy<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; European Network for Gynaecological Oncological Trial Groups; Gynecologic Oncology Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04634877",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 18 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04746638?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Breast Cancer Female<br/><b>Intervention</b>: Diagnostic Test: whole body study and SPECT with 99mTc-RM26<br/><b>Sponsors</b>: Tomsk National Research Medical Center of the Russian Academy of Sciences; Uppsala University<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT04746638",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neoadjuvant Therapy for Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01146795?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer<br/><b>Interventions</b>: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab<br/><b>Sponsors</b>: Jason D. Wright; Genentech, Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01146795",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 Jun 2010 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03913741?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Intervention</b>: Drug: tisotumab vedotin<br/><b>Sponsors</b>: Genmab; Seagen Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03913741",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 12 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04748419?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Cancer; Carcinoma, Non-Small Cell Lung<br/><b>Interventions</b>: Radiation: consolidative hypofractionated radiation therapy (hfRT); Drug: Durvalumab 50 MG/ML<br/><b>Sponsors</b>: Chi Zhang; AstraZeneca<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04748419",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Effectiveness of a Cream for Treatment of Dermatitis in Patients Whith Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04116151?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: DERMATITIS INDUCED BY RADIOTHERAPY IN PATIENTS WHITH CANCER<br/><b>Interventions</b>: Combination Product: Cosmetic cream (Alantel (R): aloe vera, chamomile and thime); Combination Product: Placebo<br/><b>Sponsor</b>: Hospital Universitario Reina Sofia de Cordoba<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04116151",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 04 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04409236?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignant Neoplasm<br/><b>Interventions</b>: Behavioral: Quit2Heal; Behavioral: QuitGuide; Other: Survey Administration<br/><b>Sponsors</b>: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); American Cancer Society, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04409236",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02480374?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer<br/><b>Intervention</b>: Biological: GEN-1<br/><b>Sponsor</b>: Celsion<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02480374",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 24 Jun 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Somatic Acupressure for Symptom Cluster Management in Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04118140?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Interventions</b>: Other: Somatic Acupressure; Other: Sham acupressure; Other: Usual care<br/><b>Sponsors</b>: Charles Darwin University; The Affiliated Hospital Of Southwest Medical University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04118140",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02794571?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced/Metastatic Tumors<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Tiragolumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Etoposide; Drug: Capecitabine; Drug: Bevacizumab; Drug: Pembrolizumab<br/><b>Sponsor</b>: Genentech, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02794571",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 09 Jun 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Vibostolimab (+) Pembrolizumab Coformulation (MK-7684A) or Vibostolimab (+) Pembrolizumab Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04725188?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Non Small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Vibostolimab (+) pembrolizumab coformuation; Drug: Docetaxel; Drug: Placebo<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04725188",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 26 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase 1 Study of PTX-100 in Patients With Advanced Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03900442?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Cancer<br/><b>Intervention</b>: Drug: PTX-100<br/><b>Sponsor</b>: Prescient Therapeutics, Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03900442",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04731909?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: SCLC, Extensive Stage; Lung Cancer; Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Toripalimab; Drug: Anlotinib; Drug: Cisplatin; Drug: Carboplatin<br/><b>Sponsor</b>: Third Military Medical University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04731909",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04493060?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8<br/><b>Interventions</b>: Biological: Dostarlimab; Drug: Niraparib<br/><b>Sponsors</b>: Mayo Clinic; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04493060",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00781612?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasm Metastasis<br/><b>Interventions</b>: Drug: Docetaxel; Drug: Paclitaxel; Drug: Pertuzumab; Drug: Trastuzumab; Drug: Trastuzumab Emtansine; Drug: Atezolizumab<br/><b>Sponsors</b>: Genentech, Inc.; Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00781612",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Oct 2008 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03073525?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Gynecological Cancers; Ovarian Cancer; Cervical Cancer; Uterine Cancer<br/><b>Interventions</b>: Biological: Vigil; Drug: Atezolizumab<br/><b>Sponsors</b>: Gradalis, Inc.; Roche-Genentech<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03073525",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 08 Mar 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03065062?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer<br/><b>Interventions</b>: Drug: Palbociclib; Drug: Gedatolisib<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03065062",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Feb 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03495323?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Interventions</b>: Drug: LY3300054; Drug: Prexasertib<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; Eli Lilly and Company<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03495323",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04119622?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Cancer Stage II; Gastric Cancer Stage III<br/><b>Interventions</b>: Drug: Toripalimab; Drug: oxaliplatin; Drug: capecitabine<br/><b>Sponsor</b>: Aiping Zhou<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04119622",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04748042?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Castrate Sensitive Prostate Cancer; Oligometastatic Disease<br/><b>Interventions</b>: Drug: Abiraterone; Drug: Prednisone; Radiation: External Beam Radiotherapy; Biological: Androgen Deprivation Therapy (ADT); Drug: Olaparib<br/><b>Sponsor</b>: University of Michigan Rogel Cancer Center<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04748042",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01767675?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Fallopian Tubes Cancer; Peritoneal Cancer<br/><b>Interventions</b>: Procedure: Secondary Cytoreductive Surgery; Drug: Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC); Drug: platinum-based systemic chemotherapy postoperatively<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Mayo Clinic; Baptist Health South Florida; Hartford HealthCare; University of Pittsburgh; University of Chicago<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01767675",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 14 Jan 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00799110?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer<br/><b>Interventions</b>: Drug: GM-CSF; Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: imiquimod<br/><b>Sponsors</b>: Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00799110",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 27 Nov 2008 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02710721?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Fasting; Prostatic Neoplasms<br/><b>Interventions</b>: Other: Fasting; Other: Control<br/><b>Sponsor</b>: Charite University, Berlin, Germany<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02710721",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Mar 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04741204?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer Stage; Insulin Resistance; Racial Bias<br/><b>Intervention</b>: Drug: Metformin Extended Release Oral Tablet<br/><b>Sponsors</b>: Woman's; Our Lady of the Lake Regional Medical Center; American Cancer Society, Inc.; Pfizer<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04741204",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Virtual Reality for the Education of Cancer Patients Undergoing Radiation Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04278534?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignant Neoplasm<br/><b>Interventions</b>: Other: Educational Intervention; Other: Survey Administration<br/><b>Sponsors</b>: OHSU Knight Cancer Institute; Oregon Health and Science University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04278534",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 20 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02204072?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms, Castration-Resistant<br/><b>Interventions</b>: Drug: BI 836845; Drug: Enzalutamide<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02204072",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 30 Jul 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04613492?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Biological: MEDI9253; Biological: Durvalumab<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04613492",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 03 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02004418?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Intervention</b>: Radiation: 11C-Choline<br/><b>Sponsor</b>: AHS Cancer Control Alberta<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02004418",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Dec 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03976375?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Lenvatinib; Drug: Docetaxel<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; Eisai Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03976375",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Nivolumab+Ipilimumab+RT in MSS mCRC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04575922?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Microsatellite Stable Colorectal Cancer<br/><b>Interventions</b>: Drug: Nivolumab; Drug: Ipilimumab; Radiation: Radiation Therapy<br/><b>Sponsors</b>: Massachusetts General Hospital; Bristol-Myers Squibb<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04575922",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 05 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03808077?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Rocuronium 0.3mg/kg/hr; Drug: Rocuronium 1.5mg/kg/hr<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03808077",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04708470?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Solid Tumor; Metastatic Checkpoint Refractory HPV Associated Malignancies; Microsatellite Stable Colon Cancer (MSS)<br/><b>Interventions</b>: Drug: Bintrafusp Alfa; Drug: NHS-IL12; Drug: Entinostat<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04708470",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Three Times Weekly Symptom Screening for Children With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04275102?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Relapsed Cancer<br/><b>Intervention</b>: Other: SPARK<br/><b>Sponsor</b>: The Hospital for Sick Children<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04275102",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 19 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04548752?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8<br/><b>Interventions</b>: Drug: Olaparib; Biological: Pembrolizumab<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04548752",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Relationship Between Methods of Bladder Tumor Extraction and Local Recurrence Rate"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04750590?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bladder Cancer<br/><b>Interventions</b>: Procedure: en bloc resection, morcellation; Procedure: piecemeal resection, tissue removal by loop<br/><b>Sponsor</b>: I.M. Sechenov First Moscow State Medical University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04750590",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04740866?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: High-Risk Cancer; Urothelial Carcinoma Bladder<br/><b>Intervention</b>: Radiation: Adjuvant Radiotherapy<br/><b>Sponsor</b>: Cairo University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04740866",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02584244?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Cancer<br/><b>Interventions</b>: Drug: LUM015; Device: LUM 2.6 Imaging Device<br/><b>Sponsors</b>: Lumicell, Inc.; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02584244",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 22 Oct 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03377036?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer Screening<br/><b>Interventions</b>: Diagnostic Test: DBT+s2D; Diagnostic Test: 2D-FFDM<br/><b>Sponsors</b>: University Hospital Muenster; German Research Foundation<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03377036",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04632199?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Pancreatic Ductal Adenocarcinoma; Colorectal Cancer<br/><b>Interventions</b>: Drug: 111In-IPN01087 Low dose; Drug: 111In-IPN01087 High dose<br/><b>Sponsor</b>: Ipsen<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04632199",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 17 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04241185?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Neoplasms<br/><b>Interventions</b>: Drug: Pembrolizumab; Radiation: Conventional Radiotherapy (Bladder only); Radiation: Conventional Radiotherapy (Bladder and pelvic nodes); Radiation: Hypofractionated Radiotherapy (Bladder only); Drug: Cisplatin; Drug: Fluorouracil (5-FU); Drug: Mitomycin C (MMC); Drug: Gemcitabine; Drug: Placebo to Pembrolizumab<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04241185",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04089358?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm<br/><b>Interventions</b>: Other: Educational Intervention; Device: FitBit; Other: Goal Setting; Other: Health Promotion and Education; Other: Media Intervention; Behavioral: Telephone-Based Intervention<br/><b>Sponsors</b>: Children's Oncology Group; National Cancer Institute (NCI); Yale University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04089358",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Role of Ultrasound Guided Peripheral Thoracic Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04741958?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Thoracic Neoplasms<br/><b>Intervention</b>: Diagnostic Test: Ultrasound Guided Peripheral Thoracic Tumors<br/><b>Sponsor</b>: Beni-Suef University<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04741958",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03040986?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: KRAS NP_004976.2:p.G12R; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7<br/><b>Interventions</b>: Other: Laboratory Biomarker Analysis; Drug: Selumetinib Sulfate<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03040986",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 02 Feb 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04221945?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Uterine Cervical Neoplasms<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Placebo for pembrolizumab; Drug: Cisplatin; Radiation: External Beam Radiotherapy (EBRT); Radiation: Brachytherapy<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; European Network for Gynaecological Oncological Trial Groups; Gynecologic Oncology Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04221945",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 09 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04640623?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Neoplasms<br/><b>Interventions</b>: Drug: TAR-200; Drug: Cetrelimab<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04640623",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 23 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04678921?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumor; Metastatic Cancer; Advanced Cancer<br/><b>Intervention</b>: Drug: TJ210001<br/><b>Sponsor</b>: I-Mab Biopharma Co. Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04678921",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03740165?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Placebo for pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Olaparib; Drug: Placebo for olaparib; Biological: Bevacizumab; Drug: Docetaxel<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; European Network for Gynaecological Oncological Trial Groups; Gynecologic Oncology Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03740165",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 14 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02873962?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Peritoneal Cancer; Ovarian Cancer; Fallopian Tube Cancer<br/><b>Interventions</b>: Drug: Bevacizumab; Drug: Nivolumab; Drug: Rucaparib<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; Bristol-Myers Squibb<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02873962",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 22 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02286713?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Cancer; Smoking Cessation; Tobacco Use Cessation<br/><b>Interventions</b>: Behavioral: Patient Decision Aid; Behavioral: Standard Educational Information; Behavioral: Follow-Up Assessments: Questionnaires<br/><b>Sponsors</b>: M.D. Anderson Cancer Center; Patient-Centered Outcomes Research Institute<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02286713",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Nov 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04744506?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Surgery; Lymph Node Metastases<br/><b>Intervention</b>: Device: Tissue Marker Clip<br/><b>Sponsor</b>: Second Affiliated Hospital, School of Medicine, Zhejiang University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04744506",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02365597?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urothelial Cancer<br/><b>Interventions</b>: Drug: Erdafitinib; Drug: Midazolam; Drug: Metformin<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02365597",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 19 Feb 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of DS-7300a in Participants With Advanced Solid Malignant Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04145622?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Tumor; Malignant Solid Tumor<br/><b>Intervention</b>: Drug: DS-7300a<br/><b>Sponsor</b>: Daiichi Sankyo Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04145622",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 30 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04592913?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastrointestinal Neoplasms; Esophagogastric Junction<br/><b>Interventions</b>: Drug: Durvalumab; Drug: FLOT chemotherapy<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04592913",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03066947?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breastcancer; Breast Neoplasm<br/><b>Interventions</b>: Biological: SV-BR-1-GM; Drug: Cyclophosphamide; Biological: Interferon-alpha-2b<br/><b>Sponsors</b>: BriaCell Therapeutics Corporation; Cancer Insight, LLC<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03066947",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 01 Mar 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04188548?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer<br/><b>Interventions</b>: Drug: LY3484356; Drug: Abemaciclib; Drug: Everolimus; Drug: Alpelisib; Drug: Trastuzumab; Drug: Aromatase Inhibitor (AI)<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04188548",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03333031?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Intervention</b>: Drug: HS-196<br/><b>Sponsor</b>: Herbert Lyerly<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03333031",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 06 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04750954?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neuroendocrine Neoplasm<br/><b>Interventions</b>: Drug: Lutetium Lu 177 Dotatate; Drug: Peposertib<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04750954",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03717480?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Hematologic Malignancy<br/><b>Intervention</b>: Device: ClinicMACs<br/><b>Sponsor</b>: Dana-Farber Cancer Institute<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03717480",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 24 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of IMP4297 in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03508011?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Tumours; Breast Cancer; Ovarian Cancer; Prostate Cancer<br/><b>Intervention</b>: Drug: IMP4297<br/><b>Sponsor</b>: Impact Therapeutics, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03508011",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 25 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01849874?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Low-grade Serous Ovarian Cancer; Low-grade Serous Fallopian Tube Cancer; Low-grade Serous Peritoneal Cancer<br/><b>Interventions</b>: Drug: MEK162, MEK inhibitor; oral; Drug: Physician's choice chemotherapy<br/><b>Sponsor</b>: Pfizer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01849874",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 09 May 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in HIV Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04735445?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HIV/AIDS; Cancer<br/><b>Interventions</b>: Diagnostic Test: Digital rectal exam and / or anal cytology (day 1 and after 36 months); Diagnostic Test: Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy; Diagnostic Test: Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months); Diagnostic Test: Semestral cervical cytology and cervical sample for HPV detection; Diagnostic Test: Appointment for mammography (day 1 and after 36 months); Diagnostic Test: Annual appointment for mammography; Diagnostic Test: Semestral appointment for liver ultrasound; Diagnostic Test: Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination; Diagnostic Test: Fecal occult blood test (day 1 and after 36 months); Diagnostic Test: Annual fecal occult blood test; Diagnostic Test: Digital rectal exam and PSA determination (day 1 and after 36 months); Diagnostic Test: Annual digital rectal exam and PSA determination; Diagnostic Test: Annual appointment for low dose computed tomography for lung screening; Diagnostic Test: Annual general inspection for skin lesions suggestive of malignancy<br/><b>Sponsors</b>: Felix Gutierrez; Instituto de Salud Carlos III (Funding reference PI18/01861); Hospital General Universitario Reina Sofía de Murcia; Hospital Universitario Reina Sofia de Cordoba; Hospital General Universitario de Alicante; Hospital Clinic of Barcelona; Hospital Universitario Ramon y Cajal; Hospital General Universitario Santa Lucia; Fundación de Investigación Biomédica - Hospital Universitario de La Princesa; Hospital Universitario de Guadalajara; Hospital Universitario Virgen de la Arrixaca; Hospital Parc Taulí, Sabadell; Hospital Universitario La Fe; Germans Trias i Pujol Hospital; Complejo Hospitalario Universitario de Albacete; Hospital Universitario Fundación Alcorcón; Hospital General Universitario Elche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04735445",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04746924?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non-small Cell Lung Cancer; NSCLC<br/><b>Interventions</b>: Drug: Tislelizumab; Drug: BGB-A1217; Drug: Pembrolizumab; Drug: Placebo<br/><b>Sponsor</b>: BeiGene<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04746924",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03181867?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Neoplasms; Prostatic Cancer; Prostate Cancer; Cancer Of Prostate; Metastatic Prostate Cancer<br/><b>Intervention</b>: Drug: 18F-DCFPyL<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03181867",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 09 Jun 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01833208?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer<br/><b>Interventions</b>: Other: Laboratory Biomarker Analysis; Radiation: Radiation Therapy<br/><b>Sponsors</b>: Roswell Park Cancer Institute; National Cancer Institute (NCI); Dendreon<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01833208",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Apr 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Role of 68Ga-FAPI-04 PET/CT as a Problem Solving Imaging Modality in Various Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04441606?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Different Types of Cancer<br/><b>Intervention</b>: Radiation: 68Ga-FAPI-04 PET/CT<br/><b>Sponsor</b>: Tel-Aviv Sourasky Medical Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04441606",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 22 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03190967?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Brain Metastasis; Brain Cancer<br/><b>Interventions</b>: Drug: T-DM1; Drug: TMZ<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03190967",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 19 Jun 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04553471?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Sarcoma; Thoracic Cancer; Abdominal Cancer; Pelvic Cancer<br/><b>Interventions</b>: Radiation: Stereotactic body radiotherapy; Procedure: Research blood draw<br/><b>Sponsors</b>: Washington University School of Medicine; Goldman Sachs Foundation (Emerson Collective)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04553471",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "CancerLife: Patient-Driven Solution in Cancer Care"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03371147?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Intervention</b>: Other: CancerLife<br/><b>Sponsors</b>: John Wayne Cancer Institute; Healthy Platforms, LLC<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03371147",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 13 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04644770?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostatic Neoplasms; Adenocarcinoma<br/><b>Intervention</b>: Drug: JNJ-69086420<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04644770",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 25 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04728893?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Hematologic Malignancies<br/><b>Intervention</b>: Drug: MK-1026<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04728893",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04741503?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer Screening; Oncology; Preventative Medicine; Mammography<br/><b>Interventions</b>: Other: Breast Cancer Screening Decision Support Tool; Other: National Cancer Institute Breast Cancer Screening PDQ<br/><b>Sponsors</b>: Washington University School of Medicine; National Institute on Minority Health and Health Disparities (NIMHD)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04741503",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04234568?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Digestive System Neuroendocrine Tumor; Metastatic Well Differentiated Neuroendocrine Neoplasm<br/><b>Interventions</b>: Drug: Lutetium Lu 177 Dotatate; Drug: Triapine<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04234568",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 21 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Evaluation of PET-CT Scanner Performances to Detect Infra-centimetric Lesions in Patients With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03956459?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Intervention</b>: Other: Patients with a cancer for which a FDG-PET scanner must be performed<br/><b>Sponsor</b>: Institut Claudius Regaud<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03956459",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 20 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04743310?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Central Nervous System Tumor<br/><b>Interventions</b>: Drug: tozuleristide; Device: Canvas imaging system; Procedure: Surgical resection of tumor<br/><b>Sponsors</b>: John Yu; Blaze Bioscience Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04743310",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 08 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03792841?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Castration-resistant Prostate Cancer; Prostate Cancer<br/><b>Interventions</b>: Drug: AMG 160; Drug: Pembrolizumab; Drug: Etanercept; Drug: Immunomodulating Agent<br/><b>Sponsor</b>: Amgen<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03792841",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 03 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03558945?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pancreatic Tumor<br/><b>Intervention</b>: Biological: Personalized neoantigen vaccine<br/><b>Sponsor</b>: Changhai Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03558945",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 15 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Reducing Cancer Side-effects With Systematic Light Exposure"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02661308?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer-related Fatigue; Cancer-related Cognitive Impairment<br/><b>Intervention</b>: Device: Litebook<br/><b>Sponsor</b>: Aarhus University Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02661308",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 22 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "US NAB With ROSE Versus US FNAB With no ROSE"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04618874?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Intervention</b>: Diagnostic Test: Rapid on-site evaluation<br/><b>Sponsor</b>: Fondazione Policlinico Universitario Agostino Gemelli IRCCS<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04618874",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04614766?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastro-enteropancreatic Neuroendocrine Tumor; Neuroendocrine Tumors<br/><b>Interventions</b>: Drug: Lutathera; Drug: Azedra<br/><b>Sponsors</b>: David Bushnell; National Institutes of Health (NIH); National Cancer Institute (NCI); Progenics Pharmaceuticals, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04614766",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 04 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04327986?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Histologically or Cytologically Confirmed Pancreatic Cancer; Unresectable or Borderline Resectable Pancreatic Cancer; Pancreatic Neoplasms; Pancreatic Cancer; Metastatic Pancreatic Cancer<br/><b>Interventions</b>: Drug: M7824; Drug: M9241; Radiation: SBRT<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04327986",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 31 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03648372?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Lymphoma; Hematologic Neoplasms<br/><b>Intervention</b>: Drug: TAK-981<br/><b>Sponsor</b>: Takeda<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03648372",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04446117?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Prostate Cancer; Prostate Adenocarcinoma<br/><b>Interventions</b>: Drug: Cabozantinib; Drug: Atezolizumab; Drug: Abiraterone Acetate; Drug: Enzalutamide; Drug: Prednisone<br/><b>Sponsors</b>: Exelixis; Roche-Genentech; Takeda<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04446117",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 24 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Claudin18.2 CAR-T (CT041) in Patients With Gastric or Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04404595?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Cancer; Pancreatic Cancer<br/><b>Intervention</b>: Biological: CT041<br/><b>Sponsor</b>: Carsgen Therapeutics, Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04404595",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 27 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03162289?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Ovarian Cancer<br/><b>Interventions</b>: Other: Fasting; Other: Vegan<br/><b>Sponsor</b>: Charite University, Berlin, Germany<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03162289",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 22 May 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03036228?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Intervention</b>: Drug: Karonudib<br/><b>Sponsor</b>: Thomas Helleday Foundation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03036228",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 30 Jan 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02104986?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Extra Cranial Non Seminomateous Malignant Germ Cell Tumour<br/><b>Interventions</b>: Drug: Velbe-Bleomycin-Cisplatin; Drug: Vepeside-ifosfamide-Cisplatin<br/><b>Sponsor</b>: Centre Leon Berard<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02104986",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Apr 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01352962?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Urethral Neoplasms; Neoplasms, Urethral; Cancer of the Urethra; Urethral Cancer<br/><b>Interventions</b>: Drug: Gemcitabine; Drug: Carboplatin; Drug: Lenalidomide<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01352962",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 May 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02603432?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urothelial Cancer<br/><b>Interventions</b>: Biological: Avelumab; Other: Best Supportive Care; Biological: Following the planned interim analysis for this study: Avelumab<br/><b>Sponsor</b>: Pfizer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02603432",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 11 Nov 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04732455?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Peripheral Neuropathy; Chemotherapy-induced Peripheral Neuropathy; Breast Cancer<br/><b>Interventions</b>: Drug: Lidocaine in Saline; Drug: Duloxetine 30 MG; Drug: Normal saline<br/><b>Sponsor</b>: Gamal Mohamed Taha Abouelmagd<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04732455",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04620330?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non Small Cell Lung Cancer; KRAS Activating Mutation<br/><b>Interventions</b>: Drug: VS-6766; Drug: VS-6766 and Defactinib<br/><b>Sponsor</b>: Verastem, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04620330",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 06 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04468061?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative<br/><b>Interventions</b>: Drug: Sacituzumab Govitecan; Drug: Pembrolizumab<br/><b>Sponsors</b>: Dana-Farber Cancer Institute; Immunomedics, Inc.; Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04468061",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 13 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Salvage Ovarian FANG™ Vaccine + Bevacizumab"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01551745?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Stage III Ovarian Cancer; Stage IV Ovarian Cancer<br/><b>Interventions</b>: Biological: Vigil™ Vaccine; Drug: Bevacizumab<br/><b>Sponsor</b>: Gradalis, Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01551745",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 13 Mar 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04610684?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Small-cell Lung Cancer; Brain Metastases<br/><b>Interventions</b>: Drug: Carboplatin; Drug: Etoposide; Drug: Atezolizumab<br/><b>Sponsors</b>: Jeffrey Clarke; Genentech, Inc.; Duke University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04610684",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 30 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Single Dose Partial Breast Radiotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00944528?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Radiation: Radiosurgery<br/><b>Sponsor</b>: Duke University<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00944528",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Jul 2009 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03682068?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer<br/><b>Interventions</b>: Drug: Durvalumab; Drug: Tremelimumab; Drug: Cisplatin + Gemcitabine; Drug: Carboplatin + Gemcitabine<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03682068",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Sep 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04607668?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer Metastatic; Myelosuppression Adult; Chemotherapeutic Toxicity<br/><b>Interventions</b>: Drug: Trilaciclib; Drug: Placebo<br/><b>Sponsor</b>: G1 Therapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04607668",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 29 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02176902?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer<br/><b>Interventions</b>: Behavioral: behavioral dietary intervention; Dietary Supplement: omega-3 fatty acid; Other: laboratory biomarker analysis<br/><b>Sponsors</b>: Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI); Pharmavite LLC; Seafood Industry Research Fund<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02176902",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Jun 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02704312?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Radiation: Radiotherapy by Prone and decubitus<br/><b>Sponsor</b>: University Hospital Center of Martinique<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02704312",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 10 Mar 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04500145?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small-cell Lung Cancer<br/><b>Interventions</b>: Radiation: SIB-IMRT; Radiation: routine IMRT<br/><b>Sponsor</b>: Chinese Academy of Medical Sciences<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04500145",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03663712?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected<br/><b>Intervention</b>: Biological: Talimogene Laherparepvec<br/><b>Sponsor</b>: Dan Blazer III, M.D.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03663712",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Sep 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Effectiveness of autoHYpnosis in the Prevention of Anxiety During Radiotherapy of Head and Neck Tumors (HYMACO)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04671485?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Head and Neck Tumors<br/><b>Interventions</b>: Other: Standard care; Other: Autohypnosis; Other: Musicotherapy<br/><b>Sponsor</b>: Institut de Cancérologie de Lorraine<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04671485",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "FAMily Oriented Support (FAMOS): Psychosocial Intervention for Childhood Cancer Survivors and Their Families"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02200731?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Childhood Cancer<br/><b>Intervention</b>: Behavioral: FAMOS: psychosocial family intervention<br/><b>Sponsors</b>: Pernille Bidstrup; Rigshospitalet, Denmark; Odense University Hospital; Aarhus University Hospital Skejby; Aarhus University Hospital<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02200731",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Jul 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04626635?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Interventions</b>: Drug: REGN7075; Drug: cemiplimab<br/><b>Sponsor</b>: Regeneron Pharmaceuticals<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04626635",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Hybrid APC for Gastric Low Grade Intraepithelial Neoplasia"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04197180?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastric Low Grade Intraepithelial Neoplasia<br/><b>Intervention</b>: Procedure: Hybrid Argon Plasma Coagulation<br/><b>Sponsors</b>: Chinese University of Hong Kong; Nanfang Hospital of Southern Medical University; Shenzhen Hospital of Southern Medical University; The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04197180",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03809000?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Radiation: Radiation Therapy; Drug: Enzalutamide; Drug: Bicalutamide; Drug: GnRH analog<br/><b>Sponsors</b>: RTOG Foundation, Inc.; Pfizer; Astellas Pharma Inc<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03809000",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 18 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03534453?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platinum Sensitive<br/><b>Intervention</b>: Drug: Olaparib 300mg tablets<br/><b>Sponsor</b>: AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03534453",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 23 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02810418?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Pancreatic Neoplasms<br/><b>Interventions</b>: Drug: LMB-100; Drug: Nab-Paclitaxel; Device: Mesothelin Expression<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02810418",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Jun 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02489318?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Apalutamide; Drug: Placebo; Drug: Androgen Deprivation Therapy (ADT)<br/><b>Sponsor</b>: Aragon Pharmaceuticals, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02489318",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 03 Jul 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03173924?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Prostate Cancer; Prostatic Neoplasms; Prostate Cancer; Prostatic Cancer; Prostate Neoplasms<br/><b>Interventions</b>: Drug: 18F-NaF; Drug: 18F-DCFPyL; Drug: 18F-FDG<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03173924",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 02 Jun 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01795586?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Interventions</b>: Drug: Eribulin; Drug: Carboplatin<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Eisai Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01795586",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Feb 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Virtual Exercise Program to Reduce Cancer Related Fatigue"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04533165?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Cancer-related Problem/Condition; Fatigue<br/><b>Intervention</b>: Behavioral: Exercise<br/><b>Sponsors</b>: University of Colorado, Denver; Cancer League of Colorado<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04533165",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 31 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04209660?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Adenoid Cystic Carcinoma; Salivary Gland Cancer<br/><b>Interventions</b>: Drug: Lenvatinib; Drug: Pembrolizumab<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme Corp.; Eisai Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04209660",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04381832?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostatic Neoplasms, Castration-Resistant; Androgen-Resistant Prostatic Neoplasms; Castration Resistant Prostatic Neoplasms; Prostatic Cancer, Castration-Resistant<br/><b>Interventions</b>: Drug: Etrumadenant; Drug: Zimberelimab; Drug: AB680; Drug: Enzalutamide; Drug: Docetaxel<br/><b>Sponsor</b>: Arcus Biosciences, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04381832",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 11 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Personalized Oncogenomics (POG) Program of British Columbia"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02155621?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Cancers; Advanced Cancers; Cancers That Cannot be Treated With Curative Intent<br/><b>Intervention</b>: Genetic: Genome sequencing<br/><b>Sponsors</b>: British Columbia Cancer Agency; BC Cancer Foundation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02155621",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 04 Jun 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Clinician Communication About Sexual Health"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04262219?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Behavioral: iShare<br/><b>Sponsors</b>: Fox Chase Cancer Center; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04262219",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02463799?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Radium-223; Biological: Sipuleucel-T<br/><b>Sponsors</b>: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Dendreon; Bayer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02463799",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Jun 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03163732?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumor<br/><b>Intervention</b>: Genetic: Blood and tumor samples<br/><b>Sponsors</b>: Centre Leon Berard; Roche Pharma AG<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03163732",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 23 May 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03223753?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Carcinoma In Situ; Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm<br/><b>Interventions</b>: Other: Educational Intervention; Other: Internet-Based Intervention; Other: Laboratory Biomarker Analysis; Device: Medical Device Usage and Evaluation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration<br/><b>Sponsors</b>: Children's Oncology Group; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03223753",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 21 Jul 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Cabozantinib in High Grade Neuroendocrine Neoplasms"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04412629?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: High Grade Neuroendocrine Neoplasms<br/><b>Interventions</b>: Drug: Cabozantinib; Procedure: Blood for plasma biomarkers; Procedure: Tissue biopsy<br/><b>Sponsors</b>: Washington University School of Medicine; Exelixis<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04412629",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Intraoperative Radiotherapy for Early Stage Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01189851?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Device: Intraoperative Radiotherapy<br/><b>Sponsor</b>: Hoag Memorial Hospital Presbyterian<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01189851",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Aug 2010 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03005782?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignancies<br/><b>Interventions</b>: Drug: REGN3767; Drug: cemiplimab<br/><b>Sponsors</b>: Regeneron Pharmaceuticals; Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03005782",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 29 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02661971?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Stomach Cancer; Gastroesophageal Junction Cancer<br/><b>Interventions</b>: Drug: Docetaxel; Drug: Oxaliplatin; Drug: Calciumfolinat; Drug: 5-Fluorouracil; Biological: Ramucirumab<br/><b>Sponsor</b>: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02661971",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Jan 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03098836?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: ARN-509; Drug: Abiraterone Acetate; Drug: Prednisone<br/><b>Sponsors</b>: Daniel George, MD; Janssen Scientific Affairs, LLC<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03098836",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Apr 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04224272?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HER2+/HR+ Breast Cancer<br/><b>Interventions</b>: Drug: ZW25 (Zanidatamab); Drug: Palbociclib; Drug: Fulvestrant<br/><b>Sponsor</b>: Zymeworks Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04224272",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 13 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The Family Talk Intervention in Pediatric Oncology"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03650530?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pediatric Oncology<br/><b>Intervention</b>: Other: The Family Talk Intervention<br/><b>Sponsor</b>: Ersta Sköndal University College<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03650530",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Moving On - An RCT to Test Physical Therapy Education"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04731805?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Behavioral: Moving On After Breast Cancer<br/><b>Sponsors</b>: Northeastern University; American Physical Therapy Association<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04731805",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04653142?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: BI 765063; Drug: BI 754091<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04653142",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 04 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738786?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Tongue Cancer; Tongue Cancer TNM Staging Primary Tumor (T) T1; Tongue Cancer TNM Staging Primary Tumor (T) T2; Surgery; Resection Margin; Squamous Cell Carcinoma<br/><b>Interventions</b>: Procedure: 1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers; Procedure: 1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers<br/><b>Sponsors</b>: Samsung Medical Center; Seoul National University Hospital; Asan Medical Center; Ajou University School of Medicine; National Cancer Center, Korea; Inje University; Seoul National University Bundang Hospital; Kangbuk Samsung Hospital; Dong-A University Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04738786",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The SONImage Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04125277?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Other: FES-PET scan, and possibly one additional visit for an FDG-PET<br/><b>Sponsors</b>: University Medical Center Groningen; Dutch Cancer Society; BOOG Study Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04125277",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 14 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Hypofractionated LocoRegional Radiotherapy in Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04228991?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Neoplasms; Radiotherapy; Lymphedema<br/><b>Interventions</b>: Radiation: Locoregional radiation treatment - Conventional fractionation; Radiation: Locoregional radiation treatment - Hypofractionation<br/><b>Sponsor</b>: Ontario Clinical Oncology Group (OCOG)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04228991",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 14 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04697524?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Malignant Solid Neoplasm; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm<br/><b>Interventions</b>: Behavioral: Support Group Therapy; Behavioral: Symptom Management Service (SMS) Consultation; Other: Quality of Life (QOL) Questionnaires; Other: Interview<br/><b>Sponsor</b>: University of California, San Francisco<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04697524",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 06 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Effect of Mirtazapine Versus Placebo in Reversing Anorexia in Non-small Cell Lung cáncer Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04748523?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anorexia; Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Mirtazapine; Drug: Placebo Oral Tablet<br/><b>Sponsor</b>: Instituto Nacional de Cancerologia de Mexico<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04748523",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03057600?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer<br/><b>Intervention</b>: Drug: Pac-CB<br/><b>Sponsor</b>: Calithera Biosciences, Inc<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03057600",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 20 Feb 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04297423?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Drug: Plenvu<br/><b>Sponsors</b>: Hospital Clinic of Barcelona; Casen Recordati S.L.; Fundacion Clinic per a la Recerca Biomédica<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04297423",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 Mar 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03076203?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Carcinoma Metastatic to the Bone; Stage IV Prostate Adenocarcinoma; Hormone-refractory Prostate Cancer<br/><b>Interventions</b>: Drug: Niraparib; Radiation: Radium Ra 223 Dichloride<br/><b>Sponsors</b>: Sidney Kimmel Cancer Center at Thomas Jefferson University; Janssen, LP; Prostate Cancer Clinical Trials Consortium; Bayer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03076203",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 10 Mar 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03766009?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer Stage 0; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III<br/><b>Interventions</b>: Other: Usual Care; Other: Web-based decision aid<br/><b>Sponsors</b>: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Agency for Healthcare Research and Quality (AHRQ)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03766009",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03377361?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm<br/><b>Interventions</b>: Biological: Nivolumab; Drug: Trametinib; Biological: Ipilimumab; Drug: Regorafenib<br/><b>Sponsors</b>: Bristol-Myers Squibb; Novartis<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03377361",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04521621?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasm Metastasis<br/><b>Interventions</b>: Biological: V937; Drug: Pembrolizumab<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04521621",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 20 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03386721?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers<br/><b>Interventions</b>: Drug: simlukafusp alfa; Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Drug: Gemcitabine; Drug: Vinorelbine<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03386721",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01945775?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Neoplasms; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation<br/><b>Interventions</b>: Drug: talazoparib; Drug: Physician's-Choice<br/><b>Sponsors</b>: Pfizer; Medivation, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01945775",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 19 Sep 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03084757?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Solid Tumor, Adult<br/><b>Intervention</b>: Diagnostic Test: research of druggable molecular alterations on tumor biopsy<br/><b>Sponsor</b>: Institut Curie<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03084757",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 21 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04235101?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Intervention</b>: Drug: SYD985 + Niraparib<br/><b>Sponsor</b>: Byondis B.V.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04235101",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 21 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738955?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease<br/><b>Intervention</b>: Drug: Micafungin Sodium<br/><b>Sponsor</b>: Shandong Provincial Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04738955",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02476786?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast<br/><b>Interventions</b>: Behavioral: FACT-B; Drug: Goserelin; Drug: Anastrozole; Drug: Exemestane; Drug: Fulvestrant; Drug: Tamoxifen; Other: Archived tissue collection<br/><b>Sponsors</b>: Washington University School of Medicine; Genomic Health®, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02476786",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 19 Jun 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Stay on Track: A Study of Exercise Effects During Radiation"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03243786?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Behavioral: Lifestyle- Supportive Care<br/><b>Sponsor</b>: Medical College of Wisconsin<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03243786",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 09 Aug 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of LY3023414 in Participants With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01655225?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer<br/><b>Interventions</b>: Drug: LY3023414; Drug: Midazolam; Drug: Fulvestrant; Drug: Pemetrexed; Drug: Cisplatin; Drug: Abemaciclib; Drug: Letrozole<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01655225",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 01 Aug 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01554371?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Malignant Solid Tumour; Breast Cancer Nos Metastatic Recurrent; Neuropathy<br/><b>Interventions</b>: Drug: Eribulin; Drug: Cyclophosphamide<br/><b>Sponsors</b>: University of California, San Francisco; Eisai Inc.<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01554371",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 15 Mar 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01271712?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastrointestinal Stromal Tumors<br/><b>Interventions</b>: Drug: Regorafenib (Stivarga, BAY73-4506); Drug: Placebo; Drug: Best supportive care<br/><b>Sponsor</b>: Bayer<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01271712",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 07 Jan 2011 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04171700?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Intervention</b>: Drug: Rucaparib<br/><b>Sponsor</b>: Clovis Oncology, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04171700",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Ribociclib and Bicalutamide in AR+ TNBC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03090165?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Cancer<br/><b>Interventions</b>: Drug: ribociclib; Drug: Bicalutamide<br/><b>Sponsors</b>: Ruth O'Regan, M.D.; Novartis; Big Ten Cancer Research Consortium; University of Wisconsin, Madison<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03090165",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04276415?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Gastrointestinal Stromal Tumors<br/><b>Intervention</b>: Drug: DS-6157a<br/><b>Sponsor</b>: Daiichi Sankyo, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04276415",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 19 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02997228?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7<br/><b>Interventions</b>: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Other: Quality-of-Life Assessment; Other: Questionnaire Administration<br/><b>Sponsors</b>: National Cancer Institute (NCI); NRG Oncology<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02997228",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 20 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Trial of Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04749602?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Renal Cell Cancer Metastatic; Non-small Cell Lung Cancer Metastatic; Pleural Effusion, Malignant<br/><b>Intervention</b>: Drug: Nivolumab<br/><b>Sponsor</b>: Kidney Cancer Research Bureau<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04749602",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Prostate PMSABR Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04742972?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Radiation: SABR; Other: SOC<br/><b>Sponsor</b>: Darren Poon<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04742972",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 08 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01130519?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HLRCC; Sporadic Papillary Renal Cell Cancer<br/><b>Interventions</b>: Drug: Bevacizumab; Drug: Erlotinib<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01130519",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 26 May 2010 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Self-sampling for Non-attenders to Cervical Cancer Screening"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04226313?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cervical Cancer; Cervical Dysplasia; Human Papillomavirus Infection<br/><b>Interventions</b>: Diagnostic Test: Self-sampling by Evalyn Brush; Diagnostic Test: Self sampling by Evalyn Brush home or in GP´s clinic<br/><b>Sponsors</b>: The Institute of Molecular and Translational Medicine, Czech Republic; Cancer Research Czech Republic<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04226313",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 13 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04128332?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer of Pancreas<br/><b>Intervention</b>: Radiation: Pre-operative stereotactic ablative body radiotherapy<br/><b>Sponsors</b>: CCTU- Cancer Theme; AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04128332",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03556358?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Breast Neoplasms; HER2-positive Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer<br/><b>Interventions</b>: Biological: TX05 (trastuzumab); Biological: Herceptin®; Drug: Paclitaxel; Drug: Epirubicin; Drug: Cyclophosphamide<br/><b>Sponsor</b>: Tanvex BioPharma USA, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03556358",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of SRF617 in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04336098?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumor<br/><b>Interventions</b>: Drug: SRF617; Drug: Gemcitabine; Drug: Albumin-Bound Paclitaxel; Drug: Pembrolizumab<br/><b>Sponsor</b>: Surface Oncology<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04336098",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SGM-101 in Colorectal Lung Metastases"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04737213?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Metastatic Colon Cancer<br/><b>Intervention</b>: Drug: SGM-101<br/><b>Sponsors</b>: Leiden University Medical Center; Erasmus Medical Center; Surgimab<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04737213",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00768664?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Head and Neck Neoplasms<br/><b>Intervention</b>: Drug: PF-00299804<br/><b>Sponsor</b>: Pfizer<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00768664",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 08 Oct 2008 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01614990?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer Cachexia<br/><b>Interventions</b>: Drug: Macimorelin; Drug: Placebo<br/><b>Sponsors</b>: Garcia, Jose M., MD, PhD; VA Office of Research and Development; Baylor College of Medicine; AEterna Zentaris<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01614990",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 Jun 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04508764?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Hereditary Breast and Ovarian Cancer; Lynch Syndrome<br/><b>Intervention</b>: Other: Families Accelerating Cascade Testing Toolkit<br/><b>Sponsors</b>: Washington University School of Medicine; Barnes-Jewish Hospital<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04508764",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 11 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03970382?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Interventions</b>: Biological: NeoTCR-P1 adoptive cell therapy; Biological: nivolumab; Biological: IL-2<br/><b>Sponsor</b>: PACT Pharma, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03970382",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 31 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03697304?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasm Metastasis<br/><b>Interventions</b>: Drug: BI 754091; Drug: BI 754111; Drug: BI 836880<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03697304",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02891161?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urothelial Cancer<br/><b>Interventions</b>: Drug: durvalumab; Radiation: Radiation Therapy<br/><b>Sponsors</b>: Monika Joshi, MD; AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02891161",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 Sep 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "TAC T-cells for the Treatment of HER2-positive Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04727151?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HER2-Positive Solid Tumors<br/><b>Intervention</b>: Biological: TAC01-HER2<br/><b>Sponsor</b>: Triumvira Immunologics, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04727151",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 27 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04743102?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rectal Cancer; Neoadjuvant Therapy; Complete Remission; Metastasis<br/><b>Interventions</b>: Procedure: multi-points and full-thickness Biopsy; Diagnostic Test: traditional cCR<br/><b>Sponsor</b>: Beijing Chao Yang Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04743102",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 08 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02857270?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Cancer; Metastatic Melanoma; Metastatic Non-small Cell Lung Cancer; Colorectal Cancer<br/><b>Interventions</b>: Drug: LY3214996; Drug: Midazolam; Drug: Abemaciclib; Drug: Nab-paclitaxel; Drug: Gemcitabine; Drug: Encorafenib; Drug: Cetuximab<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02857270",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Identifying and Caring for Individuals With Inherited Cancer Syndrome"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04494945?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Hereditary Breast and Ovarian Cancer Syndrome; Hereditary Neoplastic Syndrome; Lynch Syndrome<br/><b>Interventions</b>: Procedure: Biospecimen Collection; Other: Genetic Counseling; Other: Genetic Testing<br/><b>Sponsors</b>: OHSU Knight Cancer Institute; National Cancer Institute (NCI); Oregon Health and Science University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04494945",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 31 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04272203?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Acute Myeloid Leukemia (AML); Non Small Cell Lung Cancer; Cancer<br/><b>Intervention</b>: Drug: ABBV-184<br/><b>Sponsor</b>: AbbVie<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04272203",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 17 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02236572?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer<br/><b>Intervention</b>: Drug: Everolimus<br/><b>Sponsors</b>: Yale University; Novartis Pharmaceuticals<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02236572",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Sep 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02534376?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Intervention</b>: Drug: ezetimibe 10mg-simvastatin 40mg<br/><b>Sponsors</b>: Cedars-Sinai Medical Center; Roswell Park Cancer Institute<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02534376",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 27 Aug 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04688931?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder<br/><b>Interventions</b>: Drug: UGN-102; Procedure: TURBT<br/><b>Sponsor</b>: UroGen Pharma Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04688931",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 30 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04728035?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Breast Cancer<br/><b>Intervention</b>: Drug: Irinotecan Liposome Injection<br/><b>Sponsor</b>: CSPC Ouyi Pharmaceutical Co., Ltd.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04728035",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of RP3 Monotherapy and RP3 in Combination With Anti-PD1 Therapy in Patients With Solid Tumours"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04735978?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumor<br/><b>Interventions</b>: Biological: RP3; Biological: anti-PD1 monoclonal antibody<br/><b>Sponsor</b>: Replimune Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04735978",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of AMG 650 in Adult Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04293094?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: AMG 650<br/><b>Sponsor</b>: Amgen<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04293094",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 03 Mar 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04033354?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Squamous Non Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: HLX10; Drug: carboplatin and nab paclitaxel; Drug: Placebo<br/><b>Sponsor</b>: Shanghai Henlius Biotech<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04033354",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 26 Jul 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Efficacy of Kinesio Taping on Lymphedema Following Head and Neck Cancer Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04691310?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lymphedema; Head and Neck Cancer; Kinesio Taping; Therapy<br/><b>Intervention</b>: Device: Kinesio Tex Gold<br/><b>Sponsor</b>: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04691310",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 31 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03003065?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cholangiocarcinoma; Tumor; Klatskin Tumor<br/><b>Intervention</b>: Drug: Temoporfin<br/><b>Sponsor</b>: Chinese University of Hong Kong<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03003065",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 26 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01744249?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neuroendocrine Tumors; Advanced Cancer<br/><b>Interventions</b>: Drug: Axitinib; Drug: Sandostatin LAR; Drug: Placebo<br/><b>Sponsors</b>: Grupo Espanol de Tumores Neuroendocrinos; Pfizer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01744249",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Dec 2012 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Therapeutic Instillation of Mistletoe"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02106572?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Superficial Bladder Cancer<br/><b>Interventions</b>: Drug: abnobaVISCUM 900; Drug: Mitomycin C<br/><b>Sponsor</b>: Abnoba Gmbh<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02106572",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 Apr 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04438304?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neuroendocrine Tumors<br/><b>Intervention</b>: Drug: 64Cu-SARTATE<br/><b>Sponsor</b>: Clarity Pharmaceuticals Ltd<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04438304",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 18 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03724409?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neuroendocrine Tumors<br/><b>Intervention</b>: Drug: [90]Y-DOTATOC<br/><b>Sponsors</b>: Sandeep Laroia; National Institutes of Health (NIH); Holden Comprehensive Cancer Center; National Cancer Institute (NCI)<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT03724409",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Endoscopic Visualisation of Anastomosis in Colorectal Cancer Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738240?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rectal Cancer; Colorectal Cancer; Anastomotic Leak; Intraoperative Endoscopy<br/><b>Intervention</b>: Diagnostic Test: Intra-operative endoscopy<br/><b>Sponsor</b>: University of Plymouth<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04738240",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02316457?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Cancer (Triple Negative Breast Cancer (TNBC))<br/><b>Interventions</b>: Biological: IVAC_W_bre1_uID; Biological: IVAC_W_bre1_uID/IVAC_M_uID<br/><b>Sponsors</b>: BioNTech SE; Seventh Framework Programme<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02316457",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 15 Dec 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "SABR for T1-2a N1 NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03321760?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Intervention</b>: Radiation: Stereotactic Ablative Radiation Therapy (SABR)<br/><b>Sponsors</b>: Indiana University; Indiana University School of Medicine<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03321760",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Oct 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03366116?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Solid Tumors<br/><b>Intervention</b>: Drug: aza-TdCyd<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03366116",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03797391?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Neoplasm Metastasis; Non-Small-Cell Lung Cancer<br/><b>Intervention</b>: Drug: EMB-01<br/><b>Sponsors</b>: Shanghai EpimAb Biotherapeutics Co., Ltd.; Covance<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03797391",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 09 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04238819?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Relapsed Solid Tumor; Refractory Solid Tumor<br/><b>Interventions</b>: Drug: Abemaciclib; Drug: Irinotecan; Drug: Temozolomide<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04238819",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 23 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00060398?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anemia; Fatigue; Prostate Cancer<br/><b>Interventions</b>: Biological: epoetin alfa; Drug: dexamethasone<br/><b>Sponsors</b>: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00060398",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 May 2003 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02694822?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Cancers; Advanced Solid Cancers Refractory to PD-1<br/><b>Intervention</b>: Drug: AGEN1884<br/><b>Sponsor</b>: Agenus Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02694822",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 Mar 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04111458?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors, KRAS Mutation<br/><b>Interventions</b>: Drug: BI 1701963; Drug: Trametinib<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04111458",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03526887?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer<br/><b>Intervention</b>: Drug: Pembrolizumab<br/><b>Sponsor</b>: Spanish Lung Cancer Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03526887",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03926143?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Intervention</b>: Drug: BAY94-9343 (Anetumab ravtansine)<br/><b>Sponsor</b>: Bayer<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT03926143",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 24 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03889275?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Interventions</b>: Biological: MEDI5395; Biological: Durvalumab<br/><b>Sponsor</b>: MedImmune LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03889275",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 26 Mar 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03332498?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colon Cancer; Colorectal Cancer; Colorectal Carcinoma; Colon Disease<br/><b>Interventions</b>: Drug: Pembrolizumab; Drug: Ibrutinib<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; Janssen Scientific Affairs, LLC; Merck Sharp & Dohme Corp.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03332498",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 06 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis (Atavistic Chemotherapy)."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02366884?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Interventions</b>: Drug: Anti-Bacterial Agents; Drug: Anti-Fungal Agents; Drug: Anti-Protozoal Agents<br/><b>Sponsors</b>: Dr. Frank Arguello Cancer Clinic; Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02366884",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 19 Feb 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Optimized Rehabilitation Following Primary Breast Cancer Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03434717?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rehabilitation; Breast Neoplasms; Psychological Distress<br/><b>Interventions</b>: Other: Individualised rehabilitation; Other: Care as usual<br/><b>Sponsor</b>: Lund University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03434717",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 15 Feb 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01445509?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: Bevacizumab; Drug: Dasatinib<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01445509",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 03 Oct 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03093116?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Locally Advanced Solid Tumors; Metastatic Solid Tumors<br/><b>Intervention</b>: Drug: Oral repotrectinib (TPX-0005)<br/><b>Sponsor</b>: Turning Point Therapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03093116",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Dose EScalation Induction of EvERolimus"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02387099?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Hormone Receptor Positive Tumor<br/><b>Interventions</b>: Drug: 3 weeks Dose Induction of Everolimus; Drug: 3 weeks Conventional Everolimus Dosing; Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24; Drug: Standard Care after 24 weeks<br/><b>Sponsors</b>: German Breast Group; Novartis<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02387099",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Mar 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Prospective Randomized Trial to Compare Survival Rates and to Observe Quality of Life According to Follow-up Period After Gastrectomy for Advanced Gastric Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04740346?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Cancer; Recurrence; Quality of Life<br/><b>Intervention</b>: Diagnostic Test: Computed tomography, Chest X-ray, and blood test<br/><b>Sponsors</b>: National Cancer Center, Korea; Korea Health Industry Development Institute<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04740346",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01543698?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors Harboring a BRAF V600 Mutation<br/><b>Interventions</b>: Drug: LGX818; Drug: MEK162; Drug: LEE011<br/><b>Sponsor</b>: Pfizer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01543698",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 05 Mar 2012 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04086485?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine Neoplasms<br/><b>Interventions</b>: Drug: Lu-177-DOTATATE; Drug: Olaparib; Diagnostic Test: Ga dotatate scanning; Diagnostic Test: FDG-PET scanning<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04086485",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 11 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of EMB-02 in Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04618393?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Biological: EMB-02<br/><b>Sponsor</b>: Shanghai EpimAb Biotherapeutics Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04618393",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02411786?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Biological: pTVG-AR; Biological: gm-csf<br/><b>Sponsors</b>: University of Wisconsin, Madison; Madison Vaccines Incorporated<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02411786",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 08 Apr 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02379416?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Intervention</b>: Drug: Nilotinib + Paclitaxel<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02379416",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 05 Mar 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04653480?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Drug: Surufatinib; Drug: Toripalimab; Drug: chemotherapy<br/><b>Sponsor</b>: Zhejiang University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04653480",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 04 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04482309?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors<br/><b>Intervention</b>: Drug: Trastuzumab deruxtecan<br/><b>Sponsors</b>: AstraZeneca; Daiichi Sankyo Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04482309",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 22 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The PRIME-CRC Trial to Promote CRC Screening in Rural Communities"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04313114?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Interventions</b>: Behavioral: health literacy appropriate education and demonstration; Behavioral: shared decision making; Behavioral: automated call reminders or automated texts<br/><b>Sponsors</b>: Louisiana State University Health Sciences Center Shreveport; National Cancer Institute (NCI); Northwestern University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04313114",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 18 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04456699?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Metastatic Colorectal Cancer<br/><b>Interventions</b>: Drug: Olaparib; Drug: 5-FU; Drug: Bevacizumab<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04456699",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 02 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04084951?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Adult Solid Tumor<br/><b>Interventions</b>: Biological: SQZ-PBMC-HPV; Drug: Atezolizumab<br/><b>Sponsor</b>: SQZ Biotechnologies<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04084951",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02840149?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neuroendocrine Tumors<br/><b>Intervention</b>: Drug: 68Ga-DOTATATE PET/CT<br/><b>Sponsor</b>: Jewish General Hospital<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT02840149",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 Jul 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Vibostolimab (MK-7684) With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738487?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Neoplasms; Non-Small-Cell Lung Carcinoma<br/><b>Interventions</b>: Biological: MK-7684A; Biological: Pembrolizumab<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04738487",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03347123?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: Epacadostat; Drug: Nivolumab; Drug: Ipilimumab; Drug: Lirilumab<br/><b>Sponsor</b>: Incyte Corporation<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03347123",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 20 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02890355?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7<br/><b>Interventions</b>: Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Veliparib<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02890355",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 Sep 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02085148?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pediatric Oncology<br/><b>Interventions</b>: Drug: Regorafenib (BAY73-4506); Drug: Vincristine (Cellcristin®); Drug: Irinotecan (Irinotecan Cell pharm®)<br/><b>Sponsor</b>: Bayer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02085148",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 12 Mar 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "XL-184+Abiraterone in Post-Chemo CRPC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01574937?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: Cabozantinib; Drug: Abiraterone<br/><b>Sponsor</b>: Dana-Farber Cancer Institute<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01574937",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Apr 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Impact of Compliance With Fluoride Use on Caries Incidence After Cancer Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03267914?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Dental Caries; Oral Cavity Cancer; Oral Complications of Chemotherapy and Head/Neck Radiation<br/><b>Interventions</b>: Other: Tray; Other: Brush<br/><b>Sponsor</b>: A.T. Still University of Health Sciences<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03267914",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 31 Aug 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "FACBC Outcomes for Post Prostatectomy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01666808?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Drug: FACBC; Radiation: Radiation therapy<br/><b>Sponsors</b>: Emory University; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01666808",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 16 Aug 2012 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04380636?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung<br/><b>Interventions</b>: Biological: Pembrolizumab; Drug: Olaparib; Drug: Placebo for olaparib; Drug: Etoposide; Drug: Carboplatin; Drug: Cisplatin; Drug: Paclitaxel; Drug: Pemetrexed; Radiation: Thoracic Radiotherapy; Drug: Durvalumab<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04380636",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 08 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03980925?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neuroendocrine Tumors; Neuroendocrine Neoplasm; Gastroenteropancreatic Neuroendocrine Tumor<br/><b>Interventions</b>: Drug: Nivolumab; Drug: Carboplatin; Drug: Etoposide<br/><b>Sponsor</b>: Grupo Espanol de Tumores Neuroendocrinos<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03980925",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03092518?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Gastric Adenocarcinoma; Esophagogastric Junction; Gastric Cancer<br/><b>Interventions</b>: Procedure: Surgery; Drug: Cisplatin; Drug: Mitomycin C; Drug: Sodium Thiosulfate<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03092518",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02922764?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignant Neoplasms<br/><b>Interventions</b>: Drug: RGX-104; Drug: Nivolumab; Drug: Ipilimumab; Drug: Docetaxel; Drug: Pembrolizumab; Drug: Carboplatin; Drug: Pemetrexed<br/><b>Sponsor</b>: Rgenix, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02922764",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Oct 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04749394?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Locally Advanced Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Camrelizumab, PD-1 monoclonal antibody; Drug: Apatinib, VEGFR2 antibody<br/><b>Sponsor</b>: Chinese Academy of Medical Sciences<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04749394",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04053673?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor, Adult<br/><b>Intervention</b>: Drug: RBN-2397<br/><b>Sponsor</b>: Ribon Therapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04053673",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 12 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04521413?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Malignancies<br/><b>Interventions</b>: Drug: CFI-402411; Drug: Pembrolizumab<br/><b>Sponsors</b>: Treadwell Therapeutics, Inc; TIO Discovery Engine<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04521413",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 20 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03567720?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Triple Negative Breast Cancer<br/><b>Interventions</b>: Biological: tavokinogene telseplasmid; Biological: Pembrolizumab; Device: Immunopulse; Drug: nab paclitaxel<br/><b>Sponsors</b>: OncoSec Medical Incorporated; Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03567720",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 26 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02822157?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Epithelial Cancer<br/><b>Interventions</b>: Drug: Olaparib; Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly<br/><b>Sponsors</b>: Universitaire Ziekenhuizen Leuven; AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02822157",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 04 Jul 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03525262?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer Adenocarcinoma<br/><b>Intervention</b>: Radiation: 30Gy (Gray) planning target volume (PTV)<br/><b>Sponsors</b>: University of Texas Southwestern Medical Center; Boston Scientific Corporation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03525262",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 15 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Application of 3D Printing in Laparoscopic Surgery of Liver Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03744624?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Liver Cancer; Hepatocellular Carcinoma; Liver Metastases<br/><b>Interventions</b>: Procedure: Laparoscopic liver resection; Device: 3D printing model<br/><b>Sponsor</b>: Jagiellonian University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03744624",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "FOLFIRINOX for 2nd-line Treatment of BTC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03778593?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Biliary Tract Cancer<br/><b>Interventions</b>: Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Irinotecan; Drug: Oxaliplatin; Drug: 5% dextrose water<br/><b>Sponsor</b>: Dong-A University Hospital<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03778593",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 19 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02201381?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Overall Survival<br/><b>Intervention</b>: Drug: Metabolic treatment<br/><b>Sponsor</b>: Health Clinics Limited<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02201381",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 28 Jul 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01781741?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer<br/><b>Interventions</b>: Combination Product: therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT); Other: quality-of-life assessment<br/><b>Sponsors</b>: Roswell Park Cancer Institute; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01781741",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Feb 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "PRS-343 in HER2-Positive Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03330561?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Bladder Cancer; HER2-positive Solid Tumor<br/><b>Intervention</b>: Drug: PRS-343<br/><b>Sponsor</b>: Pieris Pharmaceuticals, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03330561",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 06 Nov 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03519178?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer<br/><b>Interventions</b>: Drug: PF-06873600; Drug: Endocrine Therapy 1; Drug: Endocrine Therapy 2<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03519178",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "TR1801-ADC in Patients With Tumors That Express c-Met"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03859752?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Unspecified Adult Solid Tumor, Protocol Specific<br/><b>Intervention</b>: Biological: TR1801-ADC<br/><b>Sponsors</b>: Tanabe Research Laboratories USA Inc; Open Innovation Partners<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03859752",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Mar 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04729543?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Melanoma; Melanoma, Uveal; Head and Neck Cancer<br/><b>Intervention</b>: Biological: Adoptive therapy with autologous MC2 TCR T cells<br/><b>Sponsors</b>: Erasmus Medical Center; Ludwig Institute for Cancer Research; Dutch Cancer Society; Stichting Coolsingel Rotterdam grant; Jan Ivo Stichting grant<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04729543",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02576431?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors Harboring NTRK Fusion<br/><b>Intervention</b>: Drug: BAY2757556 (Larotrectinib, Vitrakvi)<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02576431",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 15 Oct 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03095274?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neuroendocrine Tumors; Neuroendocrine Neoplasm of Lung<br/><b>Interventions</b>: Drug: Durvalumab; Drug: Tremelimumab<br/><b>Sponsor</b>: Grupo Espanol de Tumores Neuroendocrinos<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03095274",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738162?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Brain Tumor, Pediatric<br/><b>Intervention</b>: Drug: 5-Aminolevulinic Acid Hydrochloride, Oral<br/><b>Sponsors</b>: Westfälische Wilhelms-Universität Münster; photonamic GmbH & Co. KG; medac GmbH<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04738162",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03650348?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Bladder Cancer; HER2-positive Solid Tumor<br/><b>Intervention</b>: Drug: PRS-343 in Combination with Atezolizumab<br/><b>Sponsor</b>: Pieris Pharmaceuticals, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03650348",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04730843?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumors; Neoplasms; Malignant Tumor<br/><b>Intervention</b>: Drug: ES102<br/><b>Sponsor</b>: Elpiscience Biopharma, Ltd.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04730843",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04294875?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Tumor; Metastatic Solid Tumor<br/><b>Intervention</b>: Drug: MPT0B640<br/><b>Sponsor</b>: Joseah Bio<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04294875",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 04 Mar 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02769962?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Urothelial Carcinoma; Urothelial Cancer; Lung Neoplasms; Small Cell Lung Cancer; Prostate Cancer<br/><b>Interventions</b>: Drug: EP0057; Drug: olaparib<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02769962",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 May 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of BAY1834942 in Patients With Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03596372?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced CEACAM6-expressing Solid Tumors<br/><b>Intervention</b>: Drug: BAY1834942<br/><b>Sponsor</b>: Bayer<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03596372",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 23 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03186638?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cognitive Impairment; Malignant Neoplasm<br/><b>Interventions</b>: Drug: Ibuprofen; Other: Placebo; Other: Questionnaire Administration<br/><b>Sponsors</b>: University of Rochester NCORP Research Base; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03186638",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 14 Jun 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of TAK-102 in Adult With Previously-Treated Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04405778?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Intervention</b>: Biological: TAK-102<br/><b>Sponsor</b>: Takeda<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04405778",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04102553?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Prostate Cancer Recurrent<br/><b>Interventions</b>: Drug: F-18-PSMA-1007; Drug: F-18-Fluorocholine<br/><b>Sponsor</b>: ABX advanced biochemical compounds GmbH<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04102553",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 25 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Second-line Surufatinib Combined With Chemotherapy in Advanced CRC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04734249?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Colorectal Cancer<br/><b>Intervention</b>: Drug: Surufatinib(HMPL-012)<br/><b>Sponsor</b>: Fujian Cancer Hospital<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04734249",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00653068?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Childhood Atypical Teratoid/Rhabdoid Tumor<br/><b>Interventions</b>: Radiation: 3-Dimensional Conformal Radiation Therapy; Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Etoposide; Biological: Filgrastim; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Methotrexate; Drug: Thiotepa; Drug: Vincristine Sulfate<br/><b>Sponsors</b>: Children's Oncology Group; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00653068",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 04 Apr 2008 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04346381?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Interventions</b>: Drug: Camrelizumab; Drug: Famitinib<br/><b>Sponsor</b>: Jiangsu HengRui Medicine Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04346381",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 15 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03360721?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma Without Neuroendocrine Differentiation; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8<br/><b>Interventions</b>: Drug: Abiraterone Acetate; Drug: Apalutamide; Drug: Prednisone<br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03360721",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 04 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00819221?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: AZD2281; Drug: liposomal doxorubicin<br/><b>Sponsor</b>: AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00819221",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 08 Jan 2009 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03834220?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Intervention</b>: Drug: Debio 1347<br/><b>Sponsors</b>: Debiopharm International SA; Caris Life Sciences; Optimal Research (Just In Time sites)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03834220",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 07 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04341259?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Intervention</b>: Drug: Ipatasertib<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04341259",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 10 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04704154?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: Regorafenib, (Stivarga, BAY73-4506); Drug: Nivolumab (Opdivo)<br/><b>Sponsors</b>: Bayer; Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04704154",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 11 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04644315?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Intervention</b>: Drug: Alectinib<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04644315",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 25 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04108858?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma<br/><b>Interventions</b>: Drug: Copanlisib; Biological: Pertuzumab; Biological: Trastuzumab<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04108858",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 30 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04397276?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Intervention</b>: Drug: JNJ-70218902<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04397276",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04158583?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Intervention</b>: Drug: RO7296682<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04158583",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 12 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04642365?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: RO7296682; Drug: Atezolizumab<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04642365",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of AZD2811 + Durvalumab in ES-SCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04745689?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Small-Cell Lung Cancer<br/><b>Interventions</b>: Drug: Durvalumab; Drug: AZD2811; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide<br/><b>Sponsor</b>: AstraZeneca<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04745689",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Evaluation of the Impact of Water Method During Insertion Phase of Flexible Sigmoidoscopy in Training"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03208283?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer Screening<br/><b>Interventions</b>: Diagnostic Test: Water method group; Diagnostic Test: Air insufflation group<br/><b>Sponsor</b>: Chinese University of Hong Kong<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03208283",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Jul 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02589938?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Radiation-Induced Xerostomia; Head and Neck Cancer; Radiation Toxicity; Oral Complications of Chemotherapy and Head/Neck Radiation<br/><b>Interventions</b>: Other: Standard Oral Hygiene; Other: Standard Oral Hygiene + True Acupuncture; Other: Standard Oral Hygiene + Sham Acupuncture<br/><b>Sponsor</b>: Wake Forest University Health Sciences<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02589938",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 28 Oct 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03290937?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8<br/><b>Interventions</b>: Biological: Cetuximab; Drug: Irinotecan Hydrochloride; Other: Pharmacodynamic Study; Biological: Utomilumab<br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03290937",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02637687?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors Harboring NTRK Fusion<br/><b>Intervention</b>: Drug: Larotrectinib (Vitravki, BAY2757556)<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02637687",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 22 Dec 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04669899?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancer<br/><b>Interventions</b>: Drug: JTX-8064; Drug: JTX-4014; Drug: Pembrolizumab<br/><b>Sponsor</b>: Jounce Therapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04669899",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03988283?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Pediatric Recurrent Brain Tumor<br/><b>Interventions</b>: Biological: Personalized neoantigen DNA vaccine; Device: TDS-IM System; Procedure: Peripheral blood draw<br/><b>Sponsors</b>: Washington University School of Medicine; Children's Discovery Institute<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03988283",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 17 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03517969?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8<br/><b>Interventions</b>: Drug: Berzosertib; Drug: Carboplatin; Drug: Docetaxel; Other: Laboratory Biomarker Analysis<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03517969",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 May 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Connected Prehabilitation Program During Neo Adjuvant Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04451369?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Ovarian Cancer<br/><b>Intervention</b>: Other: Prehabilitation program<br/><b>Sponsor</b>: Institut Paoli-Calmettes<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04451369",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03603951?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Relapsed or Refractory Mature Lymphoid Neoplasms<br/><b>Intervention</b>: Drug: SHR2554<br/><b>Sponsors</b>: Jiangsu HengRui Medicine Co., Ltd.; Beijing Cancer Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03603951",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04303858?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: RO7284755; Drug: Atezolizumab<br/><b>Sponsor</b>: Hoffmann-La Roche<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04303858",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 11 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04728230?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8<br/><b>Interventions</b>: Drug: Carboplatin; Biological: Durvalumab; Drug: Etoposide; Drug: Olaparib; Radiation: Radiation Therapy<br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04728230",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 28 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04145349?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Desmoplastic Small Round Cell Tumor<br/><b>Interventions</b>: Drug: Ramucirumab; Drug: Cyclophosphamide; Drug: Vinorelbine<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04145349",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 30 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03912831?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer<br/><b>Interventions</b>: Drug: KITE-439; Drug: Cyclophosphamide; Drug: Fludarabine<br/><b>Sponsor</b>: Kite, A Gilead Company<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03912831",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02398773?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7<br/><b>Interventions</b>: Procedure: Computed Tomography; Drug: F-18 16 Alpha-Fluoroestradiol; Other: Laboratory Biomarker Analysis; Procedure: Positron Emission Tomography<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02398773",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Mar 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02972541?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Neoadjuvant Chemotherapy; Stent; Obstruction<br/><b>Interventions</b>: Device: Stenting with neoadjuvant chemotherapy; Device: Stenting with immediate Surgery<br/><b>Sponsor</b>: Beijing Chao Yang Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02972541",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 23 Nov 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of CBP-1008 in Patients With Advanced Solid Tumor"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04740398?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumor<br/><b>Intervention</b>: Drug: CBP-1008<br/><b>Sponsor</b>: Coherent Biopharma (Suzhou) Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04740398",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04363164?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Castration Resistant Metastatic Prostate Cancer<br/><b>Interventions</b>: Drug: Testosterone cypionate; Drug: Enzalutamide; Drug: Testosterone enanthate<br/><b>Sponsors</b>: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; United States Department of Defense<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04363164",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Apr 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04137107?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Stage II Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8<br/><b>Interventions</b>: Drug: Oxaliplatin; Drug: Duloxetine Hydrochloride; Drug: Duloxetine; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Placebo<br/><b>Sponsors</b>: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04137107",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 23 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04382300?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-small-cell Lung Cancer<br/><b>Intervention</b>: Drug: pyrotinib combined with thalidomide<br/><b>Sponsor</b>: Shanghai Chest Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04382300",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 11 May 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02699515?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Intervention</b>: Drug: MSB0011359C<br/><b>Sponsor</b>: Merck KGaA, Darmstadt, Germany<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02699515",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 04 Mar 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04450901?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: YBL-006<br/><b>Sponsors</b>: Y Biologics Inc.; Novotech (Australia) Pty Limited<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04450901",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Human Papillomavirus (HPV) Self-sampling as a Test of Cure After Treatment of Cervical Intra-epithelial Neoplasia"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02780960?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cervical Intra-epithelial Neoplasia Grade 1 or Worse<br/><b>Intervention</b>: Device: HPV self-testing<br/><b>Sponsor</b>: University Hospital, Geneva<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02780960",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 May 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03387553?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Breast Cancer Female; Breast Cancer, Male; Invasive Breast Cancer; HER2-positive Breast Cancer; HER2 Positive Breast Carcinoma; Stage II Breast Cancer; Stage III Breast Cancer<br/><b>Interventions</b>: Biological: Dendritic Cell Vaccine (DC1); Drug: Neoadjuvant Chemotherapy; Procedure: Curative Surgery<br/><b>Sponsors</b>: H. Lee Moffitt Cancer Center and Research Institute; United States Department of Defense<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03387553",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Jan 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "AMG 404 in Patients With Advanced Solid Tumors."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03853109?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: AMG 404<br/><b>Sponsor</b>: Amgen<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03853109",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 25 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Feasibility Bowel Dysfunction Program After Low Anterior Resection"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733794?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Rectal Cancer; Low Anterior Resection<br/><b>Intervention</b>: Procedure: Stoma reversal<br/><b>Sponsor</b>: Fox Chase Cancer Center<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04733794",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of CS1001 in Subjects With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03744403?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: CS1001<br/><b>Sponsor</b>: CStone Pharmaceuticals<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03744403",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04518137?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle<br/><b>Sponsor</b>: Shanghai Antengene Corporation Limited<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04518137",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 19 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04083976?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumor<br/><b>Intervention</b>: Drug: Erdafitinib<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04083976",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03968653?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Interventions</b>: Drug: Debio 0123; Drug: Carboplatin<br/><b>Sponsor</b>: Debiopharm International SA<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03968653",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04639219?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors With HER2 Mutation<br/><b>Intervention</b>: Drug: Trastuzumab deruxtecan<br/><b>Sponsors</b>: AstraZeneca; Daiichi Sankyo Co., Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04639219",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 20 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04746612?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: HH30134<br/><b>Sponsor</b>: ShangHai HaiHe Pharmaceutical<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04746612",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739111?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Malignant Tumor<br/><b>Intervention</b>: Drug: Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)<br/><b>Sponsors</b>: Dragonboat Biopharmaceutical Company Limited; West China Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739111",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04087018?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: Zimberelimab<br/><b>Sponsors</b>: Arcus Biosciences, Inc.; Strata Oncology<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04087018",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04747470?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: GS-3583<br/><b>Sponsor</b>: Gilead Sciences<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04747470",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 10 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04049617?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: GS-4224<br/><b>Sponsor</b>: Gilead Sciences<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04049617",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 08 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04301765?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Hypogonadism, Male; Cancer; Fatigue<br/><b>Interventions</b>: Drug: testosterone 1.62% gel; Other: placebo gel<br/><b>Sponsor</b>: Seattle Institute for Biomedical and Clinical Research<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04301765",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 10 Mar 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04606381?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Malignancies<br/><b>Interventions</b>: Drug: Ami-LC-MD; Drug: Ami-LC; Drug: Ami-HC; Drug: Ami-HC-CF<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04606381",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 28 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02070549?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Liver; Metastatic Malignant Solid Neoplasm; Unresectable Solid Neoplasm<br/><b>Intervention</b>: Drug: Trametinib<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02070549",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 25 Feb 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04475939?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer, Non-Small Cell<br/><b>Interventions</b>: Drug: Niraparib; Drug: Pembrolizumab; Drug: Placebo<br/><b>Sponsor</b>: GlaxoSmithKline<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04475939",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 17 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Suubi4Cancer: Improving Access to Pediatric Cancer Services and Treatment Adherence Among Children Living With HIV/AIDS"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03916783?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HIV/AIDS; Cancer<br/><b>Intervention</b>: Behavioral: Combination intervention<br/><b>Sponsors</b>: Washington University School of Medicine; Uganda Cancer Institute; Reach the Youth Uganda; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03916783",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02500199?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Gastric Cancer; Solid Tumors; NSCLC<br/><b>Intervention</b>: Drug: Pyrotinib<br/><b>Sponsor</b>: Hengrui Therapeutics, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02500199",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 16 Jul 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Tomosynthesis Trial in Bergen - Part 2"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03669926?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Neoplasms<br/><b>Intervention</b>: Radiation: Digital Breast Tomosynthesis+synthetic mammography<br/><b>Sponsors</b>: Cancer Registry of Norway; Haukeland University Hospital; University of Oslo; Norwegian Cancer Society<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03669926",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 13 Sep 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02498912?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Procedure: Production of Genetically-modified T cells; Drug: Cyclophosphamide; Device: IP Catheter Insertion; Genetic: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells; Drug: Fludarabine<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; Stanford University; Juno Therapeutics, Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02498912",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 15 Jul 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04242147?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumor<br/><b>Intervention</b>: Drug: KD033 for Injection<br/><b>Sponsor</b>: Kadmon Corporation, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04242147",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 27 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03154294?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumor<br/><b>Interventions</b>: Drug: paclitaxel; Drug: TAK-228; Drug: TAK-117<br/><b>Sponsor</b>: Avera McKennan Hospital & University Health Center<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03154294",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 May 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Impact of Remimazolam on Prognosis After Bladder Cancer Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04532606?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Benzodiazepines; Bladder Cancer; Delirium; Surgery; Cancer Recurrence<br/><b>Interventions</b>: Drug: Remimazolam; Drug: Propofol<br/><b>Sponsor</b>: Peking University First Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04532606",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 31 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02450903?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small-Cell Lung Cancer<br/><b>Intervention</b>: Drug: LDK378<br/><b>Sponsor</b>: Novartis Pharmaceuticals<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02450903",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 21 May 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04672460?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Interventions</b>: Drug: TALZENNA capsule; Drug: Talazoparib soft gel capsule<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04672460",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03028246?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Benign Centrally-Located Intracranial Tumors<br/><b>Intervention</b>: Device: ExAblate 4000 System<br/><b>Sponsor</b>: InSightec<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03028246",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 23 Jan 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04648904?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Invasive Breast Cancer; Post-mastectomy<br/><b>Intervention</b>: Radiation: Radiotherapy<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04648904",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 02 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04685473?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Refractory Solid Tumors<br/><b>Intervention</b>: Drug: T-1101 (Tosylate)<br/><b>Sponsor</b>: Taivex Therapeutics Corporation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04685473",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 28 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04647916?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8<br/><b>Intervention</b>: Biological: Sacituzumab Govitecan<br/><b>Sponsors</b>: Southwest Oncology Group; National Cancer Institute (NCI); Immunomedics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04647916",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 01 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04085081?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Caregiver; Lobectomy Patient; Lung Carcinoid Tumor; Lung Non-Small Cell Carcinoma<br/><b>Interventions</b>: Other: E-mail; Behavioral: Exercise Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Behavioral: Telephone-Based Intervention; Other: Text Message<br/><b>Sponsors</b>: City of Hope Medical Center; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04085081",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 11 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02285439?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Low-Grade Gliomas; Malignant Neoplasms, Brain; Soft Tissue Neoplasms<br/><b>Intervention</b>: Drug: MEK162<br/><b>Sponsors</b>: Children's Hospital Los Angeles; Dana-Farber Cancer Institute<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02285439",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 07 Nov 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Multi-center, Randomized, Open-label, Parallel-controlled Phase Ⅲ Trial to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736394?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-muscle Invasive Bladder Cancer<br/><b>Interventions</b>: Drug: APL-1202; Drug: Epirubicin Hydrochloride<br/><b>Sponsor</b>: Jiangsu Yahong Meditech Co.,Ltd.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736394",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02843763?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Disorder Related to Renal Transplantation; Cancer<br/><b>Intervention</b>: Other: Blood sample<br/><b>Sponsors</b>: Centre Hospitalier Universitaire de Besancon; University Hospital, Lille; University Hospital, Tours<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02843763",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 26 Jul 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02392793?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Childhood Solid Tumors<br/><b>Interventions</b>: Drug: Talazoparib; Drug: Irinotecan; Drug: Temozolomide; Drug: Filgrastim; Drug: Peg-filgrastim<br/><b>Sponsors</b>: St. Jude Children's Research Hospital; BioMarin Pharmaceutical; Alliance Pharma; Pfizer<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02392793",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 19 Mar 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00786669?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Interventions</b>: Drug: Bevacizumab; Drug: Temozolomide; Drug: Vincristine; Drug: Irinotecan; Drug: Cefixime<br/><b>Sponsor</b>: Children's Hospital Medical Center, Cincinnati<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00786669",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 06 Nov 2008 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neoadjuvant Radiotherapy for Malignant Lacrimal Sac Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04016675?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignant Tumor of Lacrimal Drainage Structure<br/><b>Interventions</b>: Other: Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery; Other: Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy<br/><b>Sponsors</b>: Eye & ENT Hospital of Fudan University; Zhongshan Ophthalmic Center, Sun Yat-sen University; Peking University Eye Center; Tianjin Medical University Eye Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04016675",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Jul 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase 1/2 Study of SC-43 in Combination With Cisplatin"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733521?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Non-small-cell Lung Cancer; Advanced Biliary Tract Cancer<br/><b>Interventions</b>: Drug: SC-43; Drug: Cisplatin<br/><b>Sponsor</b>: RaND Biosciences<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04733521",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02311933?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7<br/><b>Interventions</b>: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Tamoxifen Citrate; Drug: Z-Endoxifen Hydrochloride<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02311933",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Dec 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02264678?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer<br/><b>Interventions</b>: Drug: Administration of ceralasertib in combination with carboplatin; Drug: Administration of ceralasertib; Drug: Administration of ceralasertib in combination with olaparib; Drug: Administation of ceralasertib in combination with durvalumab<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02264678",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 15 Oct 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03192345?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignant Solid Tumor<br/><b>Interventions</b>: Biological: SAR439459; Drug: Cemiplimab REGN2810<br/><b>Sponsor</b>: Sanofi<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03192345",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 20 Jun 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04750473?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Lobular Carcinoma; Metastatic Breast Lobular Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8<br/><b>Interventions</b>: Procedure: Computed Tomography; Drug: Fluciclovine F18; Drug: Gallium Ga 68 Gozetotide; Procedure: Positron Emission Tomography<br/><b>Sponsors</b>: Emory University; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04750473",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04671901?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumor; Solid Tumor, Childhood; Solid Carcinoma<br/><b>Intervention</b>: Drug: Romiplostim<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04671901",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 17 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04248829?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Lazertinib 240 mg/160 mg; Drug: Gefitinib 250 mg; Drug: Lazertinib-matching placebo 240 mg/160 mg; Drug: Gefitinib-matching placebo 250 mg<br/><b>Sponsor</b>: Yuhan Corporation<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04248829",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 30 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03195764?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Refractory Solid Tumors<br/><b>Intervention</b>: Drug: T-1101 (Tosylate)<br/><b>Sponsor</b>: Taivex Therapeutics Corporation<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03195764",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 22 Jun 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04287868?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cervical Cancer; HPV Cancers; Anal Cancer; Oropharyngeal Cancer; Vulvar, Vaginal, Penile, Rectal Cancer<br/><b>Interventions</b>: Biological: PDS0101; Biological: M7824; Biological: NHS-IL12<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04287868",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 27 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04734730?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8<br/><b>Interventions</b>: Drug: Abiraterone Acetate; Drug: Bicalutamide; Drug: Degarelix; Drug: Goserelin Acetate; Drug: Leuprolide Acetate; Drug: Prednisone; Other: Questionnaire Administration; Drug: Talazoparib<br/><b>Sponsors</b>: City of Hope Medical Center; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04734730",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02018861?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: B-Cell Malignancies<br/><b>Interventions</b>: Drug: Parsaclisib; Drug: Itacitinib; Drug: Rituximab; Drug: Ifosfamide; Drug: Carboplatin; Drug: Etoposide<br/><b>Sponsor</b>: Incyte Corporation<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02018861",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 23 Dec 2013 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04147819?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Cancers With HER2 Expression<br/><b>Interventions</b>: Drug: BAY2701439; Drug: BAY2701438<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04147819",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Nov 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "NHS-IL12 for Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01417546?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Epithelial Neoplasms, Malignant; Epithelial Tumors, Malignant; Malignant Mesenchymal Tumor<br/><b>Intervention</b>: Drug: NHS-IL-12<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01417546",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Aug 2011 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04278144?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasm, Metastatic; Neoplasm, Breast; Neoplasm, Gastric<br/><b>Interventions</b>: Drug: BDC-1001; Drug: Pembrolizumab<br/><b>Sponsor</b>: Bolt Biotherapeutics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04278144",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 20 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Mindfulness and CBT for Sleep"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04736056?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Hematologic Malignancy<br/><b>Intervention</b>: Behavioral: Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills<br/><b>Sponsor</b>: Duke University<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04736056",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Clinical Impact of Respiratory-Swallow Training on Refractory Dysphagia in Oropharyngeal Head and Neck Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03377270?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Head and Neck Cancer; Dysphagia<br/><b>Intervention</b>: Behavioral: Respiratory Swallow Training<br/><b>Sponsors</b>: VA Office of Research and Development; Edward Hines Jr. VA Hospital; Medical University of South Carolina; University of South Alabama<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03377270",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 Dec 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Telehealth Based Intervention to Improve Functional Capacity in Survivors of Childhood Cancer With Significantly Limited Exercise Tolerance"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04714840?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Childhood Cancer; Mobility Limitation<br/><b>Interventions</b>: Other: Exercise testing results; Other: Individually tailored exercise program (INT); Other: Generalized exercise recommendations (AC)<br/><b>Sponsors</b>: St. Jude Children's Research Hospital; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04714840",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04716946?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: NSCLC; Non-small Cell Lung Cancer; Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IIIA; PD-L1 Gene Mutation<br/><b>Interventions</b>: Drug: Durvalumab; Radiation: Stereotactic Body Radiation Therapy<br/><b>Sponsors</b>: Memorial Sloan Kettering Cancer Center; AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04716946",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Education Tools to Support Pediatric Survivor Care"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04257058?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Pediatric Cancer<br/><b>Intervention</b>: Behavioral: Electronic educational material<br/><b>Sponsor</b>: Emory University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04257058",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Feasibility of Dignity Therapy Intervention on Cancer Patients in Charge to an Hospital Palliative Care Unit."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04738305?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Dignity; Advanced Cancer<br/><b>Intervention</b>: Other: Dignity Therapy<br/><b>Sponsor</b>: Azienda Unità Sanitaria Locale Reggio Emilia<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04738305",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04744974?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Myeloproliferative Neoplasm<br/><b>Intervention</b>: Behavioral: Diet intervention<br/><b>Sponsor</b>: University of California, Irvine<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04744974",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Durvalumab in Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03094286?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HIV; Cancer<br/><b>Intervention</b>: Drug: Durvalumab<br/><b>Sponsor</b>: Spanish Lung Cancer Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03094286",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Preoperative Paravertebral Block in Cancer Surgery of the Lung"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04209868?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Thoracic Neoplasm; Chronic Pain Post-Procedural; Acute Post-thoracotomy Pain; Anesthesia, Local<br/><b>Interventions</b>: Drug: Levo-Bupivacaine Hydrochloride (HCl) 0.25 % in 20mL Injection; Drug: 0.9% Sodium Chloride 20mL Injection<br/><b>Sponsor</b>: Guy's and St Thomas' NHS Foundation Trust<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04209868",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 24 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02399215?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Carcinoid Tumor; Metastatic Carcinoid Tumor; Neuroendocrine Neoplasm<br/><b>Interventions</b>: Other: Laboratory Biomarker Analysis; Drug: Nintedanib; Other: Pharmacological Study; Other: Quality-of-Life Assessment<br/><b>Sponsors</b>: Roswell Park Cancer Institute; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02399215",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Mar 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Pazopanib and ARQ 197 for Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01468922?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Sarcoma; Stomach Neoplasms; Neoplasms<br/><b>Interventions</b>: Drug: Pazopanib; Drug: ARQ 197<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT01468922",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 10 Nov 2011 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04214067?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Endometrial Endometrioid Adenocarcinoma; Stage I Uterine Corpus Cancer AJCC v8; Stage IA Uterine Corpus Cancer AJCC v8; Stage IB Uterine Corpus Cancer AJCC v8; Stage II Uterine Corpus Cancer AJCC v8<br/><b>Interventions</b>: Radiation: External Beam Radiation Therapy; Radiation: Internal Radiation Therapy; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration<br/><b>Sponsors</b>: National Cancer Institute (NCI); NRG Oncology<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04214067",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 30 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01856478?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Head and Neck Neoplasms<br/><b>Interventions</b>: Drug: methotrexate; Drug: afatinib<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01856478",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 17 May 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04046445?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; MSS; Stage IV Colon Cancer; Stage IV Rectal Cancer; Metastatic Colorectal Cancer; Liver Metastasis Colon Cancer<br/><b>Interventions</b>: Drug: ATP128; Drug: BI 754091<br/><b>Sponsors</b>: Amal Therapeutics; Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04046445",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 06 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03941626?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Esophagus Cancer; Hepatoma; Glioma; Gastric Cancer<br/><b>Intervention</b>: Biological: CAR-T/TCR-T cells immunotherapy<br/><b>Sponsors</b>: Shenzhen BinDeBio Ltd.; Henan Provincial People's Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03941626",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 08 May 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Effectiveness and Implementation of mPATH-CRC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03843957?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Cancer; Rectum Cancer; Colon Cancer<br/><b>Interventions</b>: Other: mPATH-CRC; Other: \"high touch\" Implementation strategy; Other: \"low touch\" Implementation Strategy<br/><b>Sponsors</b>: Wake Forest University Health Sciences; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03843957",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 18 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03460977?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Small Cell Lung Cancer (SCLC); Follicular Lymphoma (FL); Castration Resistant Prostate Cancer (CRPC); Diffuse Large B-Cell Lymphoma (DLBCL)<br/><b>Intervention</b>: Drug: PF-06821497<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03460977",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 09 Mar 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04528836?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Tumor, Solid<br/><b>Intervention</b>: Drug: BBP-398 (Formerly Known as IACS-15509)<br/><b>Sponsor</b>: Navire Pharma Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04528836",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 27 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04655976?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Lung Cancer, Non-Small Cell<br/><b>Interventions</b>: Biological: Cobolimab; Biological: Dostarlimab; Drug: Docetaxel<br/><b>Sponsor</b>: GlaxoSmithKline<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04655976",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02947386?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Other: Laboratory Biomarker Analysis; Biological: Nimotuzumab; Biological: Nivolumab<br/><b>Sponsors</b>: Roswell Park Cancer Institute; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02947386",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 27 Oct 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04449549?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Interventions</b>: Drug: Nilotinib; Drug: Paclitaxel<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04449549",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 29 Jun 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03215511?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors Harboring NTRK Fusion<br/><b>Intervention</b>: Drug: Selitrectinib (BAY2731954)<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03215511",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 12 Jul 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03775265?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Bladder Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Cisplatin; Drug: Fluorouracil; Drug: Gemcitabine; Drug: Mitomycin; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Other: Survey Administration<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03775265",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 13 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02724540?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neuroendocrine Tumor, Malignant; Liver Metastases<br/><b>Interventions</b>: Device: Bland Embolization; Combination Product: Transarterial chemoembolization; Combination Product: Drug Eluting Beads Embolization<br/><b>Sponsors</b>: University of Pennsylvania; Guerbet<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02724540",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 31 Mar 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04093167?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Intervention</b>: Drug: Pembrolizumab<br/><b>Sponsors</b>: Canadian Cancer Trials Group; Cancer Research Institute, New York City; Personal Genome Diagnostics (PGDx); Mark Foundation for Cancer Research<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04093167",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 17 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03496766?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non Small Cell Lung Cancer<br/><b>Intervention</b>: Drug: Tipifarnib<br/><b>Sponsor</b>: Spanish Lung Cancer Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03496766",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03927027?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III<br/><b>Interventions</b>: Drug: Isosulfan Blue; Procedure: Axillary Lymph Node Dissection; Procedure: Mapping; Other: Quality-of-Life Assessment; Other: Questionnaire Administration<br/><b>Sponsors</b>: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03927027",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 25 Apr 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02702492?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumors; NHL<br/><b>Interventions</b>: Drug: KPT-9274; Drug: Niacin ER; Drug: Nivolumab<br/><b>Sponsor</b>: Karyopharm Therapeutics Inc<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02702492",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 Mar 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03498183?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignancy of Thyroid Nodules<br/><b>Intervention</b>: Drug: MIBI-Tc99m/Iodine-123<br/><b>Sponsor</b>: Nantes University Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03498183",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733534?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Frailty; Childhood Cancer<br/><b>Interventions</b>: Drug: Dasatinib plus Quercetin; Drug: Fisetin<br/><b>Sponsors</b>: St. Jude Children's Research Hospital; National Institutes of Health (NIH); National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04733534",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01874353?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Platinum Sensitive; BRCA Mutated; Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy<br/><b>Interventions</b>: Drug: Olaparib 300mg tablets; Drug: Placebo to match olaparib 300mg<br/><b>Sponsors</b>: AstraZeneca; European Network of Gynaecological Oncological Trial Groups (ENGOT); Myriad Genetic Laboratories, Inc.; Merck Sharp & Dohme Corp.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01874353",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 11 Jun 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03793179?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8<br/><b>Interventions</b>: Drug: Carboplatin; Biological: Pembrolizumab; Drug: Pemetrexed<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03793179",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 04 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04572633?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Liver Tumor; HCC; Metastasis<br/><b>Intervention</b>: Device: HistoSonics Histotripsy<br/><b>Sponsor</b>: HistoSonics, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04572633",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 01 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04708483?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer, Lung; Perfusion Computed Tomography Target Lesion; Cancer Liver; Metastatic Lung Cancer; Metastatic Liver Cancer<br/><b>Intervention</b>: Device: Extra DCE-CT scan<br/><b>Sponsors</b>: Hyperfusion; University Hospital, Ghent<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04708483",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 14 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03674827?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non-Small Cell Lung Cancer; Triple-negative Breast Cancer<br/><b>Intervention</b>: Biological: PF-06936308<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03674827",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 18 Sep 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03312842?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Cancer<br/><b>Intervention</b>: Drug: CS1001<br/><b>Sponsor</b>: CStone Pharmaceuticals<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03312842",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 18 Oct 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03279250?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Adenocarcinoma; PSA Level Greater Than Ten; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Testosterone Greater Than 150 ng/dL<br/><b>Interventions</b>: Drug: Abiraterone Acetate; Drug: Apalutamide; Biological: Gonadotropin-releasing Hormone Analog; Drug: Prednisone; Procedure: Radical Prostatectomy<br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Janssen Scientific Affairs, LLC<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03279250",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 12 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02066285?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solitary Fibrous Tumor; Extraskeletal Myxoid Chondrosarcoma<br/><b>Intervention</b>: Drug: Pazopanib<br/><b>Sponsor</b>: Grupo Espanol de Investigacion en Sarcomas<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02066285",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 19 Feb 2014 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00553358?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms, Breast<br/><b>Interventions</b>: Drug: Lapatinib; Biological: Trastuzumab; Drug: Paclitaxel<br/><b>Sponsors</b>: Novartis Pharmaceuticals; Breast International Group; SOLTI Breast Cancer Research Group<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT00553358",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Sun, 04 Nov 2007 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04042545?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer Pain; Quality of Life; Pain, Acute; Cannabis Use<br/><b>Interventions</b>: Drug: PPP001; Drug: Placebo<br/><b>Sponsor</b>: Tetra Bio-Pharma<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04042545",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 02 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04621188?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non Small Cell Lung Cancer Metastatic<br/><b>Intervention</b>: Drug: Lorlatinib<br/><b>Sponsor</b>: Intergroupe Francophone de Cancerologie Thoracique<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04621188",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 09 Nov 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02273375?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: MEDI4736; Drug: Placebo<br/><b>Sponsors</b>: Canadian Cancer Trials Group; Intergroupe Francophone de Cancerologie Thoracique (IFCT); Australasian Lung Cancer Trials Group; National Health and Medical Research Council, Australia; National Cancer Institute (NCI), Naples; Central and Eastern European Oncology Group; Dutch Society of Physicians for Pulmonology and Tuberculosis; Korean Cancer Study Group; Fundación GECP; West Japan Oncology Group (WJOG); Chinese Thoracic Oncology Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02273375",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 24 Oct 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03547037?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasm<br/><b>Interventions</b>: Drug: JNJ-63723283; Drug: Erdafitinib<br/><b>Sponsor</b>: Janssen Pharmaceutical K.K.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03547037",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 06 Jun 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02595931?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Malignant Neoplasm; Refractory Malignant Neoplasm; Unresectable Malignant Neoplasm<br/><b>Interventions</b>: Drug: Berzosertib; Drug: Irinotecan Hydrochloride<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02595931",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 04 Nov 2015 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01275677?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HER2/Neu Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7<br/><b>Interventions</b>: Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Biological: Trastuzumab<br/><b>Sponsors</b>: National Cancer Institute (NCI); NRG Oncology<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01275677",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 12 Jan 2011 12:00:00 EST"
            ]
          },
          {
            "title": [
              "D-0316 First Time in Patients Ascending Dose Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03452150?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Non Small Cell Lung Cancer<br/><b>Intervention</b>: Drug: D-0316<br/><b>Sponsor</b>: InventisBio Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03452150",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 02 Mar 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02504489?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Interventions</b>: Drug: Docetaxel + Plinabulin (DP); Drug: Docetaxel (D)<br/><b>Sponsor</b>: BeyondSpring Pharmaceuticals Inc.<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02504489",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 22 Jul 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Marker Guided Breathhold Radiotherapy in NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02447900?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Non-Small Cell Lung Cancer<br/><b>Intervention</b>: Device: BioXmark<br/><b>Sponsor</b>: Steen Riisgaard Mortensen<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02447900",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 19 May 2015 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03813615?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Preoperative Aerobic Training; Solid Tumors<br/><b>Interventions</b>: Behavioral: treadmill walking (Proof-of-Concept); Behavioral: treadmill walking Dose-Finding / Escalation; Behavioral: treadmill walking Phase 1b: Dose-Expansion<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03813615",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 23 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03843359?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Interventions</b>: Drug: GSK3745417; Drug: Pembrolizumab<br/><b>Sponsor</b>: GlaxoSmithKline<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03843359",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 18 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04263025?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostate Cancer<br/><b>Interventions</b>: Biological: Cryopreserved Umbilical Cord Allograft; Procedure: Robot-Assisted Radical Prostatectomy<br/><b>Sponsor</b>: Hackensack Meridian Health<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04263025",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Feb 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02912559?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02912559",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 23 Sep 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03785210?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Heptocellular Carcinoma; Heptocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer; Liver Metastasis<br/><b>Interventions</b>: Drug: nivolumab; Drug: tadalafil; Drug: oral vancomycin<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03785210",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 24 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of ON 123300 in Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04739293?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors, Adult<br/><b>Intervention</b>: Drug: ON123300<br/><b>Sponsor</b>: Onconova Therapeutics, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04739293",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 04 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00861705?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma<br/><b>Interventions</b>: Biological: Bevacizumab; Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00861705",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 13 Mar 2009 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00310180?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7<br/><b>Interventions</b>: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen Citrate<br/><b>Sponsors</b>: National Cancer Institute (NCI); American College of Surgeons; Cancer and Leukemia Group B; NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00310180",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 03 Apr 2006 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04199754?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Pelvic Cancer; Abdominal Cancer<br/><b>Interventions</b>: Drug: Omnipaque 300mg/mL Solution for Injection; Radiation: Cone Beam CT; Radiation: Radiation Therapy; Drug: 0.9% Saline<br/><b>Sponsor</b>: Columbia University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04199754",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 16 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04123366?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors<br/><b>Interventions</b>: Drug: Olaparib; Biological: Pembrolizumab<br/><b>Sponsor</b>: Merck Sharp & Dohme Corp.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04123366",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 10 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03872427?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor; Unresectable Malignant Solid Neoplasm<br/><b>Interventions</b>: Other: Pharmacodynamic Study; Drug: Telaglenastat Hydrochloride<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03872427",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 13 Mar 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04539574?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Central Nervous System Neoplasm; Glioma; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Malignant Solid Neoplasm<br/><b>Interventions</b>: Procedure: 7 Tesla Magnetic Resonance Imaging; Other: Questionnaire Administration<br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04539574",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04718675?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Relapsed Solid Tumors; Refractory Solid Tumors; Non-Hodgkin Lymphoma<br/><b>Intervention</b>: Drug: KB-0742<br/><b>Sponsor</b>: Kronos Bio<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04718675",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 22 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03166631?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung<br/><b>Interventions</b>: Drug: BI 891065; Drug: BI 754091<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03166631",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 25 May 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Fluorescence Image Guided Foregut Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04734821?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Esophageal Cancer; Gastric Cancer<br/><b>Intervention</b>: Procedure: Near Infra-Red Fluorescence Guided Surgery<br/><b>Sponsor</b>: IHU Strasbourg<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04734821",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01913717?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Adenocarcinoma of Prostate<br/><b>Intervention</b>: Radiation: External beam radiotherapy<br/><b>Sponsor</b>: European Institute of Oncology<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01913717",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 01 Aug 2013 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04474470?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Solid Tumor, Adult; Squamous Cell Carcinoma of Head and Neck; Colorectal Adenocarcinoma; Metastatic Solid Tumor; Recurrent Solid Tumor; Head and Neck Cancer<br/><b>Interventions</b>: Drug: NT219; Drug: NT219 and ERBITUX® - Dose Escalation; Drug: NT219 and ERBITUX® - Expansion<br/><b>Sponsor</b>: TyrNovo Ltd.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04474470",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 16 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03477019?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Neoplasms; Breast Neoplasms<br/><b>Interventions</b>: Drug: SonoVue; Procedure: Focused Ultrasound<br/><b>Sponsor</b>: St. Olavs Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03477019",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 26 Mar 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04104672?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Pancreatic Cancer<br/><b>Interventions</b>: Drug: AB680; Drug: Zimberelimab; Drug: Nab-paclitaxel; Drug: Gemcitabine<br/><b>Sponsor</b>: Arcus Biosciences, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04104672",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Sep 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03240861?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: HLA-A*0201 Positive Cells Present; Locally Advanced Malignant Neoplasm; NY-ESO-1 Positive; Unresectable Malignant Neoplasm; Sarcoma<br/><b>Interventions</b>: Other: 18F-FHBG; Biological: Aldesleukin; Drug: Busulfan; Biological: Cellular Therapy; Procedure: Computed Tomography; Biological: Filgrastim; Drug: Fludarabine; Procedure: Leukapheresis; Drug: Plerixafor; Procedure: Positron Emission Tomography<br/><b>Sponsors</b>: Jonsson Comprehensive Cancer Center; California Institute for Regenerative Medicine (CIRM)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03240861",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Aug 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Enabling Symptom Identification and Tracking in Children Receiving Cancer Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03495518?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Pediatric Cancer; Quality of Life; Symptom Screening<br/><b>Interventions</b>: Other: Symptom feedback to Health Care Provider; Other: Standard of care<br/><b>Sponsors</b>: The Hospital for Sick Children; Canadian Institutes of Health Research (CIHR)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03495518",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 12 Apr 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03598257?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Breast Inflammatory Carcinoma<br/><b>Interventions</b>: Drug: Olaparib; Radiation: Radiation Therapy<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03598257",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 26 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04731844?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Multiple Myeloma; Smoldering Multiple Myeloma (SMM); Monoclonal Gammopathy of Undetermined Significance<br/><b>Intervention</b>: Drug: Curcumin plus Piperine<br/><b>Sponsor</b>: University of Rochester<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04731844",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03707093?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumors, Non-Hodgkin Lymphoma<br/><b>Intervention</b>: Drug: ADG106<br/><b>Sponsor</b>: Adagene Inc<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03707093",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 16 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04586335?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Ovarian Cancer; Breast Cancer; Solid Tumor; Prostate Cancer; Endometrial Cancer<br/><b>Intervention</b>: Drug: CYH33<br/><b>Sponsor</b>: ShangHai HaiHe Pharmaceutical<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04586335",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 14 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04071236?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Castration-Resistant Prostate Carcinoma; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8<br/><b>Interventions</b>: Drug: Avelumab; Drug: Peposertib; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radium Ra 223 Dichloride<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04071236",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 28 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04074135?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: VHL Pancreatic Neuroendocrine Tumors; Von Hippel-Lindau Disease; Neuroendocrine Tumors<br/><b>Intervention</b>: Drug: 68-Gallium DOTATATE<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04074135",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 29 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Development of Diagnostics and Treatment of Urological Cancers"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02994758?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Carcinoma; Kidney Cancer; Urothelial Carcinoma; Testicular Cancer; Penile Cancer<br/><b>Intervention</b>: Other: Personalised treatment<br/><b>Sponsors</b>: Helsinki University Central Hospital; Karolinska Institutet<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02994758",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Dec 2016 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04745910?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Tumor Lysis Syndrome<br/><b>Interventions</b>: Drug: Pegloticase; Drug: Rasburicase<br/><b>Sponsor</b>: M.D. Anderson Cancer Center<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04745910",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 09 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02952469?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Prostatic Neoplasms<br/><b>Intervention</b>: Drug: (68Ga)PSMA-HBED-CC<br/><b>Sponsor</b>: Janet Pollard<br/><b>Enrolling by invitation</b>"
            ],
            "guid": [
              {
                "_": "NCT02952469",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 02 Nov 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04658862?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Urinary Bladder Neoplasms<br/><b>Interventions</b>: Drug: Cetrelimab; Drug: TAR-200; Drug: Cisplatin; Drug: Gemcitabine; Radiation: Conventional radiation therapy; Radiation: Hypo-fractioned radiation therapy<br/><b>Sponsor</b>: Janssen Research & Development, LLC<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04658862",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 09 Dec 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00785291?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7<br/><b>Interventions</b>: Biological: Bevacizumab; Drug: Ixabepilone; Other: Laboratory Biomarker Analysis; Drug: Nab-paclitaxel; Drug: Paclitaxel; Other: Questionnaire Administration<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00785291",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Nov 2008 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04573881?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Liver Tumor; HCC; Metastasis<br/><b>Intervention</b>: Device: HistoSonics Histotripsy<br/><b>Sponsor</b>: HistoSonics, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04573881",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 05 Oct 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT00186888?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Retinoblastoma; Retinal Neoplasm<br/><b>Interventions</b>: Procedure: Enucleation; Drug: Vincristine, Carboplatin; Procedure: Focal Therapies; Radiation: External Beam Radiation; Drug: Vincristine and Topotecan; Drug: Vincristine + Carboplatin + Etoposide; Drug: vincristine, cyclophosphamide, and doxorubicin; Drug: Vincristine, Carboplatin and Etoposide; Procedure: Periocular carboplatin; Other: G-CSF<br/><b>Sponsors</b>: St. Jude Children's Research Hospital; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT00186888",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 16 Sep 2005 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04164082?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Bladder Urothelial Carcinoma In Situ; Infiltrating Bladder Mixed Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8<br/><b>Interventions</b>: Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04164082",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 15 Nov 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03830918?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Malignant Solid Neoplasm; Extensive Stage Lung Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8<br/><b>Interventions</b>: Biological: Atezolizumab; Drug: Niraparib; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Temozolomide<br/><b>Sponsors</b>: Jonsson Comprehensive Cancer Center; Translational Research in Oncology; Tesaro, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03830918",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 05 Feb 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Memory Perception Assessment in Central/Non-central Nervous System Cancers and HIV"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03975959?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Glioblastoma; Glioma; Breast Cancer; Hiv; Healthy<br/><b>Intervention</b>: Other: QMRP questionnaire<br/><b>Sponsor</b>: Institut du Cancer de Montpellier - Val d'Aurelle<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03975959",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 05 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03742895?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Neoplasms<br/><b>Intervention</b>: Drug: Olaparib<br/><b>Sponsors</b>: Merck Sharp & Dohme Corp.; AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03742895",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 15 Nov 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery."
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04735198?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Midgut Carcinoid Tumor; Biliary Stones<br/><b>Interventions</b>: Procedure: Primary tumor surgery; Procedure: Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy<br/><b>Sponsor</b>: Hospital Universitari de Bellvitge<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04735198",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Crossover Relative Bioavailability and Dose Escalation Study of TT-00420 Tablet in Patients With Advanced Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04742959?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancer<br/><b>Intervention</b>: Drug: TT-00420<br/><b>Sponsor</b>: TransThera Biosciences Co., Ltd<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04742959",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 08 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Pre-emptive US Guided Superior Hypogastric Plexus Block in Pelvic Cancer Surgeries : a Randomized Double-Blinded Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04732234?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Analgesia<br/><b>Intervention</b>: Procedure: Superior Hypogastric Plexus Block<br/><b>Sponsor</b>: National Cancer Institute, Egypt<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04732234",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04498520?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8<br/><b>Interventions</b>: Drug: Abexinostat Tosylate; Drug: Fulvestrant; Drug: Palbociclib<br/><b>Sponsors</b>: Pamela Munster; Pfizer; Xynomic Pharmaceuticals, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04498520",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 04 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04069026?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Advanced Solid Tumors<br/><b>Intervention</b>: Drug: BAY2416964<br/><b>Sponsor</b>: Bayer<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04069026",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 28 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04731675?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis<br/><b>Intervention</b>: Biological: AMB-05X<br/><b>Sponsor</b>: AmMax Bio, Inc.<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04731675",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 01 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The Effects of Cosmetic Care on Body Image in Young Chinese Breast Cancer Patients Receiving Chemotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04733482?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Body Image<br/><b>Intervention</b>: Behavioral: Cosmetic care<br/><b>Sponsor</b>: Zhenqi Lu<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04733482",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "The Effect of Wound Problems Wound Dressing in Patients With Colorectal Cancer Surgery"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04735133?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Colorectal Cancer; Surgery; Surgery--Complications; Surgical Site Infection; Wound Complication<br/><b>Intervention</b>: Device: pNBYT<br/><b>Sponsor</b>: TC Erciyes University<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT04735133",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 02 Feb 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Study of Avelumab-M3814 Combinations"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03724890?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Oncology; Solid Tumors<br/><b>Interventions</b>: Drug: M3814; Drug: Avelumab; Radiation: Radiotherapy<br/><b>Sponsors</b>: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03724890",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 30 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04716920?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8<br/><b>Interventions</b>: Other: Tai Chi; Device: FitBit; Other: Support Group Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment<br/><b>Sponsors</b>: Thomas Jefferson University; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04716920",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 20 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Research Study for Latina Women Undergoing Breast Cancer Treatment"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04064151?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer-related Problem/Condition; Quality of Life; Stress, Emotional<br/><b>Intervention</b>: Behavioral: My Guide<br/><b>Sponsor</b>: Northwestern University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04064151",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 21 Aug 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04119830?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Colorectal Adenocarcinoma; Microsatellite Stable; Mismatch Repair Proficient; Refractory Colorectal Adenocarcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma<br/><b>Interventions</b>: Biological: Pembrolizumab; Other: Questionnaire Administration; Drug: Rintatolimod<br/><b>Sponsors</b>: Roswell Park Cancer Institute; National Cancer Institute (NCI); AIM BioPharma<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04119830",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 08 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "NADIM-ADJUVANT: New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04564157?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Non-Small Cell Lung Cancer; Adjuvant Chemotherapy<br/><b>Interventions</b>: Drug: Carboplatin; Drug: Paclitaxel; Drug: Nivolumab<br/><b>Sponsor</b>: Fundación GECP<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04564157",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02151981?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Anticancer Treatment<br/><b>Interventions</b>: Drug: Chemotherapy; Drug: Cross-over to Osimertinib<br/><b>Sponsor</b>: AstraZeneca<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02151981",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 02 Jun 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04214093?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Solid Tumors; Lymphoma; Multiple Myeloma; Hematologic Malignancies<br/><b>Intervention</b>: Drug: AZD0466<br/><b>Sponsor</b>: AstraZeneca<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04214093",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 30 Dec 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04457596?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Synchronous Bilateral Breast Carcinoma<br/><b>Interventions</b>: Biological: Trastuzumab Emtansine; Drug: Placebo Administration; Drug: Tucatinib; Other: Questionnaire Administration; Other: Quality-of-Life Assessment<br/><b>Sponsors</b>: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Seagen Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04457596",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 07 Jul 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04511039?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Advanced Malignant Solid Neoplasm; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A; Locally Advanced Colorectal Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8<br/><b>Interventions</b>: Drug: Trifluridine and Tipiracil Hydrochloride; Drug: Talazoparib Tosylate<br/><b>Sponsors</b>: Roswell Park Cancer Institute; Pfizer<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04511039",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 12 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04016376?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Breast Cancer Female<br/><b>Interventions</b>: Drug: PVB Protocol; Drug: PECS-1; Drug: Serratus<br/><b>Sponsor</b>: Memorial Sloan Kettering Cancer Center<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04016376",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 11 Jul 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "The Patterns of Activity and Cognition During Treatment (PACT) Study"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04562987?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Neoplasms; Breast Cancer Female<br/><b>Interventions</b>: Behavioral: Physical Activity; Behavioral: Attentional Control<br/><b>Sponsors</b>: University of Nebraska; National Institute of General Medical Sciences (NIGMS); Wake Forest University<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04562987",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 24 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04560439?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8<br/><b>Intervention</b>: Dietary Supplement: Dietary Intervention<br/><b>Sponsors</b>: City of Hope Medical Center; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04560439",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 23 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02132845?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Malignant Neoplasm<br/><b>Interventions</b>: Other: cytology specimen collection procedure; Drug: targeted therapy; Procedure: therapeutic procedure; Other: laboratory biomarker analysis<br/><b>Sponsors</b>: Fox Chase Cancer Center; National Cancer Institute (NCI)<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT02132845",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 07 May 2014 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03233711?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage III Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8<br/><b>Interventions</b>: Biological: Nivolumab; Other: Patient Observation<br/><b>Sponsors</b>: National Cancer Institute (NCI); Canadian Cancer Trials Group<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03233711",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 31 Jul 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03093155?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer<br/><b>Interventions</b>: Drug: Ixabepilone; Drug: Bevacizumab<br/><b>Sponsors</b>: Yale University; R-Pharm-US, LLC<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03093155",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04147234?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Interventions</b>: Drug: BI 1387446; Drug: BI 754091<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04147234",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Nov 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04138823?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasm<br/><b>Interventions</b>: Drug: BI 891065; Drug: BI 754091<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04138823",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 25 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03449381?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Intervention</b>: Drug: BI 907828<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03449381",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 28 Feb 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Exercise Therapy During Radiotherapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04507789?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Exercise Therapy; Radiotherapy; Upper Extremity Problem<br/><b>Interventions</b>: Other: exercise intervention; Other: routine radiotherapy protokol<br/><b>Sponsors</b>: Hacettepe University; Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04507789",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 11 Aug 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03822351?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Stage III Non-small Cell Lung Cancer; Unresectable<br/><b>Interventions</b>: Drug: Durvalumab + Oleclumab; Drug: Durvalumab; Drug: Durvalumab + Monalizumab<br/><b>Sponsor</b>: MedImmune LLC<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03822351",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 30 Jan 2019 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study of LY3405105 in Participants With Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03770494?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Solid Tumor<br/><b>Intervention</b>: Drug: LY3405105<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03770494",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 10 Dec 2018 12:00:00 EST"
            ]
          },
          {
            "title": [
              "A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03972150?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Interventions</b>: Drug: BI 836880; Drug: BI 754091<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03972150",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 03 Jun 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03641313?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma<br/><b>Interventions</b>: Drug: Berzosertib; Drug: Irinotecan<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03641313",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 22 Aug 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03604445?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Intervention</b>: Drug: BI 905677<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03604445",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 27 Jul 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04117945?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: BRAF V600E Negative; KRAS Gene Mutation Negative; Locally Advanced Unresectable Colorectal Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; NRAS Gene Mutation Negative; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8<br/><b>Interventions</b>: Biological: Cetuximab; Drug: Irinotecan; Biological: Panitumumab; Drug: Regorafenib<br/><b>Sponsors</b>: Academic and Community Cancer Research United; National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04117945",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Mon, 07 Oct 2019 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Study of the Anti-tumoral Immune Response"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02854644?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Glioma<br/><b>Intervention</b>: Other: additional blood sample<br/><b>Sponsor</b>: Centre Hospitalier Universitaire de Besancon<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02854644",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 03 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Trial of NanoPac Focal Therapy for Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04221828?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Prostate Cancer; Prostate Adenocarcinoma; Prostate Cancer Adenocarcinoma; Prostatic Neoplasm; Urogenital Neoplasms; Genital Neoplasms, Male; Localized Cancer<br/><b>Intervention</b>: Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension<br/><b>Sponsors</b>: NanOlogy, LLC; US Biotest, Inc.<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04221828",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Thu, 09 Jan 2020 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02849496?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Locally Advanced Unresectable Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7<br/><b>Interventions</b>: Drug: Atezolizumab; Drug: Olaparib; Other: Questionnaire Administration<br/><b>Sponsor</b>: National Cancer Institute (NCI)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02849496",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 29 Jul 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "ESP in Breast Surgery Due to Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04726878?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Breast Cancer; Pain, Acute; Anesthesia, Local<br/><b>Interventions</b>: Procedure: Erector spinae plane block; Procedure: Sham block; Procedure: General anesthesia; Procedure: Patient-controlled analgesia; Drug: Oxycodone; Drug: paracetamol<br/><b>Sponsor</b>: Medical University of Lublin<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04726878",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 27 Jan 2021 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03709550?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma in the Soft Tissue; Prostate Carcinoma Metastatic in the Bone; PSA Level Greater Than or Equal to Two; PSA Progression; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8<br/><b>Interventions</b>: Drug: Decitabine; Drug: Enzalutamide<br/><b>Sponsors</b>: Roswell Park Cancer Institute; National Cancer Institute (NCI)<br/><b>Not yet recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03709550",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 17 Oct 2018 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Integrating Family Caregiver Support Into Cancer Clinical Trials"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03069287?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Clinical Trials; Caregivers<br/><b>Intervention</b>: Behavioral: Benjamin Rose Institute (BRI) Care Consultation™ Program<br/><b>Sponsor</b>: John Wayne Cancer Institute<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03069287",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 03 Mar 2017 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT01081405?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: HEMATOLOGIC MALIGNANCIES<br/><b>Intervention</b>: Other: TOTAL LYMPHOID IRRADIATION<br/><b>Sponsor</b>: Fondazione EMN Italy Onlus<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT01081405",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 05 Mar 2010 12:00:00 EST"
            ]
          },
          {
            "title": [
              "Evaluation of a Mobile Digital Solution for Cancer Care and Research"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03094741?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Cancer; Caregivers; Quality of Life<br/><b>Intervention</b>: Other: CancerLife<br/><b>Sponsors</b>: John Wayne Cancer Institute; CancerLife<br/><b>Completed</b>"
            ],
            "guid": [
              {
                "_": "NCT03094741",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 29 Mar 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03270176?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Carcinoma, Non-Small-Cell Lung; Neoplasms<br/><b>Interventions</b>: Drug: Debio 1143; Drug: Avelumab<br/><b>Sponsor</b>: Debiopharm International SA<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03270176",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 01 Sep 2017 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT02873195?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Conditions</b>: Metastatic Colorectal Carcinoma; Recurrent Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7<br/><b>Interventions</b>: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Capecitabine; Other: Laboratory Biomarker Analysis; Other: Placebo<br/><b>Sponsors</b>: Academic and Community Cancer Research United; National Cancer Institute (NCI)<br/><b>Active, not recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT02873195",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Fri, 19 Aug 2016 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "Does Routine Submucosal Injection Improve Complete Resection of 4-20 mm Neoplastic Colorectal Polyps?"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT04548947?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Colorectal Cancer<br/><b>Intervention</b>: Procedure: Cold snare polypectomy in conjunction with a submucosal injection<br/><b>Sponsor</b>: Centre hospitalier de l'Université de Montréal (CHUM)<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT04548947",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Wed, 16 Sep 2020 12:00:00 EDT"
            ]
          },
          {
            "title": [
              "A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)"
            ],
            "link": [
              "https://clinicaltrials.gov/ct2/show/NCT03964233?recrs=abdef&amp;type=Intr&amp;cond=cancer&amp;lupd_s=01%2F28%2F2021&amp;lupd_d=14"
            ],
            "description": [
              "<b>Condition</b>: Neoplasms<br/><b>Interventions</b>: Drug: BI 907828; Drug: BI 754091; Drug: BI 754111<br/><b>Sponsor</b>: Boehringer Ingelheim<br/><b>Recruiting</b>"
            ],
            "guid": [
              {
                "_": "NCT03964233",
                "isPermaLink": [
                  "false"
                ]
              }
            ],
            "pubDate": [
              "Tue, 28 May 2019 12:00:00 EDT"
            ]
          }
        ]
      }
    ]
  }
}